

COVID-19 Immunogenicity Analysis Report
mock Study

USG COVID-19 Response Biostatistics Team

May 10, 2021

Contents

1	Tabular Description of Immunogenicity Data	15
2	Graphical Description of Immunogenicity Data	409
2.1	Pairs plots of antibody markers for overall per-protocol cohort	409
2.2	RCDF plots of antibody markers for overall per-protocol cohort	428
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort	455
2.4	Box plots of antibody markers for overall per-protocol cohort	459
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort	476
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort	478
2.7	Boxplots of antibody markers by demographics for per-protocol cohort	550
3	Appendix	581

List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by All participants	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Risk for Severe Covid-19	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Sex	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, sex	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Race	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Underrepresented minority status	73
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Underrepresented minority status	78
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	89
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age	90
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19	92
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19	94

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex	97
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex	99
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity	102
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race	105
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status	111
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status	113
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants	117
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age	121
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19	129
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19	137
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex	153
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex	161
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity	177
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race	189
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status	220
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status	228
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants	244
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age	247
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19	253
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19	259
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex	270
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex	276

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity	287
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race	296
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . .	320
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	326
1.43 Table 7a. The ratios of GMTs/GMCs between groups by Age	340
1.44 Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19	344
1.45 Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19	348
1.46 Table 7d. The ratios of GMTs/GMCs between groups by Age >= 65, Risk for Severe Covid-19	354
1.47 Table 7e. The ratios of GMTs/GMCs between groups by Sex	360
1.48 Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity	364
1.49 Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status .	370
1.50 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm	376
1.51 Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2	378
1.52 Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age	380
1.53 Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19	383
1.54 Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19	386
1.55 Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age >= 65, Risk for Severe Covid-19	390
1.56 Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex	394
1.57 Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity	397
1.58 Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status	401
1.59 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)	405
1.60 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)	406
1.61 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)	407
1.62 Table 12. Antibody levels in the per-protocol cohort (placebo recipients)	408

List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm	410
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm	411
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	412
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	413
2.5	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm	414
2.6	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm	415
2.7	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm	416
2.8	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm	417
2.9	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm	418
2.10	Pair plots of D29 Ab markers: baseline positive vaccine arm	419
2.11	Pair plots of D57 Ab markers: baseline positive vaccine arm	420
2.12	Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm	421
2.13	Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm	422
2.14	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm	423
2.15	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm	424
2.16	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm	425
2.17	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm	426
2.18	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm	427
2.19	RCDF plots for D29 Ab markers: by baseline status x randomization arm	428
2.20	RCDF plots for D57 Ab markers: by baseline status x randomization arm	429
2.21	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm	430
2.22	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm	431
2.23	RCDF plots for D29 bAb markers: by baseline status for the vaccine arm	432
2.24	RCDF plots for D29 nAb markers: by baseline status for the vaccine arm	432
2.25	RCDF plots for D57 bAb markers: by baseline status for the vaccine arm	433
2.26	RCDF plots for D57 nAb markers: by baseline status for the vaccine arm	434
2.27	RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm	435
2.28	RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm	436

2.29 RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm	437
2.30 RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm	438
2.31 RCDF plots for D29 bAb markers: baseline negative vaccine arm	439
2.32 RCDF plots for D29 nAb markers: baseline negative vaccine arm	440
2.33 RCDF plots for D57 bAb markers: baseline negative vaccine arm	441
2.34 RCDF plots for D57 nAb markers: baseline negative vaccine arm	442
2.35 RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm	443
2.36 RCDF plots for D29 fold-rise over D1 nAb markers: baseline negative vaccine arm	444
2.37 RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm	445
2.38 RCDF plots for D57 fold-rise over D1 nAb markers: baseline negative vaccine arm	446
2.39 RCDF plots for D29 bAb markers: baseline positive vaccine arm	447
2.40 RCDF plots for D29 nAb markers: baseline positive vaccine arm	448
2.41 RCDF plots for D57 bAb markers: baseline positive vaccine arm	449
2.42 RCDF plots for D57 nAb markers: baseline positive vaccine arm	450
2.43 RCDF plots for D29 fold-rise over D1 bAb markers: baseline positive vaccine arm	451
2.44 RCDF plots for D29 fold-rise over D1 nAb markers: baseline positive vaccine arm	452
2.45 RCDF plots for D57 fold-rise over D1 bAb markers: baseline positive vaccine arm	453
2.46 RCDF plots for D57 fold-rise over D1 nAb markers: baseline positive vaccine arm	454
2.47 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm	455
2.48 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm	456
2.49 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm	457
2.50 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm	458
2.51 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms	460
2.52 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms	461
2.53 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	462
2.54 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	463
2.55 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms	464
2.56 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms	465
2.57 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	466
2.58 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	467
2.59 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm	468
2.60 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm	469
2.61 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	470
2.62 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	471
2.63 Boxplots of D29 Ab markers: baseline positive + negative placebo arm	472
2.64 Boxplots of D57 Ab markers: baseline positive + negative placebo arm	473

2.65 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	474
2.66 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	475
2.67 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm	476
2.68 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm	477
2.69 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.	478
2.70 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.	479
2.71 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	480
2.72 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	481
2.73 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.	482
2.74 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.	483
2.75 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	484
2.76 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	485
2.77 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	486
2.78 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	487
2.79 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	488
2.80 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	489
2.81 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.	490
2.82 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.	491
2.83 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	492
2.84 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	493
2.85 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	494
2.86 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	495
2.87 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	496
2.88 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.	497
2.89 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.	498
2.90 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.	499
2.91 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	500
2.92 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	501
2.93 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.	502
2.94 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.	503

2.95 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.	504
2.96 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.	505
2.97 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	506
2.98 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	507
2.99 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	508
2.100RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	509
2.101RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	510
2.102RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	511
2.103RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	512
2.104RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	513
2.105RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.	514
2.106RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.	515
2.107RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	516
2.108RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	517
2.109RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.	518
2.110RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.	519
2.111RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	520
2.112RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	521
2.113RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.	522
2.114RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.	523
2.115RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	524
2.116RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	525
2.117RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.	526
2.118RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.	527
2.119RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	528
2.120RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	529
2.121RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	530

2.122RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	531
2.123RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	532
2.124RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	533
2.125RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.	534
2.126RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.	535
2.127RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	536
2.128RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	537
2.129RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.	538
2.130RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.	539
2.131RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	540
2.132RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	541
2.133RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	542
2.134RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	543
2.135RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	544
2.136RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	545
2.137RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	546
2.138RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	547
2.139RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	548
2.140RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	549
2.141Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.	550
2.142Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.	551
2.143Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	552
2.144Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	553
2.145Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	554
2.146Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	555
2.147Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.	556
2.148Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.	557

2.149Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	558
2.150Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	559
2.151Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	560
2.152Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	561
2.153Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	563
2.154Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	564
2.155Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	565
2.156Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	566
2.157Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	567
2.158Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	568
2.159Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	569
2.160Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	570
2.161Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	571
2.162Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	572
2.163Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	573
2.164Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	574
2.165Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	575
2.166Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	576
2.167Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	577
2.168Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	578
2.169Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	579
2.170Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	580

Chapter 1

Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 749)	Placebo (N = 132)	Total (N = 881)
Age			
Age < 65	353 (47.1%)	66 (50.0%)	419 (47.6%)
Age ≥ 65	396 (52.9%)	66 (50.0%)	462 (52.4%)
Mean (Range)	58.7 (18.0, 85.0)	58.5 (18.0, 85.0)	58.7 (18.0, 85.0)
BMI			
Mean ± SD	29.7 ± 6.9	30.8 ± 7.3	29.9 ± 6.9
Risk for Severe Covid-19			
At-risk	379 (50.6%)	66 (50.0%)	445 (50.5%)
Not at-risk	370 (49.4%)	66 (50.0%)	436 (49.5%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	169 (22.6%)	31 (23.5%)	200 (22.7%)
Age < 65 Not at-risk	184 (24.6%)	35 (26.5%)	219 (24.9%)
Age ≥ 65	396 (52.9%)	66 (50.0%)	462 (52.4%)
Sex			
Female	443 (59.1%)	81 (61.4%)	524 (59.5%)
Male	306 (40.9%)	51 (38.6%)	357 (40.5%)
Hispanic or Latino ethnicity			
Hispanic or Latino	122 (16.3%)	15 (11.4%)	137 (15.6%)
Not Hispanic or Latino	604 (80.6%)	112 (84.8%)	716 (81.3%)
Not reported and unknown	23 (3.1%)	5 (3.8%)	28 (3.2%)
Race			
White Non-Hispanic	359 (47.9%)	66 (50.0%)	425 (48.2%)
Black or African American	172 (23.0%)	32 (24.2%)	204 (23.2%)
Asian	68 (9.1%)	11 (8.3%)	79 (9.0%)
American Indian or Alaska Native	17 (2.3%)	4 (3.0%)	21 (2.4%)
Native Hawaiian or Other Pacific Islander	13 (1.7%)	3 (2.3%)	16 (1.8%)
Multiracial	59 (7.9%)	8 (6.1%)	67 (7.6%)
Other	28 (3.7%)	4 (3.0%)	32 (3.6%)

(continued)

Characteristics	Vaccine (N = 749)	Placebo (N = 132)	Total (N = 881)
Not reported and unknown	5 (0.7%)	1 (0.8%)	6 (0.7%)
Communities of Color	390 (52.1%)	66 (50.0%)	456 (51.8%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age \geq 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 224)	Placebo (N = 226)	Total (N = 450)
Age			
Age < 65	123 (54.9%)	119 (52.7%)	242 (53.8%)
Age ≥ 65	101 (45.1%)	107 (47.3%)	208 (46.2%)
Mean (Range)	56.5 (18.0, 85.0)	55.4 (18.0, 85.0)	56.0 (18.0, 85.0)
BMI			
Mean ± SD	29.5 ± 7.0	30.2 ± 7.1	29.9 ± 7.1
Risk for Severe Covid-19			
At-risk	99 (44.2%)	103 (45.6%)	202 (44.9%)
Not at-risk	125 (55.8%)	123 (54.4%)	248 (55.1%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	60 (26.8%)	60 (26.5%)	120 (26.7%)
Age < 65 Not at-risk	63 (28.1%)	59 (26.1%)	122 (27.1%)
Age ≥ 65	101 (45.1%)	107 (47.3%)	208 (46.2%)
Sex			
Female	134 (59.8%)	125 (55.3%)	259 (57.6%)
Male	90 (40.2%)	101 (44.7%)	191 (42.4%)
Hispanic or Latino ethnicity			
Hispanic or Latino	42 (18.8%)	32 (14.2%)	74 (16.4%)
Not Hispanic or Latino	177 (79.0%)	184 (81.4%)	361 (80.2%)
Not reported and unknown	5 (2.2%)	10 (4.4%)	15 (3.3%)
Race			
White Non-Hispanic	106 (47.3%)	114 (50.4%)	220 (48.9%)
Black or African American	41 (18.3%)	56 (24.8%)	97 (21.6%)
Asian	24 (10.7%)	14 (6.2%)	38 (8.4%)
American Indian or Alaska Native	7 (3.1%)	8 (3.5%)	15 (3.3%)
Native Hawaiian or Other Pacific Islander	2 (0.9%)	3 (1.3%)	5 (1.1%)
Multiracial	18 (8.0%)	19 (8.4%)	37 (8.2%)
Other	5 (2.2%)	6 (2.7%)	11 (2.4%)
Not reported and unknown	2 (0.9%)		2 (0.4%)
Communities of Color	118 (52.7%)	112 (49.6%)	230 (51.1%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
All participants								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11007.2/11062 = 99.5% (97.3%, 99.9%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11015.2/11062 = 99.6% (97.0%, 99.9%)	11015.2/11062 = 99.6% (97.0%, 99.9%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1076.6/1094 = 98.4% (91.9%, 99.7%)	1073.6/1094 = 98.1% (92.3%, 99.6%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1079.6/1094 = 98.7% (91.1%, 99.8%)	1073.6/1094 = 98.1% (92.3%, 99.6%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1079.6/1094 = 98.7% (91.1%, 99.8%)	1079.6/1094 = 98.7% (91.1%, 99.8%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration. Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8665.2/8720 = 99.4% (96.6%, 99.9%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8673.2/8720 = 99.5% (96.3%, 99.9%)	8673.2/8720 = 99.5% (96.3%, 99.9%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	848.6/866 = 98.0% (89.8%, 99.6%)	845.6/866 = 97.6% (90.3%, 99.5%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	851.6/866 = 98.3% (88.8%, 99.8%)	845.6/866 = 97.6% (90.3%, 99.5%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	851.6/866 = 98.3% (88.8%, 99.8%)	851.6/866 = 98.3% (88.8%, 99.8%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	119	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)	0/2654 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3021.3/3029.3 = 99.7% (98.1%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)	0/3398 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	250.5/253.6 = 98.8% (91.8%, 99.8%)	247.5/253.6 = 97.6% (90.8%, 99.4%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	247.5/253.6 = 97.6% (90.8%, 99.4%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)	0/3398 = 0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	7985.9/8032.7 = 99.4% (95.9%, 99.9%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	7985.9/8032.7 = 99.4% (95.9%, 99.9%)	7985.9/8032.7 = 99.4% (95.9%, 99.9%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	826/840.4 = 98.3% (88.5%, 99.8%)	826/840.4 = 98.3% (88.5%, 99.8%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	826/840.4 = 98.3% (88.5%, 99.8%)	826/840.4 = 98.3% (88.5%, 99.8%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)	0/7732 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	826/840.4 = 98.3% (88.5%, 99.8%)	826/840.4 = 98.3% (88.5%, 99.8%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1789/1797 = 99.6% (96.9%, 99.9%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	160/163 = 98.1% (87.4%, 99.8%)	156.9/163 = 96.3% (85.9%, 99.1%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	156.9/163 = 96.3% (85.9%, 99.1%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6876.2/6923 = 99.3% (95.3%, 99.9%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6876.2/6923 = 99.3% (95.3%, 99.9%)	6876.2/6923 = 99.3% (95.3%, 99.9%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	688.6/703 = 98.0% (86.1%, 99.7%)	688.6/703 = 98.0% (86.1%, 99.7%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	688.6/703 = 98.0% (86.1%, 99.7%)	688.6/703 = 98.0% (86.1%, 99.7%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	688.6/703 = 98.0% (86.1%, 99.7%)	688.6/703 = 98.0% (86.1%, 99.7%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Sex								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	527.8/530.8 = 99.4% (95.9%, 99.9%)	524.8/530.8 = 98.9% (95.5%, 99.7%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	527.8/530.8 = 99.4% (95.9%, 99.9%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6345.3/6400 = 99.1% (95.4%, 99.8%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6353.3/6400 = 99.3% (95.0%, 99.9%)	6353.3/6400 = 99.3% (95.0%, 99.9%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	548.8/563.2 = 97.4% (83.6%, 99.7%)	548.8/563.2 = 97.4% (83.6%, 99.7%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	548.8/563.2 = 97.4% (83.6%, 99.7%)	545.8/563.2 = 96.9% (85.0%, 99.4%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)	0/6587.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	548.8/563.2 = 97.4% (83.6%, 99.7%)	548.8/563.2 = 97.4% (83.6%, 99.7%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4940.1/4994.9 = 98.9% (94.2%, 99.8%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4948.1/4994.9 = 99.1% (93.6%, 99.9%)	4948.1/4994.9 = 99.1% (93.6%, 99.9%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	404.7/419.1 = 96.6% (78.3%, 99.5%)	404.7/419.1 = 96.6% (78.3%, 99.5%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	404.7/419.1 = 96.6% (78.3%, 99.5%)	401.7/419.1 = 95.8% (80.1%, 99.2%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	404.7/419.1 = 96.6% (78.3%, 99.5%)	404.7/419.1 = 96.6% (78.3%, 99.5%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	443.9/446.9 = 99.3% (95.1%, 99.9%)	440.8/446.9 = 98.6% (94.6%, 99.7%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	443.9/446.9 = 99.3% (95.1%, 99.9%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9530.7/9585.4 = 99.4% (96.9%, 99.9%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9538.6/9585.4 = 99.5% (96.6%, 99.9%)	9538.6/9585.4 = 99.5% (96.6%, 99.9%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	907.2/924.6 = 98.1% (90.5%, 99.6%)	904.2/924.6 = 97.8% (91.0%, 99.5%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	910.2/924.6 = 98.4% (89.5%, 99.8%)	904.2/924.6 = 97.8% (91.0%, 99.5%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	910.2/924.6 = 98.4% (89.5%, 99.8%)	910.2/924.6 = 98.4% (89.5%, 99.8%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	628.6/631.6 = 99.5% (96.6%, 99.9%)	628.6/631.6 = 99.5% (96.6%, 99.9%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	625.6/631.6 = 99.0% (96.2%, 99.8%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1936.4/1944.4 = 99.6% (97.1%, 99.9%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	59.3/62.3 = 95.1% (64.9%, 99.5%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	88.5/102.9 = 86.0% (39.6%, 98.3%)	88.5/102.9 = 86.0% (39.6%, 98.3%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	88.5/102.9 = 86.0% (39.6%, 98.3%)	88.5/102.9 = 86.0% (39.6%, 98.3%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	88.5/102.9 = 86.0% (39.6%, 98.3%)	88.5/102.9 = 86.0% (39.6%, 98.3%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4641.7/4649.6 = 99.8% (98.8%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	448/462.4 = 96.9% (80.9%, 99.6%)	445/462.4 = 96.2% (82.5%, 99.3%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	448/462.4 = 96.9% (80.9%, 99.6%)	448/462.4 = 96.9% (80.9%, 99.6%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	448/462.4 = 96.9% (80.9%, 99.6%)	448/462.4 = 96.9% (80.9%, 99.6%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)	6365.6/6412.4 = 99.3% (95.0%, 99.9%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	628.6/631.6 = 99.5% (96.6%, 99.9%)	628.6/631.6 = 99.5% (96.6%, 99.9%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	625.6/631.6 = 99.0% (96.2%, 99.8%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3576.4/3584.4 = 99.8% (98.4%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	357.8/372.2 = 96.1% (76.7%, 99.5%)	354.7/372.2 = 95.3% (78.6%, 99.1%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	357.8/372.2 = 96.1% (76.7%, 99.5%)	357.8/372.2 = 96.1% (76.7%, 99.5%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	357.8/372.2 = 96.1% (76.7%, 99.5%)	357.8/372.2 = 96.1% (76.7%, 99.5%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5088.8/5135.6 = 99.1% (93.7%, 99.9%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5088.8/5135.6 = 99.1% (93.7%, 99.9%)	5088.8/5135.6 = 99.1% (93.7%, 99.9%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	490.8/493.8 = 99.4% (95.6%, 99.9%)	490.8/493.8 = 99.4% (95.6%, 99.9%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	487.8/493.8 = 98.8% (95.1%, 99.7%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
All participants								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	10968.5/11062 = 99.2% (96.7%, 99.8%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	132	393.3/11130 = 3.5% (0.9%, 12.6%)	393.3/11130 = 3.5% (0.9%, 12.6%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	226	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)	1079.6/1094 = 98.7% (91.1%, 99.8%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	749	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)	11062/11062 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	224	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)	1184/1184 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	132	121/11130 = 1.1% (0.3%, 3.4%)	121/11130 = 1.1% (0.3%, 3.4%)	0/11130 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	226	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)	1094/1094 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8626.5/8720 = 98.9% (95.8%, 99.7%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	358/8476 = 4.2% (1.0%, 16.7%)	358/8476 = 4.2% (1.0%, 16.7%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	119	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)	851.6/866 = 98.3% (88.8%, 99.8%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	353	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)	8720/8720 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	123	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)	953/953 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)	0/8476 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	119	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)	866/866 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	35.3/2654 = 1.3% (0.2%, 9.3%)	35.3/2654 = 1.3% (0.2%, 9.3%)	0/2654 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	396	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)	2342/2342 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	101	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)	231/231 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	121/2654 = 4.6% (1.4%, 13.7%)	121/2654 = 4.6% (1.4%, 13.7%)	0/2654 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	107	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)	228/228 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	35.3/3398 = 1.0% (0.1%, 7.3%)	35.3/3398 = 1.0% (0.1%, 7.3%)	0/3398 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	379	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)	3029.3/3029.3 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	99	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)	290.9/290.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	78.2/3398 = 2.3% (0.6%, 9.0%)	78.2/3398 = 2.3% (0.6%, 9.0%)	0/3398 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	103	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)	253.6/253.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	7939.1/8032.7 = 98.8% (95.4%, 99.7%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	358/7732 = 4.6% (1.0%, 18.2%)	358/7732 = 4.6% (1.0%, 18.2%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)	826/840.4 = 98.3% (88.5%, 99.8%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	370	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)	8032.7/8032.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)	893.1/893.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	42.8/7732 = 0.6% (0.1%, 4.0%)	42.8/7732 = 0.6% (0.1%, 4.0%)	0/7732 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)	840.4/840.4 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	169	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)	1797/1797 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)	199/199 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)	0/2004 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)	163/163 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6829.5/6923 = 98.6% (94.7%, 99.7%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	358/6472 = 5.5% (1.2%, 21.8%)	358/6472 = 5.5% (1.2%, 21.8%)	0/6472 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)	688.6/703 = 98.0% (86.1%, 99.7%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	184	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)	6923/6923 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	63	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)	754/754 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)	0/6472 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)	703/703 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	35.3/1394 = 2.5% (0.3%, 17.2%)	35.3/1394 = 2.5% (0.3%, 17.2%)	0/1394 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	210	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)	1232.3/1232.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	39	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)	91.9/91.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	78.2/1394 = 5.6% (1.3%, 21.2%)	78.2/1394 = 5.6% (1.3%, 21.2%)	0/1394 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	43	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)	90.6/90.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	186	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)	1109.7/1109.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)	139.1/139.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	42.8/1260 = 3.4% (0.4%, 22.3%)	42.8/1260 = 3.4% (0.4%, 22.3%)	0/1260 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)	137.4/137.4 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Sex								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4615.2/4662 = 99.0% (93.2%, 99.9%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	51	220.5/4542.8 = 4.9% (0.6%, 28.8%)	220.5/4542.8 = 4.9% (0.6%, 28.8%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	306	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)	4662/4662 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)	539.2/539.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	51	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)	0/4542.8 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	101	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)	530.8/530.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6353.3/6400 = 99.3% (95.0%, 99.9%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	172.8/6587.2 = 2.6% (0.5%, 12.5%)	172.8/6587.2 = 2.6% (0.5%, 12.5%)	0/6587.2 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)	548.8/563.2 = 97.4% (83.6%, 99.7%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	443	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)	6400/6400 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	134	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)	644.8/644.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	121/6587.2 = 1.8% (0.6%, 5.7%)	121/6587.2 = 1.8% (0.6%, 5.7%)	0/6587.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	125	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)	563.2/563.2 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4948.1/4994.9 = 99.1% (93.6%, 99.9%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	137.5/4815.4 = 2.9% (0.4%, 19.0%)	137.5/4815.4 = 2.9% (0.4%, 19.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)	404.7/419.1 = 96.6% (78.3%, 99.5%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	205	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)	4994.9/4994.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)	506.9/506.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)	0/4815.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)	419.1/419.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3678.4/3725.1 = 98.7% (91.5%, 99.8%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	220.5/3660.6 = 6.0% (0.8%, 35.2%)	220.5/3660.6 = 6.0% (0.8%, 35.2%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	148	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)	3725.1/3725.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)	446.1/446.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)	0/3660.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	62	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)	446.9/446.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	158	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)	936.8/936.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	40	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)	93.1/93.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	22	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)	0/882.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	39	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)	83.9/83.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	35.3/1771.8 = 2.0% (0.3%, 13.7%)	35.3/1771.8 = 2.0% (0.3%, 13.7%)	0/1771.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	238	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)	1405.2/1405.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)	137.9/137.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	121/1771.8 = 6.8% (2.1%, 20.0%)	121/1771.8 = 6.8% (2.1%, 20.0%)	0/1771.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)	144.1/144.1 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	122	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)	1222.8/1222.8 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	42	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)	201.7/201.7 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	35.3/1089.7 = 3.2% (0.3%, 24.4%)	35.3/1089.7 = 3.2% (0.3%, 24.4%)	0/1089.7 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	32	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9491.9/9585.4 = 99.0% (96.2%, 99.8%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	112	393.3/9753.3 = 4.0% (1.1%, 14.2%)	393.3/9753.3 = 4.0% (1.1%, 14.2%)	0/9753.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)	910.2/924.6 = 98.4% (89.5%, 99.8%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	604	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)	9585.4/9585.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	177	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)	970.8/970.8 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	112	85.6/9753.3 = 0.9% (0.2%, 3.5%)	85.6/9753.3 = 0.9% (0.2%, 3.5%)	0/9753.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	184	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)	924.6/924.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	23	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)	253.8/253.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)	11.5/11.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)	0/287 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	10	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)	41.3/41.3 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6318.8/6412.4 = 98.5% (94.3%, 99.6%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	220.5/6435.1 = 3.4% (0.4%, 21.8%)	220.5/6435.1 = 3.4% (0.4%, 21.8%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	42.8/6435.1 = 0.7% (0.1%, 4.8%)	42.8/6435.1 = 0.7% (0.1%, 4.8%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	172.8/2311.5 = 7.5% (1.3%, 32.7%)	172.8/2311.5 = 7.5% (1.3%, 32.7%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	172	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)	1944.4/1944.4 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	41	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)	173.7/173.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)	0/2311.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)	201.4/201.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	68	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)	936.4/936.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)	149.4/149.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	42.8/1043.3 = 4.1% (0.4%, 33.9%)	42.8/1043.3 = 4.1% (0.4%, 33.9%)	0/1043.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	14	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)	62.3/62.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)	234.3/234.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)	31/31 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)	0/141.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	8	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)	28.6/28.6 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	13	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)	148.3/148.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%	4.8/4.8 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	0/114.2 = 0.0%	0/114.2 = 0.0%	0/114.2 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%	12.1/12.1 = 100.0%
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)	88.5/102.9 = 86.0% (39.6%, 98.3%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)	647.5/647.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	18	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)	115.1/115.1 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	35.3/738 = 4.8% (0.3%, 44.1%)	35.3/738 = 4.8% (0.3%, 44.1%)	0/738 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	19	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)	102.9/102.9 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	28	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)	407.8/407.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%	37.3/37.3 = 100.0%
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)	0/172.6 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	6	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)	23.2/23.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	5	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)	72.5/72.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%	11.1/11.1 = 100.0%
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	0/43.5 = 0.0%	0/43.5 = 0.0%	0/43.5 = 0.0%

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	172.8/4694.9 = 3.7% (0.7%, 17.5%)	172.8/4694.9 = 3.7% (0.7%, 17.5%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)	448/462.4 = 96.9% (80.9%, 99.6%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	390	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)	4649.6/4649.6 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	118	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)	622.1/622.1 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	78.2/4694.9 = 1.7% (0.4%, 6.7%)	78.2/4694.9 = 1.7% (0.4%, 6.7%)	0/4694.9 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	112	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)	462.4/462.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6318.8/6412.4 = 98.5% (94.3%, 99.6%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	220.5/6435.1 = 3.4% (0.4%, 21.8%)	220.5/6435.1 = 3.4% (0.4%, 21.8%)	0/6435.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)	6412.4/6412.4 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	106	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)	561.9/561.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	42.8/6435.1 = 0.7% (0.1%, 4.8%)	42.8/6435.1 = 0.7% (0.1%, 4.8%)	0/6435.1 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	114	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)	631.6/631.6 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	137.5/3496.6 = 3.9% (0.5%, 25.8%)	137.5/3496.6 = 3.9% (0.5%, 25.8%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)	357.8/372.2 = 96.1% (76.7%, 99.5%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	181	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)	3584.4/3584.4 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	71	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)	526.9/526.9 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)	0/3496.6 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)	372.2/372.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5042/5135.6 = 98.2% (92.9%, 99.6%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	220.5/4979.4 = 4.4% (0.5%, 28.0%)	220.5/4979.4 = 4.4% (0.5%, 28.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	172	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)	5135.6/5135.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)	426.1/426.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)	0/4979.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	35.3/1198.3 = 2.9% (0.4%, 20.1%)	35.3/1198.3 = 2.9% (0.4%, 20.1%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	209	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)	1065.2/1065.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	47	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)	95.2/95.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	78.2/1198.3 = 6.5% (1.5%, 24.1%)	78.2/1198.3 = 6.5% (1.5%, 24.1%)	0/1198.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)	90.2/90.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	187	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)	1276.8/1276.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)	135.8/135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	42.8/1455.7 = 2.9% (0.4%, 19.7%)	42.8/1455.7 = 2.9% (0.4%, 19.7%)	0/1455.7 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)	137.8/137.8 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
All participants						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	749	0.04 (0.04, 0.04)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	0.46 (0.46, 0.46)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	0.15 (0.15, 0.15)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	749	5.00 (5.00, 5.00)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	749	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	224	0.04 (0.04, 0.04)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	0.46 (0.46, 0.46)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	0.15 (0.15, 0.15)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	132	0.04 (0.04, 0.04)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0.46 (0.46, 0.46)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0.15 (0.15, 0.15)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	132	5.09 (4.92, 5.27)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	132	5.01 (4.99, 5.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	226	0.04 (0.04, 0.04)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	226	0.46 (0.46, 0.46)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	226	0.15 (0.15, 0.15)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	749	43.07 (35.88, 51.71)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	509.98 (439.60, 591.63)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	302.60 (265.80, 344.49)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	749	251.94 (231.24, 274.49)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	749	62.12 (57.88, 66.67)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	224	104.93 (77.54, 141.98)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	1299.63 (1037.04, 1628.70)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	561.28 (456.56, 690.02)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	224	493.68 (432.71, 563.23)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	224	108.79 (97.67, 121.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	132	0.04 (0.04, 0.04)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0.46 (0.46, 0.46)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0.15 (0.15, 0.15)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	132	5.19 (4.95, 5.43)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	132	5.09 (4.94, 5.24)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	226	23.14 (16.43, 32.60)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	226	270.27 (198.78, 367.46)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	226	157.50 (121.73, 203.80)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	226	141.35 (121.40, 164.59)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	226	41.66 (36.61, 47.41)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	749	570.94 (461.75, 705.94)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	21313.15 (18157.78, 25016.84)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	13758.85 (11869.43, 15949.02)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	749	8253.83 (7607.43, 8955.14)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	749	1602.88 (1497.22, 1715.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	224	1790.43 (1245.27, 2574.24)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	56974.62 (44687.72, 72639.80)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	43125.84 (34123.09, 54503.80)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	224	24003.54 (20902.14, 27565.12)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	224	4697.51 (4168.96, 5293.07)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	132	0.04 (0.04, 0.04)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0.46 (0.46, 0.46)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0.15 (0.15, 0.15)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	132	5.05 (4.99, 5.11)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	132	5.04 (4.98, 5.10)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	226	302.00 (186.90, 487.98)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	226	11492.32 (7839.54, 16847.11)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	226	6382.66 (4697.19, 8672.91)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	226	4193.33 (3551.23, 4951.52)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	226	946.69 (803.89, 1114.85)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	353	0.04 (0.04, 0.04)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	0.46 (0.46, 0.46)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	0.15 (0.15, 0.15)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	353	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	353	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.12 (4.89, 5.35)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	119	0.04 (0.04, 0.04)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	0.46 (0.46, 0.46)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	0.15 (0.15, 0.15)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	353	33.67 (26.81, 42.27)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	390.92 (325.39, 469.66)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	229.08 (195.08, 269.00)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	353	228.10 (204.99, 253.80)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	353	57.90 (53.05, 63.20)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	123	92.62 (64.23, 133.56)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	1121.72 (854.30, 1472.86)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	443.85 (346.45, 568.64)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	123	465.67 (396.90, 546.36)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	123	102.92 (90.44, 117.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.22 (4.91, 5.54)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.10 (4.91, 5.29)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	119	16.52 (10.84, 25.17)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	119	197.05 (135.01, 287.61)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	119	111.87 (81.64, 153.31)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	119	120.14 (99.70, 144.77)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	119	36.63 (31.28, 42.89)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	353	428.64 (329.49, 557.62)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	15803.76 (12971.51, 19254.42)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	9923.86 (8268.09, 11911.22)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	353	7480.26 (6764.17, 8272.15)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	353	1510.22 (1388.84, 1642.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	123	1412.22 (909.12, 2193.75)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	42982.14 (32187.37, 57397.20)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	31653.33 (23910.26, 41903.91)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	123	22114.19 (18694.67, 26159.19)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	123	4464.66 (3864.51, 5158.02)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	119	204.27 (112.76, 370.04)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	119	7751.46 (4835.02, 12427.08)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	119	4193.83 (2882.65, 6101.41)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	119	3577.93 (2913.36, 4394.08)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	119	876.13 (715.13, 1073.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	396	0.04 (0.04, 0.04)
Age \geq 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	0.46 (0.46, 0.46)
Age \geq 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	0.15 (0.15, 0.15)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	396	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	396	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)
Age \geq 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)
Age \geq 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age \geq 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age \geq 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.95, 5.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	107	0.04 (0.04, 0.04)
Age ≥ 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	107	0.46 (0.46, 0.46)
Age ≥ 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	107	0.15 (0.15, 0.15)
Age ≥ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)
Age ≥ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	396	107.79 (91.99, 126.30)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	1372.32 (1178.18, 1598.45)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	852.99 (754.08, 964.87)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	396	364.80 (338.35, 393.31)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	396	80.68 (75.15, 86.62)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	101	175.55 (124.58, 247.36)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	2385.49 (1836.56, 3098.49)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	1478.25 (1166.20, 1873.79)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	101	628.19 (544.13, 725.24)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	101	136.73 (118.93, 157.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age \geq 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age \geq 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age \geq 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.09 (4.92, 5.27)
Age \geq 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.94, 5.19)
Age \geq 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	107	83.32 (59.92, 115.86)
Age \geq 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	107	897.31 (677.16, 1189.05)
Age \geq 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	107	577.55 (451.71, 738.44)
Age \geq 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	107	262.15 (225.01, 305.42)
Age \geq 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	107	67.94 (58.88, 78.39)
Age \geq 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	396	1660.08 (1348.16, 2044.16)
Age \geq 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	64902.03 (54667.76, 77052.25)
Age \geq 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	46443.53 (40069.32, 53831.73)
Age \geq 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	396	11906.53 (10905.08, 12999.96)
Age \geq 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	396	2000.72 (1847.92, 2166.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	101	4765.44 (3268.92, 6947.08)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	182230.11 (133129.63, 249439.69)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	154480.14 (119203.38, 200196.61)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	101	33663.74 (29201.96, 38807.23)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	101	5793.68 (5052.80, 6643.20)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.23 (4.97, 5.50)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.18 (4.93, 5.45)
Age ≥ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	107	1333.39 (892.57, 1991.92)
Age ≥ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	107	51286.07 (36987.41, 71112.34)
Age ≥ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	107	31460.53 (23599.98, 41939.22)
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	107	7662.36 (6672.78, 8798.69)
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	107	1270.48 (1107.46, 1457.49)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Risk for Severe Covid-19						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	379	0.04 (0.04, 0.04)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	0.46 (0.46, 0.46)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	0.15 (0.15, 0.15)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	379	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	379	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	99	0.04 (0.04, 0.04)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	0.46 (0.46, 0.46)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	0.15 (0.15, 0.15)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	99	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	99	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.05 (4.96, 5.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	103	0.04 (0.04, 0.04)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	103	0.46 (0.46, 0.46)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	103	0.15 (0.15, 0.15)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	103	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	103	5.00 (5.00, 5.00)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	379	47.63 (39.65, 57.23)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	536.69 (453.76, 634.78)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	360.67 (313.82, 414.53)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	379	260.65 (239.38, 283.80)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	379	63.75 (58.83, 69.09)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	99	106.44 (74.25, 152.57)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	1138.23 (843.79, 1535.41)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	609.49 (452.25, 821.39)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	99	495.10 (421.30, 581.83)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	99	112.96 (96.74, 131.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.07 (4.93, 5.21)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	103	23.85 (16.37, 34.74)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	103	328.27 (237.52, 453.70)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	103	186.87 (139.95, 249.53)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	103	152.45 (129.23, 179.85)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	103	47.57 (40.57, 55.78)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	379	788.33 (628.28, 989.15)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	25218.56 (20861.91, 30485.03)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	14665.26 (12316.35, 17462.16)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	379	8505.34 (7687.07, 9410.71)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	379	1579.79 (1455.42, 1714.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	99	2191.39 (1415.51, 3392.54)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	57248.83 (39324.67, 83342.81)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	52396.96 (36673.08, 74862.57)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	99	25589.17 (21385.56, 30619.05)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	99	4605.30 (3926.30, 5401.73)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.13 (4.95, 5.31)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	103	274.00 (178.04, 421.70)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	103	13055.30 (9073.92, 18783.61)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	103	8504.90 (6092.45, 11872.62)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	103	4779.69 (4093.32, 5581.16)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	103	1016.94 (865.76, 1194.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	370	0.04 (0.04, 0.04)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	0.46 (0.46, 0.46)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	0.15 (0.15, 0.15)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	370	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	370	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.13 (4.88, 5.39)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	370	41.47 (32.54, 52.85)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	500.26 (411.49, 608.18)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	283.21 (238.52, 336.27)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	370	248.73 (221.97, 278.72)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	370	61.51 (56.07, 67.48)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	125	104.44 (71.16, 153.27)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	1356.98 (1022.09, 1801.60)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	546.42 (422.51, 706.67)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	125	493.21 (417.45, 582.73)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	125	107.46 (94.00, 122.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.24 (4.91, 5.59)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.13 (4.92, 5.35)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	123	22.93 (14.88, 35.35)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	123	254.87 (172.76, 375.99)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	123	149.58 (108.03, 207.12)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	123	138.17 (113.99, 167.46)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	123	40.03 (34.05, 47.05)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	370	505.53 (382.04, 668.94)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	20002.76 (16219.13, 24669.05)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	13431.75 (11065.89, 16303.43)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	370	8160.92 (7341.30, 9072.04)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	370	1611.68 (1474.81, 1761.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	125	1676.39 (1057.90, 2656.46)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	56885.60 (42170.77, 76734.93)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	40475.81 (30296.14, 54075.90)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	125	23508.65 (19753.35, 27977.87)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	125	4727.93 (4071.07, 5490.78)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.02 (4.98, 5.06)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.98, 5.15)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	123	311.00 (168.65, 573.51)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	123	11058.57 (6794.47, 17998.77)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	123	5853.12 (3970.26, 8628.91)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	123	4030.96 (3261.88, 4981.38)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	123	926.46 (752.98, 1139.91)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	169	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	169	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	169	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	169	28.66 (21.95, 37.40)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	310.14 (245.07, 392.48)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	208.18 (171.26, 253.07)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	169	218.22 (192.88, 246.88)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	169	55.81 (49.56, 62.85)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	74.86 (48.78, 114.87)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	780.80 (540.54, 1127.84)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	409.69 (283.87, 591.26)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	415.91 (340.53, 507.97)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	60	99.66 (81.87, 121.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	12.85 (8.04, 20.54)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	199.36 (133.22, 298.33)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	101.06 (70.68, 144.51)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	115.12 (93.76, 141.33)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	37.45 (30.69, 45.72)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	169	517.19 (372.31, 718.46)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	14819.22 (11316.43, 19406.23)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	8024.85 (6241.95, 10317.00)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	169	6995.80 (6065.33, 8069.01)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	169	1434.80 (1281.45, 1606.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	1574.27 (890.19, 2784.07)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	36161.42 (22715.38, 57566.66)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	30982.72 (19829.43, 48409.31)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	22038.60 (17325.51, 28033.81)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	60	3999.22 (3250.75, 4920.03)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	136.92 (79.51, 235.78)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	6781.74 (4298.65, 10699.16)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	4158.58 (2849.46, 6069.16)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	3651.05 (2981.32, 4471.23)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	867.67 (702.90, 1071.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.15 (4.86, 5.47)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	184	35.11 (26.58, 46.37)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	415.13 (332.20, 518.78)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	234.84 (193.06, 285.65)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	184	230.73 (202.48, 262.93)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	184	58.46 (52.59, 64.99)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	63	97.97 (62.56, 153.42)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	1234.28 (887.43, 1716.69)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	453.34 (336.59, 610.58)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	63	479.77 (394.81, 583.01)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	63	103.80 (88.90, 121.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	5.28 (4.89, 5.71)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	35	5.13 (4.88, 5.39)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	17.51 (10.54, 29.07)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	196.52 (124.51, 310.17)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	114.54 (78.40, 167.35)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	121.33 (96.91, 151.91)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	59	36.44 (30.17, 44.02)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	184	408.25 (296.40, 562.30)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	16069.84 (12657.39, 20402.28)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	10486.35 (8411.64, 13072.79)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	184	7611.40 (6742.55, 8592.21)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	184	1530.44 (1382.90, 1693.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	63	1372.31 (802.96, 2345.38)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	44987.70 (31884.97, 63474.82)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	31832.73 (22783.88, 44475.43)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	63	22134.18 (18074.96, 27105.02)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	63	4596.29 (3862.21, 5469.90)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	224.13 (109.00, 460.83)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	7995.43 (4513.85, 14162.38)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	4202.05 (2670.15, 6612.81)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	3561.18 (2777.01, 4566.79)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	59	878.11 (687.08, 1122.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	210	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	210	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	210	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.11 (4.90, 5.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	43	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	43	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	43	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	210	99.95 (80.72, 123.76)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	1194.09 (968.01, 1472.96)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	803.81 (680.81, 949.02)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	210	337.73 (304.82, 374.20)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	210	77.42 (70.60, 84.89)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	39	228.12 (122.64, 424.32)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	2575.10 (1644.37, 4032.62)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	1440.91 (930.92, 2230.27)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	39	722.21 (565.32, 922.64)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	39	148.20 (117.80, 186.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	35	5.17 (4.84, 5.53)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	43	72.54 (42.91, 122.63)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	43	805.47 (504.67, 1285.56)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	43	564.92 (395.66, 806.59)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	43	252.75 (200.68, 318.34)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	43	73.16 (58.26, 91.87)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	210	1457.59 (1105.15, 1922.43)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	54754.00 (43287.94, 69257.18)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	35328.80 (28909.66, 43173.26)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	210	11309.10 (9909.35, 12906.58)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	210	1817.86 (1620.23, 2039.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	39	4485.89 (2499.82, 8049.86)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	154860.47 (89078.89, 269219.42)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	163519.98 (102447.32, 261000.32)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	39	35364.94 (28852.23, 43347.74)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	39	6251.73 (5057.67, 7727.69)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	35	5.32 (4.89, 5.79)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	43	954.95 (524.94, 1737.21)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	43	42433.21 (26242.87, 68612.03)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	43	30823.45 (18710.02, 50779.47)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	43	7761.30 (6479.54, 9296.61)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	43	1353.22 (1078.40, 1698.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	186	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	186	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	186	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	186	117.22 (92.60, 148.38)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	1601.60 (1285.26, 1995.80)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	911.14 (758.75, 1094.14)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	186	397.40 (356.10, 443.49)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	186	84.47 (75.74, 94.21)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	147.66 (100.04, 217.96)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	2268.01 (1652.51, 3112.75)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	1503.44 (1150.43, 1964.77)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	572.91 (482.58, 680.16)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	62	129.65 (108.96, 154.27)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5.13 (4.88, 5.40)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	91.29 (59.85, 139.23)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	963.50 (678.73, 1367.75)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	586.02 (419.87, 817.92)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	268.54 (219.28, 328.86)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	64	64.70 (53.88, 77.69)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	186	1918.06 (1403.10, 2622.03)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	78390.31 (61104.62, 100565.90)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	62929.13 (51065.56, 77548.85)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	186	12607.06 (11261.61, 14113.25)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	186	2225.42 (1999.88, 2476.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	4959.53 (3028.68, 8121.32)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	202905.04 (140104.72, 293854.88)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	148786.45 (110215.28, 200856.09)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	32585.47 (26854.43, 39539.57)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	62	5509.77 (4611.24, 6583.39)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5.13 (4.88, 5.39)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5.39 (4.86, 5.98)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	1661.51 (979.36, 2818.79)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	58107.67 (37527.97, 89972.93)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	31887.56 (22577.71, 45036.32)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	7597.84 (6244.64, 9244.29)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	64	1218.73 (1027.05, 1446.19)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Sex						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	306	0.04 (0.04, 0.04)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	0.46 (0.46, 0.46)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	0.15 (0.15, 0.15)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	306	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	306	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.04 (0.04, 0.04)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.46 (0.46, 0.46)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.15 (0.15, 0.15)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	51	5.22 (4.81, 5.67)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	306	42.81 (31.52, 58.13)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	493.21 (389.71, 624.19)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	307.86 (250.35, 378.59)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	306	237.53 (206.70, 272.96)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	306	59.51 (53.34, 66.39)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	118.71 (74.65, 188.77)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	964.05 (676.43, 1373.95)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	449.00 (313.10, 643.88)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	508.62 (417.04, 620.31)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	90	108.09 (92.74, 125.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	51	5.24 (4.79, 5.72)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	51	5.18 (4.84, 5.55)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	101	21.48 (13.87, 33.27)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	101	253.73 (166.20, 387.35)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	101	143.79 (106.07, 194.92)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	101	135.78 (113.05, 163.06)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	101	40.92 (34.89, 47.98)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	306	508.79 (370.24, 699.18)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	22616.25 (17863.23, 28633.96)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	12911.06 (10212.26, 16323.08)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	306	8287.51 (7367.43, 9322.51)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	306	1545.47 (1382.32, 1727.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	1832.99 (1059.68, 3170.61)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	51676.07 (35098.76, 76082.93)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	37335.31 (25538.81, 54580.67)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	24353.26 (20077.79, 29539.17)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	90	4520.01 (3682.62, 5547.81)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	51	5.06 (4.94, 5.18)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	101	212.00 (113.30, 396.69)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	101	9578.82 (5979.12, 15345.71)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	101	5435.14 (3493.96, 8454.81)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	101	4218.45 (3435.30, 5180.14)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	101	915.82 (740.49, 1132.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	443	0.04 (0.04, 0.04)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	0.46 (0.46, 0.46)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	0.15 (0.15, 0.15)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	443	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	443	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.04 (0.04, 0.04)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.46 (0.46, 0.46)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.15 (0.15, 0.15)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.04 (0.04, 0.04)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.46 (0.46, 0.46)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.15 (0.15, 0.15)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.02 (4.98, 5.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	443	43.27 (34.49, 54.28)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	522.56 (430.73, 633.95)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	298.82 (252.25, 353.97)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	443	262.98 (235.81, 293.28)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	443	64.09 (58.42, 70.32)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	134	94.64 (64.61, 138.63)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	1668.37 (1261.61, 2206.27)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	676.46 (533.12, 858.33)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	134	481.52 (405.35, 572.00)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	134	109.37 (93.92, 127.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0.04 (0.04, 0.04)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.46 (0.46, 0.46)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.15 (0.15, 0.15)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	5.15 (4.92, 5.39)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	81	5.02 (4.98, 5.07)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	125	24.83 (14.62, 42.16)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	125	286.84 (182.47, 450.90)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	125	171.63 (112.39, 262.11)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	125	146.82 (115.07, 187.33)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	125	42.38 (34.55, 51.99)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	443	620.94 (466.25, 826.95)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	20411.45 (16364.80, 25458.74)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	14411.24 (11853.21, 17521.31)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	443	8229.37 (7350.92, 9212.80)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	443	1646.04 (1511.38, 1792.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	134	1755.59 (1084.77, 2841.26)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	61820.10 (45290.40, 84382.66)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	48651.79 (35860.32, 66006.03)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	134	23714.97 (19546.94, 28771.76)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	134	4851.27 (4228.08, 5566.32)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0.04 (0.04, 0.04)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.46 (0.46, 0.46)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.15 (0.15, 0.15)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	5.09 (4.99, 5.20)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	81	5.03 (4.97, 5.09)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	125	421.55 (205.54, 864.57)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	125	13644.57 (7448.32, 24995.50)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	125	7426.49 (4776.87, 11545.80)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	125	4169.79 (3205.80, 5423.64)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	125	976.73 (763.72, 1249.15)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, sex						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.04 (0.04, 0.04)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.46 (0.46, 0.46)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.15 (0.15, 0.15)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.04 (0.04, 0.04)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.46 (0.46, 0.46)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.15 (0.15, 0.15)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.04 (0.04, 0.04)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.46 (0.46, 0.46)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.15 (0.15, 0.15)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.04 (0.04, 0.04)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.46 (0.46, 0.46)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.15 (0.15, 0.15)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	205	33.30 (25.11, 44.16)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	389.12 (306.28, 494.35)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	221.03 (179.32, 272.44)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	205	238.48 (208.10, 273.30)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	205	60.08 (53.52, 67.43)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	77.35 (48.61, 123.08)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	1496.64 (1063.09, 2106.99)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	543.73 (409.56, 721.87)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	443.56 (358.87, 548.22)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73	101.97 (84.58, 122.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0.04 (0.04, 0.04)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.46 (0.46, 0.46)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.15 (0.15, 0.15)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5.16 (4.86, 5.48)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	16.20 (8.17, 32.11)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	192.42 (107.69, 343.81)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	115.34 (66.87, 198.95)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	119.34 (87.14, 163.45)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	57	35.05 (27.05, 45.41)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	205	451.38 (316.02, 644.72)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	14934.08 (11367.43, 19619.79)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	10341.18 (8130.61, 13152.76)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	205	7402.97 (6431.98, 8520.55)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	205	1539.64 (1385.20, 1711.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	1306.10 (725.65, 2350.86)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	46495.39 (32077.23, 67394.26)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	34668.65 (24176.92, 49713.34)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	21696.08 (17100.51, 27526.66)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	73	4612.91 (3899.89, 5456.29)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0.04 (0.04, 0.04)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.46 (0.46, 0.46)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.15 (0.15, 0.15)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	283.09 (110.47, 725.43)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	8665.45 (3942.60, 19045.79)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	4444.36 (2547.84, 7752.58)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	3420.95 (2432.62, 4810.81)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	57	882.20 (638.53, 1218.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	148	0.04 (0.04, 0.04)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	0.46 (0.46, 0.46)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	0.15 (0.15, 0.15)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.04 (0.04, 0.04)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.46 (0.46, 0.46)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.15 (0.15, 0.15)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.04 (0.04, 0.04)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.46 (0.46, 0.46)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.15 (0.15, 0.15)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.27 (4.76, 5.84)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	148	34.17 (23.48, 49.73)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	393.36 (296.00, 522.74)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	240.33 (187.27, 308.42)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	148	214.88 (181.28, 254.70)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	148	55.12 (48.24, 62.98)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	113.67 (65.58, 197.03)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	808.27 (533.48, 1224.61)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	352.42 (231.91, 535.55)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	492.14 (389.26, 622.21)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	50	104.01 (87.11, 124.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0.04 (0.04, 0.04)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.46 (0.46, 0.46)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.15 (0.15, 0.15)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	5.30 (4.75, 5.91)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	29	5.23 (4.80, 5.69)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	62	16.82 (10.16, 27.85)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	62	201.50 (123.46, 328.87)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	62	108.71 (77.56, 152.37)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	62	120.89 (98.19, 148.83)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	62	38.18 (31.76, 45.90)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	148	399.94 (272.24, 587.53)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	17049.87 (12862.70, 22600.09)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	9390.61 (7098.19, 12423.38)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	148	7585.15 (6584.65, 8737.68)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	148	1471.66 (1285.59, 1684.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	1543.35 (807.20, 2950.86)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	39310.43 (25194.35, 61335.57)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	28543.47 (18392.72, 44296.32)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	22599.18 (17999.75, 28373.89)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	50	4301.96 (3375.18, 5483.21)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	0.04 (0.04, 0.04)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.46 (0.46, 0.46)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.15 (0.15, 0.15)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	62	150.42 (72.82, 310.71)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	62	6982.09 (4073.51, 11967.46)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	62	3971.72 (2396.15, 6583.31)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	62	3731.68 (2943.89, 4730.28)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	62	870.48 (679.05, 1115.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	158	0.04 (0.04, 0.04)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	0.46 (0.46, 0.46)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	0.15 (0.15, 0.15)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	158	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	158	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	40	0.04 (0.04, 0.04)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	0.46 (0.46, 0.46)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	0.15 (0.15, 0.15)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.04 (0.04, 0.04)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.46 (0.46, 0.46)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.15 (0.15, 0.15)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	158	104.93 (82.58, 133.32)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	1212.46 (945.26, 1555.19)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	824.15 (683.12, 994.30)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	158	353.82 (314.63, 397.89)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	158	80.70 (72.50, 89.82)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	40	146.10 (86.77, 246.01)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	2242.06 (1507.18, 3335.26)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	1432.15 (977.58, 2098.11)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	40	595.51 (467.96, 757.82)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	40	129.96 (101.46, 166.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	22	0.04 (0.04, 0.04)
Age \geq 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.46 (0.46, 0.46)
Age \geq 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.15 (0.15, 0.15)
Age \geq 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	39	78.90 (45.74, 136.12)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	39	865.63 (566.06, 1323.72)
Age \geq 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	39	637.17 (422.00, 962.05)
Age \geq 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	39	251.99 (193.97, 327.37)
Age \geq 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	39	59.17 (48.73, 71.84)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	158	1325.10 (964.28, 1820.92)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	69553.89 (53566.43, 90312.96)
Age \geq 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	45789.92 (36498.55, 57446.59)
Age \geq 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	158	11785.71 (10206.83, 13608.82)
Age \geq 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	158	1877.49 (1642.87, 2145.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	40	4177.15 (2337.36, 7465.06)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	191486.76 (114054.40, 321488.52)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	135077.52 (86723.92, 210391.05)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	40	34836.13 (27717.41, 43783.15)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	40	5727.64 (4548.02, 7213.22)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	22	0.04 (0.04, 0.04)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.46 (0.46, 0.46)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.15 (0.15, 0.15)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	22	5.32 (4.72, 6.01)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	39	1317.92 (728.41, 2384.51)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	39	51580.07 (31805.27, 83649.79)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	39	28876.90 (18164.27, 45907.46)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	39	8103.34 (6787.51, 9674.27)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	39	1200.10 (969.41, 1485.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	238	0.04 (0.04, 0.04)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	0.46 (0.46, 0.46)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	0.15 (0.15, 0.15)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	238	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	238	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	44	0.04 (0.04, 0.04)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0.46 (0.46, 0.46)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0.15 (0.15, 0.15)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	44	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	44	5.09 (4.92, 5.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	238	109.74 (88.87, 135.51)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	1490.44 (1230.45, 1805.37)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	872.77 (741.73, 1026.96)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	238	372.31 (337.51, 410.69)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	238	80.67 (73.41, 88.66)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	198.73 (126.47, 312.27)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	2487.55 (1760.04, 3515.79)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	1510.23 (1116.59, 2042.64)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	651.27 (545.72, 777.24)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	61	141.51 (120.26, 166.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	44	0.04 (0.04, 0.04)
Age \geq 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0.46 (0.46, 0.46)
Age \geq 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0.15 (0.15, 0.15)
Age \geq 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	44	5.14 (4.87, 5.41)
Age \geq 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	44	5.09 (4.91, 5.28)
Age \geq 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	86.01 (56.88, 130.06)
Age \geq 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	916.31 (632.46, 1327.56)
Age \geq 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	545.42 (402.30, 739.45)
Age \geq 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	268.26 (222.40, 323.58)
Age \geq 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	68	73.63 (60.70, 89.32)
Age \geq 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	238	1929.23 (1469.37, 2533.00)
Age \geq 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	61974.87 (49386.39, 77772.14)
Age \geq 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	46884.45 (38612.59, 56928.37)
Age \geq 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	238	11987.78 (10732.16, 13390.29)
Age \geq 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	238	2087.33 (1892.57, 2302.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	5209.12 (3187.48, 8512.97)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	176230.81 (119070.06, 260832.14)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	169142.98 (123641.97, 231388.65)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	32894.07 (27496.96, 39350.52)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	61	5838.73 (4935.95, 6906.63)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	44	0.04 (0.04, 0.04)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0.46 (0.46, 0.46)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0.15 (0.15, 0.15)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	44	5.35 (4.96, 5.76)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	44	5.11 (4.89, 5.34)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	1342.49 (787.41, 2288.88)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	51115.56 (33123.53, 78880.50)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	33071.05 (22971.62, 47610.68)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	7416.59 (6119.50, 8988.60)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	68	1313.37 (1099.57, 1568.73)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino ethnicity						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	122	0.04 (0.04, 0.04)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	0.46 (0.46, 0.46)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	0.15 (0.15, 0.15)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	42	0.04 (0.04, 0.04)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	0.46 (0.46, 0.46)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	0.15 (0.15, 0.15)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.04 (0.04, 0.04)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.46 (0.46, 0.46)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.15 (0.15, 0.15)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	122	51.41 (31.86, 82.95)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	460.31 (328.17, 645.67)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	289.14 (213.10, 392.31)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	122	280.63 (226.69, 347.40)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	122	66.46 (56.22, 78.57)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	42	87.94 (43.76, 176.71)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	1473.72 (907.26, 2393.83)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	689.18 (453.58, 1047.15)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	42	445.42 (341.13, 581.59)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	42	123.31 (98.90, 153.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0.04 (0.04, 0.04)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.46 (0.46, 0.46)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.15 (0.15, 0.15)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	32	29.59 (14.63, 59.84)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	32	274.31 (136.91, 549.59)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	32	196.15 (117.29, 328.04)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	32	146.47 (108.33, 198.03)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	32	47.04 (34.09, 64.90)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	122	807.52 (493.05, 1322.56)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	20250.50 (13157.85, 31166.39)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	18385.99 (12954.05, 26095.66)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	122	9266.35 (7705.46, 11143.44)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	122	1561.22 (1331.87, 1830.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	42	2246.63 (955.99, 5279.72)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	63289.38 (39980.42, 100187.71)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	55118.85 (32914.84, 92301.46)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	42	24287.87 (18395.73, 32067.24)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	42	5699.07 (4785.57, 6786.94)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0.04 (0.04, 0.04)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.46 (0.46, 0.46)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.15 (0.15, 0.15)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	5.18 (4.83, 5.55)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	32	419.00 (120.30, 1459.32)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	32	18063.87 (8636.41, 37782.27)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	32	7534.49 (3706.57, 15315.63)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	32	4668.27 (3153.86, 6909.86)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	32	1172.49 (867.17, 1585.31)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	604	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	604	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	604	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	177	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	177	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	177	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	112	5.10 (4.90, 5.31)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	112	5.02 (4.98, 5.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	604	41.46 (33.92, 50.68)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	510.11 (432.41, 601.76)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	305.36 (264.33, 352.76)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	604	246.75 (224.49, 271.22)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	604	61.18 (56.59, 66.15)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	177	108.98 (77.95, 152.37)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	1270.55 (983.01, 1642.20)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	542.39 (428.48, 686.58)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	177	506.07 (436.03, 587.35)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	177	106.37 (94.04, 120.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	112	5.21 (4.95, 5.49)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	112	5.10 (4.93, 5.27)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	184	22.47 (15.28, 33.05)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	184	271.77 (191.37, 385.93)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	184	153.94 (114.59, 206.81)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	184	142.01 (119.32, 169.01)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	184	41.29 (35.70, 47.76)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	604	538.04 (425.25, 680.74)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	21517.43 (18044.93, 25658.17)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	13063.71 (11083.14, 15398.21)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	604	8097.92 (7395.37, 8867.20)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	604	1598.15 (1481.98, 1723.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	177	1701.66 (1134.98, 2551.27)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	56090.28 (42396.57, 74206.93)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	41053.83 (31500.20, 53504.97)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	177	23998.69 (20488.88, 28109.75)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	177	4516.36 (3926.49, 5194.86)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	112	5.04 (4.98, 5.10)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	112	5.05 (4.98, 5.12)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	184	292.03 (171.48, 497.32)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	184	11042.33 (7136.59, 17085.61)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	184	6373.04 (4499.18, 9027.35)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	184	4139.02 (3427.49, 4998.27)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	184	921.51 (764.15, 1111.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	23	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	10	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	10	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	10	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	23	77.37 (32.74, 182.80)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	827.82 (429.78, 1594.47)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	267.24 (146.93, 486.07)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	23	328.77 (215.05, 502.61)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	23	79.48 (53.61, 117.84)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	94.70 (14.07, 637.43)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	968.35 (146.10, 6418.28)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	276.38 (34.00, 2246.39)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	369.78 (154.73, 883.69)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	5	80.63 (45.92, 141.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	10	20.88 (3.50, 124.69)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	10	227.94 (128.13, 405.48)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	10	133.06 (64.26, 275.49)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	10	114.12 (65.93, 197.54)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	10	35.00 (23.87, 51.33)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	23	1010.96 (394.95, 2587.81)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	19019.53 (9531.12, 37953.81)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	24117.00 (14932.18, 38951.43)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	23	9712.42 (7065.67, 13350.63)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	23	2034.52 (1389.78, 2978.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	2446.51 (326.40, 18337.45)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	33784.88 (6129.24, 186225.13)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	37261.20 (9911.31, 140082.05)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	19861.66 (10860.17, 36324.06)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5	4382.30 (1567.66, 12250.47)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	10	231.96 (26.09, 2062.52)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	10	6909.41 (1628.69, 29311.85)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	10	3944.88 (1673.06, 9301.55)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	10	4024.87 (2896.84, 5592.15)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	10	891.47 (644.20, 1233.67)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Race						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	39.48 (30.54, 51.05)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	497.54 (405.24, 610.85)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	307.26 (254.79, 370.54)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	235.68 (208.62, 266.25)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	359	60.85 (55.49, 66.74)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	106	90.00 (57.79, 140.15)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	1241.95 (888.72, 1735.57)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	438.34 (321.05, 598.49)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	106	477.98 (391.21, 583.98)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	106	102.67 (87.22, 120.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.17 (4.85, 5.51)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.03 (4.98, 5.08)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	114	25.34 (15.92, 40.34)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	114	309.37 (205.71, 465.28)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	114	147.23 (104.74, 206.97)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	114	149.23 (120.60, 184.66)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	114	40.90 (33.87, 49.39)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	497.72 (369.31, 670.79)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	21506.39 (17275.13, 26774.02)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	11464.65 (9381.16, 14010.87)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	7879.81 (7061.06, 8793.49)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	359	1604.93 (1459.48, 1764.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	106	1424.84 (885.19, 2293.50)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	59505.71 (41439.47, 85448.23)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	37700.88 (26439.51, 53758.79)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	106	22982.81 (19438.98, 27172.70)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	106	4351.04 (3713.50, 5098.04)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.03 (4.98, 5.07)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.03 (4.97, 5.09)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	114	332.53 (182.33, 606.48)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	114	12191.15 (7328.44, 20280.45)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	114	6217.65 (4037.24, 9575.64)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	114	4179.42 (3288.18, 5312.24)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	114	1017.70 (813.39, 1273.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	41	0.04 (0.04, 0.04)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	0.46 (0.46, 0.46)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	0.15 (0.15, 0.15)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	41	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	172	52.36 (36.96, 74.19)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	581.22 (433.79, 778.75)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	289.23 (230.08, 363.59)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	172	287.52 (246.06, 335.96)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	172	67.43 (57.65, 78.88)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	41	181.80 (94.19, 350.91)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	1781.98 (1092.92, 2905.47)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	875.53 (562.24, 1363.40)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	41	594.95 (449.39, 787.65)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	41	126.60 (100.56, 159.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	5.44 (4.78, 6.20)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	15.57 (8.64, 28.06)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	254.10 (156.63, 412.22)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	164.76 (106.92, 253.88)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	129.72 (100.35, 167.67)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	56	40.02 (31.24, 51.26)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	172	740.47 (500.34, 1095.85)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	27084.48 (19598.89, 37429.12)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	17130.84 (12694.51, 23117.54)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	172	8792.10 (7578.00, 10200.72)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	172	1613.70 (1397.16, 1863.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	41	2716.15 (1383.55, 5332.27)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	66670.69 (34953.45, 127168.57)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	57419.01 (36096.35, 91337.28)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	41	31147.74 (22646.51, 42840.23)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	41	4781.44 (3554.50, 6431.90)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	234.33 (89.85, 611.13)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	11379.24 (6701.88, 19321.02)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	6000.89 (3571.69, 10082.24)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	4580.78 (3577.96, 5864.68)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	56	799.53 (571.93, 1117.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	24	0.04 (0.04, 0.04)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	0.46 (0.46, 0.46)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	0.15 (0.15, 0.15)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.04 (0.04, 0.04)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.46 (0.46, 0.46)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.15 (0.15, 0.15)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.04 (0.04, 0.04)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.46 (0.46, 0.46)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.15 (0.15, 0.15)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	68	40.37 (22.95, 71.01)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	567.04 (342.56, 938.63)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	343.28 (223.28, 527.75)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	68	254.55 (194.61, 332.95)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	68	59.37 (44.51, 79.18)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	24	80.91 (34.60, 189.19)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	653.30 (355.58, 1200.27)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	484.01 (280.87, 834.07)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	24	442.76 (336.38, 582.78)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	24	88.85 (67.37, 117.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	0.04 (0.04, 0.04)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.46 (0.46, 0.46)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.15 (0.15, 0.15)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	11	5.84 (4.48, 7.62)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	14	33.18 (13.39, 82.23)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	14	418.82 (219.88, 797.75)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	14	223.79 (116.10, 431.37)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	14	150.88 (100.80, 225.83)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	14	53.94 (39.62, 73.45)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	68	755.07 (395.03, 1443.27)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	16695.75 (9607.13, 29014.72)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	18514.02 (9999.05, 34280.18)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	68	7713.80 (5491.05, 10836.31)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	68	1549.11 (1331.25, 1802.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	24	678.16 (222.67, 2065.34)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	30346.00 (13844.52, 66515.83)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	32659.86 (14905.55, 71561.69)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24	18976.06 (12949.89, 27806.48)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	24	3662.46 (2665.57, 5032.16)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	0.04 (0.04, 0.04)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.46 (0.46, 0.46)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.15 (0.15, 0.15)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	5.23 (4.77, 5.74)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	14	412.33 (112.29, 1514.03)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	14	21635.28 (10414.62, 44945.04)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	14	8176.53 (4263.60, 15680.56)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	14	4751.37 (3585.98, 6295.51)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	14	1047.51 (718.23, 1527.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	42.86 (10.88, 168.77)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	471.45 (148.24, 1499.30)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	247.17 (107.67, 567.43)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	250.28 (137.27, 456.30)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	17	53.86 (33.44, 86.74)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	182.84 (37.69, 886.88)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	2783.86 (689.78, 11235.23)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	1278.50 (456.46, 3580.90)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	735.41 (313.77, 1723.65)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	7	114.18 (78.62, 165.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	8	64.97 (22.43, 188.21)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	8	746.30 (319.91, 1740.98)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	8	585.25 (274.15, 1249.36)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	8	272.27 (189.97, 390.21)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	8	57.13 (40.83, 79.94)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	243.78 (58.10, 1022.93)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	13992.49 (4673.73, 41891.55)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	14133.90 (5955.19, 33545.01)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	7463.71 (4049.75, 13755.68)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	17	1510.87 (1015.53, 2247.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	3009.35 (767.75, 11795.78)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	100104.52 (12472.39, 803447.77)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	85374.36 (32747.77, 222573.38)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	18232.76 (7720.59, 43058.05)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	7	5300.80 (3521.38, 7979.40)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	7.38 (3.75, 14.52)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	8	1380.36 (502.83, 3789.31)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	8	22315.64 (8557.34, 58194.23)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8	17148.38 (11231.12, 26183.23)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	8	6666.98 (4423.15, 10049.09)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	8	1129.92 (836.57, 1526.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	13	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	13	35.11 (15.23, 80.93)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	348.25 (192.96, 628.54)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	248.82 (140.20, 441.60)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	13	249.90 (171.91, 363.29)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	13	50.74 (38.38, 67.08)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	40.37 (5.08, 321.00)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	783.51 (403.85, 1520.08)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	464.42 (46.09, 4680.05)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	384.18 (236.91, 622.99)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	2	119.70 (39.55, 362.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	158.33 (64.02, 391.55)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	312.48 (77.79, 1255.20)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	331.32 (110.53, 993.16)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	237.82 (119.06, 475.04)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	3	57.63 (48.18, 68.93)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	13	280.59 (99.86, 788.43)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	15591.79 (5846.05, 41584.30)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	18579.06 (6537.48, 52800.37)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	13	6029.57 (4549.30, 7991.49)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	13	1398.46 (1094.26, 1787.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	7771.15 (620.66, 97300.21)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	16356.82 (850.38, 314617.66)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	120765.87 (40414.87, 360867.02)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	43658.14 (24258.44, 78571.97)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	2	4592.19 (4438.79, 4750.89)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	8230.63 (1967.51, 34430.89)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	114704.18 (51998.52, 253027.37)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	15155.35 (4194.31, 54761.04)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	6950.85 (5380.65, 8979.27)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	3	884.45 (587.82, 1330.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.04 (0.04, 0.04)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.46 (0.46, 0.46)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.15 (0.15, 0.15)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	19	0.04 (0.04, 0.04)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	0.46 (0.46, 0.46)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	0.15 (0.15, 0.15)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	93.83 (44.99, 195.67)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	756.24 (380.07, 1504.72)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	427.49 (236.95, 771.25)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	338.60 (231.50, 495.25)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	59	73.05 (53.03, 100.63)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	18	205.71 (86.65, 488.40)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	1476.91 (926.72, 2353.74)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	702.76 (357.80, 1380.31)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	18	593.70 (364.28, 967.60)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	18	145.38 (100.25, 210.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	19	14.25 (2.92, 69.47)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	19	102.97 (25.12, 422.03)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	19	118.17 (28.93, 482.73)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	19	98.77 (54.81, 178.00)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	19	35.73 (22.89, 55.77)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	1320.84 (464.45, 3756.30)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	21977.91 (10749.96, 44933.05)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	21174.05 (10901.48, 41126.57)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	11953.93 (8267.49, 17284.13)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	59	1936.75 (1362.78, 2752.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	18	6646.75 (1855.75, 23806.68)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	78764.94 (46691.57, 132870.15)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	58528.22 (30292.12, 113083.94)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	18	34766.43 (17704.88, 68269.60)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	18	6821.06 (3879.49, 11993.06)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	5.27 (4.75, 5.84)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	19	175.26 (14.66, 2095.36)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	19	4114.14 (668.82, 25307.51)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	19	4030.46 (1037.70, 15654.44)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	19	2976.98 (1474.53, 6010.31)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	19	781.92 (389.87, 1568.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	28	0.04 (0.04, 0.04)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	0.46 (0.46, 0.46)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	0.15 (0.15, 0.15)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.04 (0.04, 0.04)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.46 (0.46, 0.46)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.15 (0.15, 0.15)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	28	16.70 (6.17, 45.21)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	196.33 (106.25, 362.77)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	152.14 (81.05, 285.61)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	28	194.26 (127.00, 297.15)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	28	52.50 (35.25, 78.17)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	159.60 (45.35, 561.68)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	3390.80 (818.37, 14049.34)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	1105.02 (850.46, 1435.77)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	621.80 (381.83, 1012.59)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	5	97.00 (70.20, 134.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	6	32.72 (7.54, 141.96)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	6	234.74 (42.32, 1301.89)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	6	160.16 (46.35, 553.38)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	6	124.38 (48.62, 318.16)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	6	55.99 (29.22, 107.28)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	28	285.93 (114.33, 715.10)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	11546.93 (4426.09, 30123.97)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	12839.98 (5858.62, 28140.57)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	28	7390.14 (5138.46, 10628.52)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	28	1244.63 (843.99, 1835.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	9159.82 (1419.66, 59100.20)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	35578.75 (15837.10, 79929.27)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	59904.33 (27625.49, 129899.20)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	18917.31 (9322.55, 38386.96)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5	7123.09 (6048.50, 8388.60)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	6	92.16 (9.82, 864.68)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	6	2633.83 (88.80, 78121.14)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6	34177.32 (16267.50, 71805.10)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	6	3479.40 (1777.16, 6812.11)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	6	822.10 (441.02, 1532.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.04 (0.04, 0.04)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.46 (0.46, 0.46)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.15 (0.15, 0.15)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	5	23.64 (6.62, 84.37)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	210.29 (57.32, 771.50)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	178.23 (95.65, 332.09)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	5	193.74 (101.58, 369.54)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	5	43.04 (29.69, 62.38)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	2	25.60 (6.23, 105.12)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	871.79 (303.82, 2501.56)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	173.46 (129.65, 232.07)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	2	323.00 (208.88, 499.46)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	2	153.78 (119.71, 197.54)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	0.04 (0.04, 0.04)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.46 (0.46, 0.46)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.15 (0.15, 0.15)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	5	230.30 (55.80, 950.44)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	9359.08 (4262.70, 20548.56)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	8776.70 (3630.49, 21217.65)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	5	9575.89 (6457.54, 14200.10)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	5	1298.08 (943.68, 1785.56)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2	1439.73 (1322.27, 1567.61)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	112274.20 (91802.55, 137310.97)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	26194.80 (4078.69, 168232.56)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2	8733.94 (4603.81, 16569.26)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	2	3188.31 (2812.81, 3613.95)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	0.04 (0.04, 0.04)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.46 (0.46, 0.46)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.15 (0.15, 0.15)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Underrepresented minority status						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	390	0.04 (0.04, 0.04)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	0.46 (0.46, 0.46)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	0.15 (0.15, 0.15)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	390	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	390	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	118	0.04 (0.04, 0.04)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	0.46 (0.46, 0.46)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	0.15 (0.15, 0.15)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	118	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	118	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	390	48.57 (37.58, 62.76)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	527.65 (425.91, 653.70)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	296.28 (249.25, 352.19)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	390	276.22 (245.55, 310.71)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	390	63.91 (57.20, 71.40)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	118	120.53 (80.31, 180.89)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	1354.03 (992.00, 1848.20)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	701.74 (541.83, 908.83)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	118	508.30 (427.49, 604.39)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	118	114.62 (99.35, 132.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.21 (4.88, 5.57)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.18 (4.85, 5.52)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	112	20.44 (12.30, 33.97)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	112	224.71 (141.39, 357.11)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	112	172.70 (114.46, 260.58)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	112	131.26 (106.12, 162.34)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	112	42.73 (36.17, 50.48)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	390	689.90 (512.96, 927.88)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	21049.49 (16596.30, 26697.59)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	17694.42 (14199.42, 22049.67)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	390	8798.94 (7782.49, 9948.14)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	390	1600.06 (1454.00, 1760.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	118	2200.69 (1283.82, 3772.38)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	54780.82 (39160.42, 76631.91)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	48694.65 (35503.52, 66786.88)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	118	24964.55 (20108.06, 30993.99)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	118	5034.15 (4224.62, 5998.80)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.09 (4.96, 5.22)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.94, 5.18)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	112	264.78 (120.65, 581.09)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	112	10602.00 (5876.24, 19128.28)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	112	6615.17 (4294.54, 10189.79)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	112	4212.40 (3363.76, 5275.13)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	112	857.62 (679.77, 1081.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	39.48 (30.54, 51.05)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	497.54 (405.24, 610.85)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	307.26 (254.79, 370.54)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	235.68 (208.62, 266.25)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	359	60.85 (55.49, 66.74)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	106	90.00 (57.79, 140.15)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	1241.95 (888.72, 1735.57)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	438.34 (321.05, 598.49)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	106	477.98 (391.21, 583.98)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	106	102.67 (87.22, 120.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.17 (4.85, 5.51)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.03 (4.98, 5.08)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	114	25.34 (15.92, 40.34)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	114	309.37 (205.71, 465.28)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	114	147.23 (104.74, 206.97)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	114	149.23 (120.60, 184.66)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	114	40.90 (33.87, 49.39)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	497.72 (369.31, 670.79)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	21506.39 (17275.13, 26774.02)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	11464.65 (9381.16, 14010.87)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	7879.81 (7061.06, 8793.49)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	359	1604.93 (1459.48, 1764.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	106	1424.84 (885.19, 2293.50)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	59505.71 (41439.47, 85448.23)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	37700.88 (26439.51, 53758.79)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	106	22982.81 (19438.98, 27172.70)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	106	4351.04 (3713.50, 5098.04)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.03 (4.98, 5.07)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.03 (4.97, 5.09)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	114	332.53 (182.33, 606.48)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	114	12191.15 (7328.44, 20280.45)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	114	6217.65 (4037.24, 9575.64)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	114	4179.42 (3288.18, 5312.24)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	114	1017.70 (813.39, 1273.33)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Underrepresented minority status						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	181	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	181	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	181	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	71	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	71	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	71	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	181	36.73 (26.65, 50.63)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	400.48 (306.08, 524.00)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	214.36 (173.26, 265.21)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	181	248.55 (214.50, 288.01)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	181	59.03 (51.36, 67.85)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	71	111.21 (69.34, 178.36)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	1222.28 (854.36, 1748.63)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	610.00 (453.37, 820.73)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	71	494.65 (404.66, 604.66)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	71	110.30 (93.65, 129.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	5.22 (4.80, 5.67)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	34	5.24 (4.80, 5.71)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	14.36 (7.89, 26.16)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	154.14 (90.20, 263.43)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	121.78 (75.27, 197.02)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	108.97 (85.45, 138.96)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	61	38.04 (31.20, 46.37)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	181	519.14 (357.83, 753.17)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	14244.97 (10665.51, 19025.74)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	13006.94 (9876.97, 17128.80)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	181	7910.62 (6782.34, 9226.60)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	181	1446.91 (1284.18, 1630.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	71	1858.36 (994.18, 3473.72)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	43415.32 (29720.43, 63420.69)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	40128.75 (27997.11, 57517.25)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	71	23833.49 (18541.21, 30636.36)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	71	4859.37 (3964.39, 5956.39)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	164.94 (64.72, 420.32)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	6952.24 (3487.02, 13861.00)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	4466.48 (2673.13, 7462.94)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	3597.37 (2765.38, 4679.66)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	61	781.92 (591.39, 1033.85)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	52	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.20 (4.82, 5.62)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	172	31.68 (23.12, 43.41)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	384.39 (299.73, 492.95)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	239.94 (191.02, 301.40)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	172	214.83 (184.95, 249.53)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	172	57.13 (51.06, 63.93)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	52	73.87 (42.23, 129.21)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	1008.74 (661.72, 1537.77)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	299.56 (205.75, 436.16)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	52	432.17 (334.90, 557.68)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	52	94.48 (76.96, 115.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	5.22 (4.80, 5.66)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	18.35 (10.28, 32.77)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	237.11 (142.35, 394.96)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	104.95 (69.01, 159.60)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	129.31 (99.10, 168.72)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	58	35.60 (28.21, 44.93)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	172	375.00 (260.72, 539.37)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	16991.73 (13028.72, 22160.20)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	8216.25 (6448.57, 10468.49)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	172	7193.83 (6298.02, 8217.05)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	172	1556.05 (1386.98, 1745.73)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	52	1005.71 (554.44, 1824.26)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	42452.46 (27166.86, 66338.60)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	23605.20 (15352.37, 36294.42)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	52	20158.67 (16341.77, 24867.09)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	52	4020.63 (3294.37, 4907.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	240.00 (112.74, 510.91)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	8413.91 (4458.11, 15879.83)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	3999.42 (2350.38, 6805.43)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	3563.34 (2637.53, 4814.14)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	58	954.56 (719.83, 1265.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	47	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	209	124.28 (99.94, 154.55)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	1334.65 (1092.59, 1630.34)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	880.38 (750.27, 1033.06)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	209	393.99 (353.85, 438.69)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	209	83.47 (75.42, 92.38)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	47	188.19 (119.58, 296.17)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	2386.78 (1661.91, 3427.82)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	1524.38 (1111.41, 2090.79)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	47	591.01 (480.01, 727.67)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	47	141.82 (114.54, 175.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	5.20 (4.81, 5.62)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	87.64 (49.18, 156.20)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	1063.66 (646.90, 1748.92)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	729.80 (501.18, 1062.72)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	282.80 (215.17, 371.70)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	51	69.03 (56.08, 84.96)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	209	1796.28 (1361.07, 2370.65)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	78320.72 (61837.98, 99196.88)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	49843.03 (41010.26, 60578.20)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	209	12588.04 (11185.36, 14166.62)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	209	2244.75 (2023.36, 2490.37)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	47	5612.57 (3191.90, 9869.03)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	198521.66 (125720.70, 313479.41)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	142151.08 (97042.61, 208227.37)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	47	32271.72 (25411.06, 40984.68)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	47	6122.13 (5013.80, 7475.45)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	5.37 (4.87, 5.92)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	32	5.24 (4.78, 5.73)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	1865.39 (879.93, 3954.51)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	60440.97 (35843.63, 101917.97)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	33431.24 (22289.33, 50142.71)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	8077.35 (6401.68, 10191.62)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	51	1255.53 (1000.09, 1576.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	187	0.04 (0.04, 0.04)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	0.46 (0.46, 0.46)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	0.15 (0.15, 0.15)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.04 (0.04, 0.04)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.46 (0.46, 0.46)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.15 (0.15, 0.15)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.11 (4.90, 5.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	187	95.72 (76.29, 120.09)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	1404.56 (1122.25, 1757.87)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	830.79 (692.35, 996.91)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	187	342.10 (308.10, 379.86)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	187	78.43 (71.04, 86.59)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	167.20 (102.51, 272.71)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	2384.59 (1654.84, 3436.14)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	1446.77 (1033.24, 2025.82)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	655.62 (539.10, 797.32)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	54	133.28 (110.90, 160.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	34	5.11 (4.89, 5.34)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	56	80.61 (54.45, 119.34)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	56	802.75 (576.18, 1118.41)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	56	495.50 (360.62, 680.82)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56	249.45 (208.86, 297.94)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	56	67.23 (55.39, 81.60)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	187	1554.37 (1147.51, 2105.50)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	55483.60 (43451.36, 70847.72)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	43785.44 (35271.46, 54354.55)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	187	11366.28 (10008.83, 12907.82)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	187	1817.55 (1617.96, 2041.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	4249.40 (2566.31, 7036.34)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	171621.13 (111895.62, 263225.79)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	163747.94 (115297.41, 232558.46)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	34674.42 (29133.01, 41269.87)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	54	5574.16 (4628.94, 6712.39)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	5.11 (4.90, 5.34)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	34	5.14 (4.87, 5.42)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	56	1070.22 (690.39, 1659.02)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	56	46056.25 (30384.72, 69810.68)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	56	30233.41 (20381.15, 44848.27)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	56	7402.23 (6245.64, 8772.99)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	56	1280.36 (1078.44, 1520.09)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
All participants								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	749	0.04 (0.04, 0.04)	43.07 (35.88, 51.71)	1050.57 (875.11, 1261.21)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	0.46 (0.46, 0.46)	509.98 (439.60, 591.63)	1097.09 (945.68, 1272.74)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	0.15 (0.15, 0.15)	302.60 (265.80, 344.49)	1967.47 (1728.19, 2239.87)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	749	5.00 (5.00, 5.00)	251.94 (231.24, 274.49)	50.39 (46.25, 54.90)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	749	5.00 (5.00, 5.00)	62.12 (57.88, 66.67)	12.42 (11.58, 13.33)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	224	0.04 (0.04, 0.04)	104.93 (77.54, 141.98)	2559.16 (1891.22, 3462.99)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	0.46 (0.46, 0.46)	1299.63 (1037.04, 1628.70)	2795.80 (2230.91, 3503.72)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	0.15 (0.15, 0.15)	561.28 (456.56, 690.02)	3649.44 (2968.55, 4486.51)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)	493.68 (432.71, 563.23)	98.74 (86.54, 112.65)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)	108.79 (97.67, 121.17)	21.76 (19.53, 24.23)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	132	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	132	5.09 (4.92, 5.27)	5.19 (4.95, 5.43)	1.02 (0.96, 1.08)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	132	5.01 (4.99, 5.04)	5.09 (4.94, 5.24)	1.01 (0.99, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	226	0.04 (0.04, 0.04)	23.14 (16.43, 32.60)	564.45 (400.69, 795.15)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	226	0.46 (0.46, 0.46)	270.27 (198.78, 367.46)	581.40 (427.62, 790.49)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	226	0.15 (0.15, 0.15)	157.50 (121.73, 203.80)	1024.08 (791.46, 1325.07)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)	141.35 (121.40, 164.59)	28.27 (24.28, 32.92)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)	41.66 (36.61, 47.41)	8.33 (7.32, 9.48)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	749	0.04 (0.04, 0.04)	570.94 (461.75, 705.94)	13925.31 (11262.30, 17217.99)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	749	0.46 (0.46, 0.46)	21313.15 (18157.78, 25016.84)	45849.52 (39061.59, 53817.01)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	749	0.15 (0.15, 0.15)	13758.85 (11869.43, 15949.02)	89459.35 (77174.47, 103699.77)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	749	5.00 (5.00, 5.00)	8253.83 (7607.43, 8955.14)	1650.77 (1521.49, 1791.03)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	749	5.00 (5.00, 5.00)	1602.88 (1497.22, 1715.99)	320.58 (299.44, 343.20)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	224	0.04 (0.04, 0.04)	1790.43 (1245.27, 2574.24)	43668.91 (30372.47, 62786.25)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	224	0.46 (0.46, 0.46)	56974.62 (44687.72, 72639.80)	122565.60 (96133.63, 156265.03)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	224	0.15 (0.15, 0.15)	43125.84 (34123.09, 54503.80)	280402.10 (221866.66, 354381.03)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)	24003.54 (20902.14, 27565.12)	4800.71 (4180.43, 5513.02)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)	4697.51 (4168.96, 5293.07)	939.50 (833.79, 1058.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	132	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	132	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	132	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	132	5.09 (4.92, 5.27)	5.05 (4.99, 5.11)	0.99 (0.96, 1.03)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	132	5.01 (4.99, 5.04)	5.04 (4.98, 5.10)	1.01 (0.99, 1.02)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	226	0.04 (0.04, 0.04)	302.00 (186.90, 487.98)	7365.93 (4558.64, 11902.01)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	226	0.46 (0.46, 0.46)	11492.32 (7839.54, 16847.11)	24722.65 (16864.66, 36242.03)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	226	0.15 (0.15, 0.15)	6382.66 (4697.19, 8672.91)	41499.74 (30540.93, 56390.83)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)	4193.33 (3551.23, 4951.52)	838.67 (710.25, 990.30)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)	946.69 (803.89, 1114.85)	189.34 (160.78, 222.97)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	353	0.04 (0.04, 0.04)	33.67 (26.81, 42.27)	821.17 (654.02, 1031.04)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	0.46 (0.46, 0.46)	390.92 (325.39, 469.66)	840.97 (699.99, 1010.34)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	0.15 (0.15, 0.15)	229.08 (195.08, 269.00)	1489.45 (1268.42, 1748.99)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	353	5.00 (5.00, 5.00)	228.10 (204.99, 253.80)	45.62 (41.00, 50.76)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	353	5.00 (5.00, 5.00)	57.90 (53.05, 63.20)	11.58 (10.61, 12.64)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)	92.62 (64.23, 133.56)	2259.01 (1566.61, 3257.45)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)	1121.72 (854.30, 1472.86)	2413.09 (1837.80, 3168.45)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)	443.85 (346.45, 568.64)	2885.92 (2252.62, 3697.26)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	465.67 (396.90, 546.36)	93.13 (79.38, 109.27)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	102.92 (90.44, 117.13)	20.58 (18.09, 23.43)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.12 (4.89, 5.35)	5.22 (4.91, 5.54)	1.02 (0.94, 1.10)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.10 (4.91, 5.29)	1.02 (0.98, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	119	0.04 (0.04, 0.04)	16.52 (10.84, 25.17)	402.86 (264.37, 613.89)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	0.46 (0.46, 0.46)	197.05 (135.01, 287.61)	423.90 (290.43, 618.72)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	0.15 (0.15, 0.15)	111.87 (81.64, 153.31)	727.39 (530.80, 996.80)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	120.14 (99.70, 144.77)	24.03 (19.94, 28.95)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	36.63 (31.28, 42.89)	7.33 (6.26, 8.58)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	353	0.04 (0.04, 0.04)	428.64 (329.49, 557.62)	10454.62 (8036.42, 13600.48)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	353	0.46 (0.46, 0.46)	15803.76 (12971.51, 19254.42)	33997.55 (27904.71, 41420.71)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	353	0.15 (0.15, 0.15)	9923.86 (8268.09, 11911.22)	64524.46 (53758.72, 77446.16)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	353	5.00 (5.00, 5.00)	7480.26 (6764.17, 8272.15)	1496.05 (1352.83, 1654.43)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	353	5.00 (5.00, 5.00)	1510.22 (1388.84, 1642.21)	302.04 (277.77, 328.44)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)	1412.22 (909.12, 2193.75)	34444.50 (22173.66, 53506.01)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)	42982.14 (32187.37, 57397.20)	92464.55 (69242.48, 123474.66)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)	31653.33 (23910.26, 41903.91)	205808.41 (155463.35, 272457.14)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	22114.19 (18694.67, 26159.19)	4422.84 (3738.93, 5231.84)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	4464.66 (3864.51, 5158.02)	892.93 (772.90, 1031.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.12 (4.89, 5.35)	5.00 (5.00, 5.00)	0.98 (0.93, 1.02)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	119	0.04 (0.04, 0.04)	204.27 (112.76, 370.04)	4982.26 (2750.34, 9025.42)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	119	0.46 (0.46, 0.46)	7751.46 (4835.02, 12427.08)	16675.19 (10401.25, 26733.53)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	119	0.15 (0.15, 0.15)	4193.83 (2882.65, 6101.41)	27268.09 (18742.85, 39671.07)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	3577.93 (2913.36, 4394.08)	715.59 (582.67, 878.82)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	876.13 (715.13, 1073.38)	175.23 (143.03, 214.68)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	396	0.04 (0.04, 0.04)	107.79 (91.99, 126.30)	2629.01 (2243.65, 3080.56)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	0.46 (0.46, 0.46)	1372.32 (1178.18, 1598.45)	2952.18 (2534.54, 3438.63)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	0.15 (0.15, 0.15)	852.99 (754.08, 964.87)	5546.09 (4902.98, 6273.56)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	396	5.00 (5.00, 5.00)	364.80 (338.35, 393.31)	72.96 (67.67, 78.66)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	396	5.00 (5.00, 5.00)	80.68 (75.15, 86.62)	16.14 (15.03, 17.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)	175.55 (124.58, 247.36)	4281.64 (3038.56, 6033.28)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)	2385.49 (1836.56, 3098.49)	5131.74 (3950.87, 6665.58)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)	1478.25 (1166.20, 1873.79)	9611.51 (7582.59, 12183.31)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)	628.19 (544.13, 725.24)	125.64 (108.83, 145.05)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)	136.73 (118.93, 157.20)	27.35 (23.79, 31.44)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.09 (4.92, 5.27)	1.02 (0.98, 1.05)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.95, 5.17)	5.06 (4.94, 5.19)	1.00 (0.97, 1.03)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	107	0.04 (0.04, 0.04)	83.32 (59.92, 115.86)	2032.24 (1461.52, 2825.81)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	107	0.46 (0.46, 0.46)	897.31 (677.16, 1189.05)	1930.33 (1456.72, 2557.92)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	107	0.15 (0.15, 0.15)	577.55 (451.71, 738.44)	3755.18 (2936.99, 4801.31)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	262.15 (225.01, 305.42)	52.43 (45.00, 61.08)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	67.94 (58.88, 78.39)	13.59 (11.78, 15.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	396	0.04 (0.04, 0.04)	1660.08 (1348.16, 2044.16)	40489.65 (32881.89, 49857.58)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	396	0.46 (0.46, 0.46)	64902.03 (54667.76, 77052.25)	139619.30 (117603.01, 165757.23)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	396	0.15 (0.15, 0.15)	46443.53 (40069.32, 53831.73)	301973.51 (260528.75, 350011.28)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	396	5.00 (5.00, 5.00)	11906.53 (10905.08, 12999.96)	2381.31 (2181.02, 2599.99)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	396	5.00 (5.00, 5.00)	2000.72 (1847.92, 2166.15)	400.14 (369.58, 433.23)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)	4765.44 (3268.92, 6947.08)	116230.29 (79729.74, 169440.92)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)	182230.11 (133129.63, 249439.69)	392019.18 (286392.67, 536602.55)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)	154480.14 (119203.38, 200196.61)	1004422.22 (775054.48, 1301668.49)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)	33663.74 (29201.96, 38807.23)	6732.75 (5840.39, 7761.45)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)	5793.68 (5052.80, 6643.20)	1158.74 (1010.56, 1328.64)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.23 (4.97, 5.50)	1.05 (0.99, 1.10)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.06 (4.95, 5.17)	5.18 (4.93, 5.45)	1.02 (0.97, 1.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	107	0.04 (0.04, 0.04)	1333.39 (892.57, 1991.92)	32521.75 (21770.08, 48583.39)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	107	0.46 (0.46, 0.46)	51286.07 (36987.41, 71112.34)	110328.22 (79568.49, 152979.12)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	107	0.15 (0.15, 0.15)	31460.53 (23599.98, 41939.22)	204554.80 (153445.92, 272686.73)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	7662.36 (6672.78, 8798.69)	1532.47 (1334.56, 1759.74)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	1270.48 (1107.46, 1457.49)	254.10 (221.49, 291.50)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Risk for Severe Covid-19								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	379	0.04 (0.04, 0.04)	47.63 (39.65, 57.23)	1161.82 (967.00, 1395.90)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	0.46 (0.46, 0.46)	536.69 (453.76, 634.78)	1154.55 (976.14, 1365.57)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	0.15 (0.15, 0.15)	360.67 (313.82, 414.53)	2345.09 (2040.41, 2695.25)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	379	5.00 (5.00, 5.00)	260.65 (239.38, 283.80)	52.13 (47.88, 56.76)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	379	5.00 (5.00, 5.00)	63.75 (58.83, 69.09)	12.75 (11.77, 13.82)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	99	0.04 (0.04, 0.04)	106.44 (74.25, 152.57)	2596.03 (1811.05, 3721.25)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	0.46 (0.46, 0.46)	1138.23 (843.79, 1535.41)	2448.60 (1815.20, 3303.02)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	0.15 (0.15, 0.15)	609.49 (452.25, 821.39)	3962.86 (2940.53, 5340.61)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	99	5.00 (5.00, 5.00)	495.10 (421.30, 581.83)	99.02 (84.26, 116.37)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	99	5.00 (5.00, 5.00)	112.96 (96.74, 131.90)	22.59 (19.35, 26.38)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.07 (4.93, 5.21)	1.01 (0.99, 1.04)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.05 (4.96, 5.13)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	103	0.04 (0.04, 0.04)	23.85 (16.37, 34.74)	581.61 (399.23, 847.32)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	103	0.46 (0.46, 0.46)	328.27 (237.52, 453.70)	706.19 (510.96, 976.01)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	103	0.15 (0.15, 0.15)	186.87 (139.95, 249.53)	1215.03 (909.92, 1622.45)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	103	5.00 (5.00, 5.00)	152.45 (129.23, 179.85)	30.49 (25.85, 35.97)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	103	5.00 (5.00, 5.00)	47.57 (40.57, 55.78)	9.51 (8.11, 11.16)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	379	0.04 (0.04, 0.04)	788.33 (628.28, 989.15)	19227.48 (15323.82, 24125.57)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	379	0.46 (0.46, 0.46)	25218.56 (20861.91, 30485.03)	54250.97 (44878.79, 65580.37)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	379	0.15 (0.15, 0.15)	14665.26 (12316.35, 17462.16)	95352.82 (80080.27, 113538.07)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	379	5.00 (5.00, 5.00)	8505.34 (7687.07, 9410.71)	1701.07 (1537.41, 1882.14)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	379	5.00 (5.00, 5.00)	1579.79 (1455.42, 1714.78)	315.96 (291.08, 342.96)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	99	0.04 (0.04, 0.04)	2191.39 (1415.51, 3392.54)	53448.46 (34524.61, 82744.97)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	99	0.46 (0.46, 0.46)	57248.83 (39324.67, 83342.81)	123155.49 (84596.48, 179289.68)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	99	0.15 (0.15, 0.15)	52396.96 (36673.08, 74862.57)	340682.45 (238446.58, 486752.76)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	99	5.00 (5.00, 5.00)	25589.17 (21385.56, 30619.05)	5117.83 (4277.11, 6123.81)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	99	5.00 (5.00, 5.00)	4605.30 (3926.30, 5401.73)	921.06 (785.26, 1080.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.13 (4.95, 5.31)	1.03 (0.99, 1.06)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.05 (4.96, 5.13)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	103	0.04 (0.04, 0.04)	274.00 (178.04, 421.70)	6682.99 (4342.37, 10285.26)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	103	0.46 (0.46, 0.46)	13055.30 (9073.92, 18783.61)	28084.98 (19520.10, 40407.90)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	103	0.15 (0.15, 0.15)	8504.90 (6092.45, 11872.62)	55298.47 (39612.83, 77195.20)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	103	5.00 (5.00, 5.00)	4779.69 (4093.32, 5581.16)	955.94 (818.66, 1116.23)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	103	5.00 (5.00, 5.00)	1016.94 (865.76, 1194.51)	203.39 (173.15, 238.90)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	370	0.04 (0.04, 0.04)	41.47 (32.54, 52.85)	1011.44 (793.64, 1289.01)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	0.46 (0.46, 0.46)	500.26 (411.49, 608.18)	1076.17 (885.20, 1308.33)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	0.15 (0.15, 0.15)	283.21 (238.52, 336.27)	1841.42 (1550.87, 2186.39)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	370	5.00 (5.00, 5.00)	248.73 (221.97, 278.72)	49.75 (44.39, 55.74)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	370	5.00 (5.00, 5.00)	61.51 (56.07, 67.48)	12.30 (11.21, 13.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)	104.44 (71.16, 153.27)	2547.26 (1735.64, 3738.41)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)	1356.98 (1022.09, 1801.60)	2919.18 (2198.76, 3875.65)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)	546.42 (422.51, 706.67)	3552.82 (2747.15, 4594.75)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)	493.21 (417.45, 582.73)	98.64 (83.49, 116.55)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)	107.46 (94.00, 122.84)	21.49 (18.80, 24.57)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.13 (4.88, 5.39)	5.24 (4.91, 5.59)	1.02 (0.94, 1.11)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.13 (4.92, 5.35)	1.03 (0.98, 1.07)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)	22.93 (14.88, 35.35)	559.37 (362.90, 862.22)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)	254.87 (172.76, 375.99)	548.28 (371.65, 808.84)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)	149.58 (108.03, 207.12)	972.59 (702.44, 1346.66)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	138.17 (113.99, 167.46)	27.63 (22.80, 33.49)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	40.03 (34.05, 47.05)	8.01 (6.81, 9.41)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	370	0.04 (0.04, 0.04)	505.53 (382.04, 668.94)	12330.00 (9318.04, 16315.54)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	370	0.46 (0.46, 0.46)	20002.76 (16219.13, 24669.05)	43030.58 (34891.10, 53068.85)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	370	0.15 (0.15, 0.15)	13431.75 (11065.89, 16303.43)	87332.60 (71949.88, 106004.12)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	370	5.00 (5.00, 5.00)	8160.92 (7341.30, 9072.04)	1632.18 (1468.26, 1814.41)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	370	5.00 (5.00, 5.00)	1611.68 (1474.81, 1761.25)	322.34 (294.96, 352.25)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)	1676.39 (1057.90, 2656.46)	40887.44 (25802.39, 64791.80)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)	56885.60 (42170.77, 76734.93)	122374.09 (90719.09, 165074.60)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)	40475.81 (30296.14, 54075.90)	263171.69 (196983.98, 351598.84)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)	23508.65 (19753.35, 27977.87)	4701.73 (3950.67, 5595.57)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)	4727.93 (4071.07, 5490.78)	945.59 (814.21, 1098.16)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.13 (4.88, 5.39)	5.02 (4.98, 5.06)	0.98 (0.93, 1.03)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.06 (4.98, 5.15)	1.01 (1.00, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	123	0.04 (0.04, 0.04)	311.00 (168.65, 573.51)	7585.38 (4113.37, 13988.04)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	123	0.46 (0.46, 0.46)	11058.57 (6794.47, 17998.77)	23789.55 (14616.47, 38719.53)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	123	0.15 (0.15, 0.15)	5853.12 (3970.26, 8628.91)	38056.71 (25814.45, 56104.73)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	4030.96 (3261.88, 4981.38)	806.19 (652.38, 996.28)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	926.46 (752.98, 1139.91)	185.29 (150.60, 227.98)

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Risk for Severe Covid-19								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	169	0.04 (0.04, 0.04)	28.66 (21.95, 37.40)	698.91 (535.45, 912.26)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	0.46 (0.46, 0.46)	310.14 (245.07, 392.48)	667.17 (527.20, 844.31)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	0.15 (0.15, 0.15)	208.18 (171.26, 253.07)	1353.59 (1113.52, 1645.42)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	169	5.00 (5.00, 5.00)	218.22 (192.88, 246.88)	43.64 (38.58, 49.38)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	169	5.00 (5.00, 5.00)	55.81 (49.56, 62.85)	11.16 (9.91, 12.57)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)	74.86 (48.78, 114.87)	1825.84 (1189.85, 2801.78)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)	780.80 (540.54, 1127.84)	1679.68 (1162.83, 2426.26)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)	409.69 (283.87, 591.26)	2663.77 (1845.73, 3844.36)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	415.91 (340.53, 507.97)	83.18 (68.11, 101.59)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	99.66 (81.87, 121.30)	19.93 (16.37, 24.26)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)	12.85 (8.04, 20.54)	313.44 (196.07, 501.06)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)	199.36 (133.22, 298.33)	428.86 (286.59, 641.77)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)	101.06 (70.68, 144.51)	657.10 (459.53, 939.61)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	115.12 (93.76, 141.33)	23.02 (18.75, 28.27)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	37.45 (30.69, 45.72)	7.49 (6.14, 9.14)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	169	0.04 (0.04, 0.04)	517.19 (372.31, 718.46)	12614.51 (9080.70, 17523.51)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	169	0.46 (0.46, 0.46)	14819.22 (11316.43, 19406.23)	31879.57 (24344.27, 41747.29)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	169	0.15 (0.15, 0.15)	8024.85 (6241.95, 10317.00)	52177.17 (40584.85, 67080.62)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	169	5.00 (5.00, 5.00)	6995.80 (6065.33, 8069.01)	1399.16 (1213.07, 1613.80)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	169	5.00 (5.00, 5.00)	1434.80 (1281.45, 1606.50)	286.96 (256.29, 321.30)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)	1574.27 (890.19, 2784.07)	38396.93 (21711.83, 67904.19)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)	36161.42 (22715.38, 57566.66)	77791.59 (48866.03, 123839.22)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)	30982.72 (19829.43, 48409.31)	201448.15 (128930.00, 314754.95)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	22038.60 (17325.51, 28033.81)	4407.72 (3465.10, 5606.76)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	3999.22 (3250.75, 4920.03)	799.84 (650.15, 984.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.04 (0.04, 0.04)	136.92 (79.51, 235.78)	3339.53 (1939.34, 5750.66)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.46 (0.46, 0.46)	6781.74 (4298.65, 10699.16)	14589.09 (9247.40, 23016.37)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.15 (0.15, 0.15)	4158.58 (2849.46, 6069.16)	27038.91 (18527.04, 39461.37)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	3651.05 (2981.32, 4471.23)	730.21 (596.26, 894.25)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	867.67 (702.90, 1071.05)	173.53 (140.58, 214.21)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)	35.11 (26.58, 46.37)	856.26 (648.31, 1130.91)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)	415.13 (332.20, 518.78)	893.05 (714.63, 1116.01)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)	234.84 (193.06, 285.65)	1526.89 (1255.28, 1857.27)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)	230.73 (202.48, 262.93)	46.15 (40.50, 52.59)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)	58.46 (52.59, 64.99)	11.69 (10.52, 13.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.04 (0.04, 0.04)	97.97 (62.56, 153.42)	2389.57 (1525.92, 3742.04)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.46 (0.46, 0.46)	1234.28 (887.43, 1716.69)	2655.22 (1909.07, 3692.99)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.15 (0.15, 0.15)	453.34 (336.59, 610.58)	2947.58 (2188.49, 3969.96)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	479.77 (394.81, 583.01)	95.95 (78.96, 116.60)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	103.80 (88.90, 121.20)	20.76 (17.78, 24.24)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.15 (4.86, 5.47)	5.28 (4.89, 5.71)	1.03 (0.93, 1.13)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)	5.13 (4.88, 5.39)	1.03 (0.98, 1.08)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)	17.51 (10.54, 29.07)	426.99 (257.10, 709.14)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)	196.52 (124.51, 310.17)	422.76 (267.86, 667.25)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)	114.54 (78.40, 167.35)	744.73 (509.72, 1088.10)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	121.33 (96.91, 151.91)	24.27 (19.38, 30.38)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	36.44 (30.17, 44.02)	7.29 (6.03, 8.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)	408.25 (296.40, 562.30)	9957.20 (7229.26, 13714.54)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)	16069.84 (12657.39, 20402.28)	34569.94 (27228.98, 43890.04)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)	10486.35 (8411.64, 13072.79)	68181.74 (54692.07, 84998.61)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)	7611.40 (6742.55, 8592.21)	1522.28 (1348.51, 1718.44)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)	1530.44 (1382.90, 1693.72)	306.09 (276.58, 338.74)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.04 (0.04, 0.04)	1372.31 (802.96, 2345.38)	33471.01 (19584.34, 57204.30)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.46 (0.46, 0.46)	44987.70 (31884.97, 63474.82)	96778.95 (68591.96, 136549.04)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.15 (0.15, 0.15)	31832.73 (22783.88, 44475.43)	206974.85 (148139.65, 289177.06)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	22134.18 (18074.96, 27105.02)	4426.84 (3614.99, 5421.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	4596.29 (3862.21, 5469.90)	919.26 (772.44, 1093.98)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.15 (4.86, 5.47)	5.00 (5.00, 5.00)	0.97 (0.91, 1.03)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)	224.13 (109.00, 460.83)	5466.52 (2658.66, 11239.83)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)	7995.43 (4513.85, 14162.38)	17200.02 (9710.33, 30466.57)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)	4202.05 (2670.15, 6612.81)	27321.51 (17361.19, 42996.18)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	3561.18 (2777.01, 4566.79)	712.24 (555.40, 913.36)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	878.11 (687.08, 1122.25)	175.62 (137.42, 224.45)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	210	0.04 (0.04, 0.04)	99.95 (80.72, 123.76)	2437.81 (1968.79, 3018.56)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	0.46 (0.46, 0.46)	1194.09 (968.01, 1472.96)	2568.76 (2082.42, 3168.67)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	0.15 (0.15, 0.15)	803.81 (680.81, 949.02)	5226.30 (4426.60, 6170.48)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	210	5.00 (5.00, 5.00)	337.73 (304.82, 374.20)	67.55 (60.96, 74.84)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	210	5.00 (5.00, 5.00)	77.42 (70.60, 84.89)	15.48 (14.12, 16.98)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)	228.12 (122.64, 424.32)	5563.95 (2991.25, 10349.36)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)	2575.10 (1644.37, 4032.62)	5539.63 (3537.42, 8675.10)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)	1440.91 (930.92, 2230.27)	9368.70 (6052.81, 14501.12)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	722.21 (565.32, 922.64)	144.44 (113.06, 184.53)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	148.20 (117.80, 186.44)	29.64 (23.56, 37.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.00 (5.00, 5.00)	5.17 (4.84, 5.53)	1.03 (0.97, 1.11)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.11 (4.90, 5.33)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	43	0.04 (0.04, 0.04)	72.54 (42.91, 122.63)	1769.36 (1046.66, 2991.07)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	0.46 (0.46, 0.46)	805.47 (504.67, 1285.56)	1732.76 (1085.67, 2765.53)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	0.15 (0.15, 0.15)	564.92 (395.66, 806.59)	3673.08 (2572.54, 5244.44)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	43	5.00 (5.00, 5.00)	252.75 (200.68, 318.34)	50.55 (40.14, 63.67)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	43	5.00 (5.00, 5.00)	73.16 (58.26, 91.87)	14.63 (11.65, 18.37)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	210	0.04 (0.04, 0.04)	1457.59 (1105.15, 1922.43)	35551.05 (26954.93, 46888.52)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	210	0.46 (0.46, 0.46)	54754.00 (43287.94, 69257.18)	117788.53 (93122.38, 148988.23)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	210	0.15 (0.15, 0.15)	35328.80 (28909.66, 43173.26)	229706.14 (187969.19, 280710.43)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	210	5.00 (5.00, 5.00)	11309.10 (9909.35, 12906.58)	2261.82 (1981.87, 2581.32)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	210	5.00 (5.00, 5.00)	1817.86 (1620.23, 2039.61)	363.57 (324.05, 407.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)	4485.89 (2499.82, 8049.86)	109411.91 (60971.20, 196338.03)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)	154860.47 (89078.89, 269219.42)	333140.74 (191629.31, 579153.33)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)	163519.98 (102447.32, 261000.32)	1063198.84 (666107.44, 1697011.20)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	35364.94 (28852.23, 43347.74)	7072.99 (5770.45, 8669.55)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	6251.73 (5057.67, 7727.69)	1250.35 (1011.53, 1545.54)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	35	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	35	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	35	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	35	5.00 (5.00, 5.00)	5.32 (4.89, 5.79)	1.06 (0.98, 1.16)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	35	5.11 (4.90, 5.33)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	43	0.04 (0.04, 0.04)	954.95 (524.94, 1737.21)	23291.41 (12803.35, 42370.94)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	43	0.46 (0.46, 0.46)	42433.21 (26242.87, 68612.03)	91283.65 (56454.50, 147600.37)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	43	0.15 (0.15, 0.15)	30823.45 (18710.02, 50779.47)	200412.54 (121651.65, 330165.59)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	43	5.00 (5.00, 5.00)	7761.30 (6479.54, 9296.61)	1552.26 (1295.91, 1859.32)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	43	5.00 (5.00, 5.00)	1353.22 (1078.40, 1698.06)	270.64 (215.68, 339.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	186	0.04 (0.04, 0.04)	117.22 (92.60, 148.38)	2858.97 (2258.60, 3618.92)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	0.46 (0.46, 0.46)	1601.60 (1285.26, 1995.80)	3445.41 (2764.88, 4293.43)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	0.15 (0.15, 0.15)	911.14 (758.75, 1094.14)	5924.21 (4933.36, 7114.07)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	186	5.00 (5.00, 5.00)	397.40 (356.10, 443.49)	79.48 (71.22, 88.70)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	186	5.00 (5.00, 5.00)	84.47 (75.74, 94.21)	16.89 (15.15, 18.84)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)	147.66 (100.04, 217.96)	3601.48 (2439.91, 5316.04)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)	2268.01 (1652.51, 3112.75)	4879.01 (3554.93, 6696.25)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)	1503.44 (1150.43, 1964.77)	9775.29 (7480.03, 12774.85)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	572.91 (482.58, 680.16)	114.58 (96.52, 136.03)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	129.65 (108.96, 154.27)	25.93 (21.79, 30.85)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.13 (4.88, 5.40)	1.03 (0.98, 1.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.04 (0.04, 0.04)	91.29 (59.85, 139.23)	2226.50 (1459.80, 3395.86)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.46 (0.46, 0.46)	963.50 (678.73, 1367.75)	2072.70 (1460.10, 2942.34)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.15 (0.15, 0.15)	586.02 (419.87, 817.92)	3810.29 (2729.99, 5318.09)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	268.54 (219.28, 328.86)	53.71 (43.86, 65.77)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	64.70 (53.88, 77.69)	12.94 (10.78, 15.54)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	186	0.04 (0.04, 0.04)	1918.06 (1403.10, 2622.03)	46782.07 (34221.99, 63951.93)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	186	0.46 (0.46, 0.46)	78390.31 (61104.62, 100565.90)	168635.72 (131450.19, 216340.55)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	186	0.15 (0.15, 0.15)	62929.13 (51065.56, 77548.85)	409162.07 (332025.72, 504218.78)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	186	5.00 (5.00, 5.00)	12607.06 (11261.61, 14113.25)	2521.41 (2252.32, 2822.65)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	186	5.00 (5.00, 5.00)	2225.42 (1999.88, 2476.38)	445.08 (399.98, 495.28)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)	4959.53 (3028.68, 8121.32)	120964.08 (73870.33, 198080.99)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)	202905.04 (140104.72, 293854.88)	436495.73 (301397.70, 632149.90)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)	148786.45 (110215.28, 200856.09)	967402.18 (716614.27, 1305956.36)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	32585.47 (26854.43, 39539.57)	6517.09 (5370.89, 7907.91)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	5509.77 (4611.24, 6583.39)	1101.95 (922.25, 1316.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)	5.13 (4.88, 5.39)	1.03 (0.98, 1.08)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.39 (4.86, 5.98)	1.08 (0.97, 1.20)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.04 (0.04, 0.04)	1661.51 (979.36, 2818.79)	40524.61 (23886.81, 68751.10)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.46 (0.46, 0.46)	58107.67 (37527.97, 89972.93)	125003.06 (80731.35, 193552.61)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.15 (0.15, 0.15)	31887.56 (22577.71, 45036.32)	207331.37 (146799.14, 292823.91)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	7597.84 (6244.64, 9244.29)	1519.57 (1248.93, 1848.86)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	1218.73 (1027.05, 1446.19)	243.75 (205.41, 289.24)



Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Sex								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	306	0.04 (0.04, 0.04)	42.81 (31.52, 58.13)	1044.13 (768.88, 1417.92)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	0.46 (0.46, 0.46)	493.21 (389.71, 624.19)	1061.00 (838.36, 1342.77)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	0.15 (0.15, 0.15)	307.86 (250.35, 378.59)	2001.72 (1627.77, 2461.57)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	306	5.00 (5.00, 5.00)	237.53 (206.70, 272.96)	47.51 (41.34, 54.59)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	306	5.00 (5.00, 5.00)	59.51 (53.34, 66.39)	11.90 (10.67, 13.28)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.04 (0.04, 0.04)	118.71 (74.65, 188.77)	2895.27 (1820.70, 4604.04)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.46 (0.46, 0.46)	964.05 (676.43, 1373.95)	2073.89 (1455.16, 2955.68)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.15 (0.15, 0.15)	449.00 (313.10, 643.88)	2919.39 (2035.79, 4186.50)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)	508.62 (417.04, 620.31)	101.72 (83.41, 124.06)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)	108.09 (92.74, 125.99)	21.62 (18.55, 25.20)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	51	5.22 (4.81, 5.67)	5.24 (4.79, 5.72)	1.00 (0.88, 1.14)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	5.18 (4.84, 5.55)	1.04 (0.97, 1.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)	21.48 (13.87, 33.27)	523.84 (338.21, 811.36)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)	253.73 (166.20, 387.35)	545.83 (357.54, 833.29)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)	143.79 (106.07, 194.92)	934.89 (689.64, 1267.35)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)	135.78 (113.05, 163.06)	27.16 (22.61, 32.61)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)	40.92 (34.89, 47.98)	8.18 (6.98, 9.60)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	306	0.04 (0.04, 0.04)	508.79 (370.24, 699.18)	12409.50 (9030.33, 17053.15)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	306	0.46 (0.46, 0.46)	22616.25 (17863.23, 28633.96)	48652.80 (38427.94, 61598.28)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	306	0.15 (0.15, 0.15)	12911.06 (10212.26, 16323.08)	83947.09 (66399.61, 106131.84)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	306	5.00 (5.00, 5.00)	8287.51 (7367.43, 9322.51)	1657.50 (1473.49, 1864.50)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	306	5.00 (5.00, 5.00)	1545.47 (1382.32, 1727.88)	309.09 (276.46, 345.58)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.04 (0.04, 0.04)	1832.99 (1059.68, 3170.61)	44707.03 (25845.97, 77331.93)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.46 (0.46, 0.46)	51676.07 (35098.76, 76082.93)	111167.20 (75505.56, 163672.01)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.15 (0.15, 0.15)	37335.31 (25538.81, 54580.67)	242752.35 (166052.11, 354880.79)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)	24353.26 (20077.79, 29539.17)	4870.65 (4015.56, 5907.83)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)	4520.01 (3682.62, 5547.81)	904.00 (736.52, 1109.56)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	51	5.22 (4.81, 5.67)	5.00 (5.00, 5.00)	0.96 (0.88, 1.04)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	5.06 (4.94, 5.18)	1.01 (0.99, 1.04)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	101	0.04 (0.04, 0.04)	212.00 (113.30, 396.69)	5170.85 (2763.46, 9675.47)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	101	0.46 (0.46, 0.46)	9578.82 (5979.12, 15345.71)	20606.27 (12862.48, 33012.18)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	101	0.15 (0.15, 0.15)	5435.14 (3493.96, 8454.81)	35339.01 (22717.53, 54972.77)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	101	5.00 (5.00, 5.00)	4218.45 (3435.30, 5180.14)	843.69 (687.06, 1036.03)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	101	5.00 (5.00, 5.00)	915.82 (740.49, 1132.67)	183.16 (148.10, 226.53)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	443	0.04 (0.04, 0.04)	43.27 (34.49, 54.28)	1055.29 (841.21, 1323.84)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	0.46 (0.46, 0.46)	522.56 (430.73, 633.95)	1124.14 (926.61, 1363.78)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	0.15 (0.15, 0.15)	298.82 (252.25, 353.97)	1942.89 (1640.15, 2301.52)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	443	5.00 (5.00, 5.00)	262.98 (235.81, 293.28)	52.60 (47.16, 58.66)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	443	5.00 (5.00, 5.00)	64.09 (58.42, 70.32)	12.82 (11.68, 14.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.04 (0.04, 0.04)	94.64 (64.61, 138.63)	2308.25 (1575.73, 3381.31)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.46 (0.46, 0.46)	1668.37 (1261.61, 2206.27)	3589.05 (2714.02, 4746.19)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.15 (0.15, 0.15)	676.46 (533.12, 858.33)	4398.28 (3466.32, 5580.80)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)	481.52 (405.35, 572.00)	96.30 (81.07, 114.40)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)	109.37 (93.92, 127.36)	21.87 (18.78, 25.47)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.00 (5.00, 5.00)	5.15 (4.92, 5.39)	1.03 (0.98, 1.08)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.02 (4.98, 5.07)	5.02 (4.98, 5.07)	1.00 (0.99, 1.01)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)	24.83 (14.62, 42.16)	605.60 (356.68, 1028.24)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)	286.84 (182.47, 450.90)	617.05 (392.53, 970.00)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)	171.63 (112.39, 262.11)	1115.93 (730.73, 1704.20)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)	146.82 (115.07, 187.33)	29.36 (23.01, 37.47)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)	42.38 (34.55, 51.99)	8.48 (6.91, 10.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	443	0.04 (0.04, 0.04)	620.94 (466.25, 826.95)	15144.78 (11371.90, 20169.40)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	443	0.46 (0.46, 0.46)	20411.45 (16364.80, 25458.74)	43909.75 (35204.47, 54767.65)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	443	0.15 (0.15, 0.15)	14411.24 (11853.21, 17521.31)	93701.16 (77068.98, 113922.72)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	443	5.00 (5.00, 5.00)	8229.37 (7350.92, 9212.80)	1645.87 (1470.18, 1842.56)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	443	5.00 (5.00, 5.00)	1646.04 (1511.38, 1792.68)	329.21 (302.28, 358.54)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.04 (0.04, 0.04)	1755.59 (1084.77, 2841.26)	42819.36 (26457.81, 69298.91)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.46 (0.46, 0.46)	61820.10 (45290.40, 84382.66)	132989.35 (97430.14, 181526.65)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.15 (0.15, 0.15)	48651.79 (35860.32, 66006.03)	316331.56 (233162.00, 429167.93)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)	23714.97 (19546.94, 28771.76)	4742.99 (3909.39, 5754.35)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)	4851.27 (4228.08, 5566.32)	970.25 (845.62, 1113.26)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.00 (5.00, 5.00)	5.09 (4.99, 5.20)	1.02 (1.00, 1.04)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.02 (4.98, 5.07)	5.03 (4.97, 5.09)	1.00 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.04 (0.04, 0.04)	421.55 (205.54, 864.57)	10281.74 (5013.22, 21087.08)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.46 (0.46, 0.46)	13644.57 (7448.32, 24995.50)	29352.64 (16023.05, 53771.11)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.15 (0.15, 0.15)	7426.49 (4776.87, 11545.80)	48286.68 (31058.97, 75070.22)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.00 (5.00, 5.00)	4169.79 (3205.80, 5423.64)	833.96 (641.16, 1084.73)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.00 (5.00, 5.00)	976.73 (763.72, 1249.15)	195.35 (152.74, 249.83)

Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, sex								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.04 (0.04, 0.04)	33.30 (25.11, 44.16)	812.19 (612.41, 1077.13)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.46 (0.46, 0.46)	389.12 (306.28, 494.35)	837.08 (658.88, 1063.47)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.15 (0.15, 0.15)	221.03 (179.32, 272.44)	1437.12 (1165.91, 1771.41)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.00 (5.00, 5.00)	238.48 (208.10, 273.30)	47.70 (41.62, 54.66)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.00 (5.00, 5.00)	60.08 (53.52, 67.43)	12.02 (10.70, 13.49)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.04 (0.04, 0.04)	77.35 (48.61, 123.08)	1886.54 (1185.60, 3001.87)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.46 (0.46, 0.46)	1496.64 (1063.09, 2106.99)	3219.61 (2286.95, 4532.63)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.15 (0.15, 0.15)	543.73 (409.56, 721.87)	3535.32 (2662.91, 4693.55)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	443.56 (358.87, 548.22)	88.71 (71.77, 109.64)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	101.97 (84.58, 122.93)	20.39 (16.92, 24.59)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)	5.16 (4.86, 5.48)	1.03 (0.97, 1.10)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.04 (0.04, 0.04)	16.20 (8.17, 32.11)	395.10 (199.33, 783.18)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.46 (0.46, 0.46)	192.42 (107.69, 343.81)	413.94 (231.67, 739.62)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.15 (0.15, 0.15)	115.34 (66.87, 198.95)	749.95 (434.79, 1293.54)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	119.34 (87.14, 163.45)	23.87 (17.43, 32.69)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	35.05 (27.05, 45.41)	7.01 (5.41, 9.08)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.04 (0.04, 0.04)	451.38 (316.02, 644.72)	11009.20 (7707.72, 15724.84)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.46 (0.46, 0.46)	14934.08 (11367.43, 19619.79)	32126.66 (24453.98, 42206.72)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.15 (0.15, 0.15)	10341.18 (8130.61, 13152.76)	67237.85 (52864.85, 85518.60)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.00 (5.00, 5.00)	7402.97 (6431.98, 8520.55)	1480.59 (1286.40, 1704.11)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.00 (5.00, 5.00)	1539.64 (1385.20, 1711.30)	307.93 (277.04, 342.26)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.04 (0.04, 0.04)	1306.10 (725.65, 2350.86)	31856.04 (17698.71, 57337.94)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.46 (0.46, 0.46)	46495.39 (32077.23, 67394.26)	100022.34 (69005.55, 144980.66)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.15 (0.15, 0.15)	34668.65 (24176.92, 49713.34)	225413.87 (157197.15, 323233.68)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	21696.08 (17100.51, 27526.66)	4339.22 (3420.10, 5505.33)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	4612.91 (3899.89, 5456.29)	922.58 (779.98, 1091.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.04 (0.04, 0.04)	283.09 (110.47, 725.43)	6904.67 (2694.47, 17693.44)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.46 (0.46, 0.46)	8665.45 (3942.60, 19045.79)	18641.39 (8481.46, 40971.90)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.15 (0.15, 0.15)	4444.36 (2547.84, 7752.58)	28897.03 (16565.96, 50406.90)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	3420.95 (2432.62, 4810.81)	684.19 (486.52, 962.16)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	882.20 (638.53, 1218.86)	176.44 (127.71, 243.77)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	148	0.04 (0.04, 0.04)	34.17 (23.48, 49.73)	833.37 (572.61, 1212.89)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	0.46 (0.46, 0.46)	393.36 (296.00, 522.74)	846.21 (636.77, 1124.54)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	0.15 (0.15, 0.15)	240.33 (187.27, 308.42)	1562.63 (1217.65, 2005.35)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	214.88 (181.28, 254.70)	42.98 (36.26, 50.94)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	55.12 (48.24, 62.98)	11.02 (9.65, 12.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.04 (0.04, 0.04)	113.67 (65.58, 197.03)	2772.40 (1599.44, 4805.57)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.46 (0.46, 0.46)	808.27 (533.48, 1224.61)	1738.78 (1147.64, 2634.42)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.15 (0.15, 0.15)	352.42 (231.91, 535.55)	2291.42 (1507.87, 3482.15)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	492.14 (389.26, 622.21)	98.43 (77.85, 124.44)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	104.01 (87.11, 124.19)	20.80 (17.42, 24.84)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.27 (4.76, 5.84)	5.30 (4.75, 5.91)	1.00 (0.86, 1.18)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	5.23 (4.80, 5.69)	1.05 (0.96, 1.14)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)	16.82 (10.16, 27.85)	410.27 (247.81, 679.21)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)	201.50 (123.46, 328.87)	433.47 (265.58, 707.48)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)	108.71 (77.56, 152.37)	706.85 (504.32, 990.71)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	120.89 (98.19, 148.83)	24.18 (19.64, 29.77)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	38.18 (31.76, 45.90)	7.64 (6.35, 9.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	148	0.04 (0.04, 0.04)	399.94 (272.24, 587.53)	9754.60 (6640.11, 14329.93)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	148	0.46 (0.46, 0.46)	17049.87 (12862.70, 22600.09)	36678.23 (27670.65, 48618.03)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	148	0.15 (0.15, 0.15)	9390.61 (7098.19, 12423.38)	61057.28 (46152.09, 80776.21)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	7585.15 (6584.65, 8737.68)	1517.03 (1316.93, 1747.54)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	1471.66 (1285.59, 1684.65)	294.33 (257.12, 336.93)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.04 (0.04, 0.04)	1543.35 (807.20, 2950.86)	37642.64 (19687.74, 71972.13)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.46 (0.46, 0.46)	39310.43 (25194.35, 61335.57)	84565.84 (54198.88, 131947.02)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.15 (0.15, 0.15)	28543.47 (18392.72, 44296.32)	185588.22 (119588.53, 288012.47)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	22599.18 (17999.75, 28373.89)	4519.84 (3599.95, 5674.78)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	4301.96 (3375.18, 5483.21)	860.39 (675.04, 1096.64)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.27 (4.76, 5.84)	5.00 (5.00, 5.00)	0.95 (0.86, 1.05)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	62	0.04 (0.04, 0.04)	150.42 (72.82, 310.71)	3668.77 (1776.14, 7578.17)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	62	0.46 (0.46, 0.46)	6982.09 (4073.51, 11967.46)	15020.10 (8763.07, 25744.78)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	62	0.15 (0.15, 0.15)	3971.72 (2396.15, 6583.31)	25823.95 (15579.64, 42804.37)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	3731.68 (2943.89, 4730.28)	746.34 (588.78, 946.06)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	870.48 (679.05, 1115.87)	174.10 (135.81, 223.17)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	158	0.04 (0.04, 0.04)	104.93 (82.58, 133.32)	2559.22 (2014.19, 3251.74)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	0.46 (0.46, 0.46)	1212.46 (945.26, 1555.19)	2608.28 (2033.46, 3345.58)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	0.15 (0.15, 0.15)	824.15 (683.12, 994.30)	5358.61 (4441.63, 6464.91)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	158	5.00 (5.00, 5.00)	353.82 (314.63, 397.89)	70.76 (62.93, 79.58)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	158	5.00 (5.00, 5.00)	80.70 (72.50, 89.82)	16.14 (14.50, 17.96)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	40	0.04 (0.04, 0.04)	146.10 (86.77, 246.01)	3563.52 (2116.38, 6000.18)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	0.46 (0.46, 0.46)	2242.06 (1507.18, 3335.26)	4823.19 (3242.29, 7174.92)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	0.15 (0.15, 0.15)	1432.15 (977.58, 2098.11)	9311.79 (6356.15, 13641.83)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	595.51 (467.96, 757.82)	119.10 (93.59, 151.56)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	129.96 (101.46, 166.47)	25.99 (20.29, 33.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)	78.90 (45.74, 136.12)	1924.46 (1115.51, 3320.05)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)	865.63 (566.06, 1323.72)	1862.16 (1217.73, 2847.64)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)	637.17 (422.00, 962.05)	4142.83 (2743.80, 6255.21)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	251.99 (193.97, 327.37)	50.40 (38.79, 65.47)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	59.17 (48.73, 71.84)	11.83 (9.75, 14.37)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	158	0.04 (0.04, 0.04)	1325.10 (964.28, 1820.92)	32319.43 (23519.13, 44412.60)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	158	0.46 (0.46, 0.46)	69553.89 (53566.43, 90312.96)	149626.51 (115233.79, 194284.10)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	158	0.15 (0.15, 0.15)	45789.92 (36498.55, 57446.59)	297723.83 (237311.77, 373514.87)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	158	5.00 (5.00, 5.00)	11785.71 (10206.83, 13608.82)	2357.14 (2041.37, 2721.76)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	158	5.00 (5.00, 5.00)	1877.49 (1642.87, 2145.62)	375.50 (328.57, 429.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	40	0.04 (0.04, 0.04)	4177.15 (2337.36, 7465.06)	101881.63 (57008.85, 182074.64)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	40	0.46 (0.46, 0.46)	191486.76 (114054.40, 321488.52)	411932.37 (245357.42, 691596.26)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	40	0.15 (0.15, 0.15)	135077.52 (86723.92, 210391.05)	878267.35 (563874.63, 1367952.19)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	34836.13 (27717.41, 43783.15)	6967.23 (5543.48, 8756.63)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5727.64 (4548.02, 7213.22)	1145.53 (909.60, 1442.64)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	5.32 (4.72, 6.01)	1.06 (0.94, 1.20)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	39	0.04 (0.04, 0.04)	1317.92 (728.41, 2384.51)	32144.34 (17766.19, 58158.72)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	39	0.46 (0.46, 0.46)	51580.07 (31805.27, 83649.79)	110960.68 (68420.50, 179950.06)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	39	0.15 (0.15, 0.15)	28876.90 (18164.27, 45907.46)	187756.21 (118103.20, 298488.04)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	8103.34 (6787.51, 9674.27)	1620.67 (1357.50, 1934.85)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	1200.10 (969.41, 1485.68)	240.02 (193.88, 297.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	238	0.04 (0.04, 0.04)	109.74 (88.87, 135.51)	2676.59 (2167.52, 3305.22)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	0.46 (0.46, 0.46)	1490.44 (1230.45, 1805.37)	3206.29 (2646.99, 3883.77)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	0.15 (0.15, 0.15)	872.77 (741.73, 1026.96)	5674.71 (4822.72, 6677.23)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	238	5.00 (5.00, 5.00)	372.31 (337.51, 410.69)	74.46 (67.50, 82.14)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	238	5.00 (5.00, 5.00)	80.67 (73.41, 88.66)	16.13 (14.68, 17.73)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)	198.73 (126.47, 312.27)	4847.06 (3084.69, 7616.32)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)	2487.55 (1760.04, 3515.79)	5351.30 (3786.25, 7563.28)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)	1510.23 (1116.59, 2042.64)	9819.44 (7260.04, 13281.12)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	651.27 (545.72, 777.24)	130.25 (109.14, 155.45)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	141.51 (120.26, 166.51)	28.30 (24.05, 33.30)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5.00 (5.00, 5.00)	5.14 (4.87, 5.41)	1.03 (0.97, 1.08)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5.09 (4.92, 5.26)	5.09 (4.91, 5.28)	1.00 (0.95, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)	86.01 (56.88, 130.06)	2097.80 (1387.26, 3172.27)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)	916.31 (632.46, 1327.56)	1971.19 (1360.56, 2855.88)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)	545.42 (402.30, 739.45)	3546.28 (2615.74, 4807.87)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)	268.26 (222.40, 323.58)	53.65 (44.48, 64.72)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)	73.63 (60.70, 89.32)	14.73 (12.14, 17.86)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	238	0.04 (0.04, 0.04)	1929.23 (1469.37, 2533.00)	47054.31 (35838.32, 61780.47)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	238	0.46 (0.46, 0.46)	61974.87 (49386.39, 77772.14)	133322.30 (106241.55, 167305.88)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	238	0.15 (0.15, 0.15)	46884.45 (38612.59, 56928.37)	304840.36 (251057.13, 370145.43)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	238	5.00 (5.00, 5.00)	11987.78 (10732.16, 13390.29)	2397.56 (2146.43, 2678.06)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	238	5.00 (5.00, 5.00)	2087.33 (1892.57, 2302.15)	417.47 (378.51, 460.43)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)	5209.12 (3187.48, 8512.97)	127051.66 (77743.40, 207633.40)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)	176230.81 (119070.06, 260832.14)	379113.29 (256147.28, 561110.34)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)	169142.98 (123641.97, 231388.65)	1099759.30 (803913.95, 1504477.59)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	32894.07 (27496.96, 39350.52)	6578.81 (5499.39, 7870.10)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	5838.73 (4935.95, 6906.63)	1167.75 (987.19, 1381.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	44	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	44	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	44	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	44	5.00 (5.00, 5.00)	5.35 (4.96, 5.76)	1.07 (0.99, 1.15)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	44	5.09 (4.92, 5.26)	5.11 (4.89, 5.34)	1.01 (0.95, 1.06)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)	1342.49 (787.41, 2288.88)	32743.67 (19205.03, 55826.39)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)	51115.56 (33123.53, 78880.50)	109961.41 (71256.38, 169690.23)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)	33071.05 (22971.62, 47610.68)	215026.33 (149360.31, 309562.31)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)	7416.59 (6119.50, 8988.60)	1483.32 (1223.90, 1797.72)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)	1313.37 (1099.57, 1568.73)	262.67 (219.91, 313.75)

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino ethnicity								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	122	0.04 (0.04, 0.04)	51.41 (31.86, 82.95)	1253.86 (777.12, 2023.07)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	0.46 (0.46, 0.46)	460.31 (328.17, 645.67)	990.23 (705.96, 1388.98)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	0.15 (0.15, 0.15)	289.14 (213.10, 392.31)	1879.96 (1385.56, 2550.78)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	280.63 (226.69, 347.40)	56.13 (45.34, 69.48)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	66.46 (56.22, 78.57)	13.29 (11.24, 15.71)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	42	0.04 (0.04, 0.04)	87.94 (43.76, 176.71)	2144.84 (1067.36, 4310.00)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	0.46 (0.46, 0.46)	1473.72 (907.26, 2393.83)	3170.30 (1951.74, 5149.69)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	0.15 (0.15, 0.15)	689.18 (453.58, 1047.15)	4481.00 (2949.16, 6808.51)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)	445.42 (341.13, 581.59)	89.08 (68.23, 116.32)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)	123.31 (98.90, 153.75)	24.66 (19.78, 30.75)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	29.59 (14.63, 59.84)	721.59 (356.77, 1459.47)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	274.31 (136.91, 549.59)	590.11 (294.53, 1182.30)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	196.15 (117.29, 328.04)	1275.36 (762.59, 2132.93)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	146.47 (108.33, 198.03)	29.29 (21.67, 39.61)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	47.04 (34.09, 64.90)	9.41 (6.82, 12.98)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	122	0.04 (0.04, 0.04)	807.52 (493.05, 1322.56)	19695.53 (12025.49, 32257.63)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	122	0.46 (0.46, 0.46)	20250.50 (13157.85, 31166.39)	43563.51 (28305.58, 67046.12)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	122	0.15 (0.15, 0.15)	18385.99 (12954.05, 26095.66)	119544.79 (84226.61, 169672.69)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	9266.35 (7705.46, 11143.44)	1853.27 (1541.09, 2228.69)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	1561.22 (1331.87, 1830.07)	312.24 (266.37, 366.01)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	42	0.04 (0.04, 0.04)	2246.63 (955.99, 5279.72)	54795.83 (23316.74, 128773.70)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	42	0.46 (0.46, 0.46)	63289.38 (39980.42, 100187.71)	136150.12 (86007.13, 215526.96)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	42	0.15 (0.15, 0.15)	55118.85 (32914.84, 92301.46)	358380.06 (214010.68, 600139.52)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)	24287.87 (18395.73, 32067.24)	4857.57 (3679.15, 6413.45)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)	5699.07 (4785.57, 6786.94)	1139.81 (957.11, 1357.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	5.18 (4.83, 5.55)	1.04 (0.97, 1.11)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	419.00 (120.30, 1459.32)	10219.56 (2934.26, 35593.08)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	18063.87 (8636.41, 37782.27)	38859.57 (18578.93, 81278.42)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	7534.49 (3706.57, 15315.63)	48988.88 (24099.97, 99581.48)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	4668.27 (3153.86, 6909.86)	933.65 (630.77, 1381.97)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	1172.49 (867.17, 1585.31)	234.50 (173.43, 317.06)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	604	0.04 (0.04, 0.04)	41.46 (33.92, 50.68)	1011.32 (827.39, 1236.15)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	0.46 (0.46, 0.46)	510.11 (432.41, 601.76)	1097.35 (930.21, 1294.53)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	0.15 (0.15, 0.15)	305.36 (264.33, 352.76)	1985.44 (1718.66, 2293.64)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	604	5.00 (5.00, 5.00)	246.75 (224.49, 271.22)	49.35 (44.90, 54.24)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	604	5.00 (5.00, 5.00)	61.18 (56.59, 66.15)	12.24 (11.32, 13.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	177	0.04 (0.04, 0.04)	108.98 (77.95, 152.37)	2658.02 (1901.12, 3716.27)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	0.46 (0.46, 0.46)	1270.55 (983.01, 1642.20)	2733.25 (2114.69, 3532.74)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	0.15 (0.15, 0.15)	542.39 (428.48, 686.58)	3526.57 (2785.94, 4464.10)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	177	5.00 (5.00, 5.00)	506.07 (436.03, 587.35)	101.21 (87.21, 117.47)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	177	5.00 (5.00, 5.00)	106.37 (94.04, 120.30)	21.27 (18.81, 24.06)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	112	5.10 (4.90, 5.31)	5.21 (4.95, 5.49)	1.02 (0.96, 1.09)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	112	5.02 (4.98, 5.05)	5.10 (4.93, 5.27)	1.02 (0.98, 1.05)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)	22.47 (15.28, 33.05)	548.07 (372.65, 806.08)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)	271.77 (191.37, 385.93)	584.64 (411.69, 830.23)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)	153.94 (114.59, 206.81)	1000.93 (745.07, 1344.65)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)	142.01 (119.32, 169.01)	28.40 (23.86, 33.80)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)	41.29 (35.70, 47.76)	8.26 (7.14, 9.55)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	604	0.04 (0.04, 0.04)	538.04 (425.25, 680.74)	13122.82 (10371.84, 16603.46)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	604	0.46 (0.46, 0.46)	21517.43 (18044.93, 25658.17)	46288.98 (38818.83, 55196.66)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	604	0.15 (0.15, 0.15)	13063.71 (11083.14, 15398.21)	84939.60 (72062.04, 100118.40)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	604	5.00 (5.00, 5.00)	8097.92 (7395.37, 8867.20)	1619.58 (1479.07, 1773.44)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	604	5.00 (5.00, 5.00)	1598.15 (1481.98, 1723.43)	319.63 (296.40, 344.69)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	177	0.04 (0.04, 0.04)	1701.66 (1134.98, 2551.27)	41503.93 (27682.54, 62226.08)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	177	0.46 (0.46, 0.46)	56090.28 (42396.57, 74206.93)	120663.19 (91204.85, 159636.30)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	177	0.15 (0.15, 0.15)	41053.83 (31500.20, 53504.97)	266929.97 (204812.72, 347886.65)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	177	5.00 (5.00, 5.00)	23998.69 (20488.88, 28109.75)	4799.74 (4097.78, 5621.95)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	177	5.00 (5.00, 5.00)	4516.36 (3926.49, 5194.86)	903.27 (785.30, 1038.97)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	112	5.10 (4.90, 5.31)	5.04 (4.98, 5.10)	0.99 (0.95, 1.03)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	112	5.02 (4.98, 5.05)	5.05 (4.98, 5.12)	1.01 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	184	0.04 (0.04, 0.04)	292.03 (171.48, 497.32)	7122.64 (4182.41, 12129.88)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	184	0.46 (0.46, 0.46)	11042.33 (7136.59, 17085.61)	23754.60 (15352.46, 36755.10)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	184	0.15 (0.15, 0.15)	6373.04 (4499.18, 9027.35)	41437.20 (29253.42, 58695.41)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	184	5.00 (5.00, 5.00)	4139.02 (3427.49, 4998.27)	827.80 (685.50, 999.65)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	184	5.00 (5.00, 5.00)	921.51 (764.15, 1111.28)	184.30 (152.83, 222.26)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	23	0.04 (0.04, 0.04)	77.37 (32.74, 182.80)	1886.96 (798.63, 4458.42)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	0.46 (0.46, 0.46)	827.82 (429.78, 1594.47)	1780.82 (924.56, 3430.08)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	0.15 (0.15, 0.15)	267.24 (146.93, 486.07)	1737.58 (955.33, 3160.38)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	328.77 (215.05, 502.61)	65.75 (43.01, 100.52)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)	79.48 (53.61, 117.84)	15.90 (10.72, 23.57)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	94.70 (14.07, 637.43)	2309.72 (343.14, 15547.12)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	968.35 (146.10, 6418.28)	2083.14 (314.29, 13807.20)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	276.38 (34.00, 2246.39)	1797.02 (221.09, 14605.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	369.78 (154.73, 883.69)	73.96 (30.95, 176.74)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	80.63 (45.92, 141.59)	16.13 (9.18, 28.32)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	10	0.04 (0.04, 0.04)	20.88 (3.50, 124.69)	509.35 (85.31, 3041.17)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	10	0.46 (0.46, 0.46)	227.94 (128.13, 405.48)	490.35 (275.64, 872.28)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	10	0.15 (0.15, 0.15)	133.06 (64.26, 275.49)	865.13 (417.84, 1791.22)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)	114.12 (65.93, 197.54)	22.82 (13.19, 39.51)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)	35.00 (23.87, 51.33)	7.00 (4.77, 10.27)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	23	0.04 (0.04, 0.04)	1010.96 (394.95, 2587.81)	24657.63 (9632.84, 63117.30)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	23	0.46 (0.46, 0.46)	19019.53 (9531.12, 37953.81)	40915.41 (20503.65, 81647.44)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	23	0.15 (0.15, 0.15)	24117.00 (14932.18, 38951.43)	156807.56 (97088.30, 253260.29)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	9712.42 (7065.67, 13350.63)	1942.48 (1413.13, 2670.13)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)	2034.52 (1389.78, 2978.38)	406.90 (277.96, 595.68)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	2446.51 (326.40, 18337.45)	59671.04 (7961.08, 447254.95)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	33784.88 (6129.24, 186225.13)	72679.10 (13185.41, 400613.37)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	37261.20 (9911.31, 140082.05)	242270.48 (64442.87, 910806.56)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	19861.66 (10860.17, 36324.06)	3972.33 (2172.03, 7264.81)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	4382.30 (1567.66, 12250.47)	876.46 (313.53, 2450.09)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	10	0.04 (0.04, 0.04)	231.96 (26.09, 2062.52)	5657.66 (636.30, 50305.43)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	10	0.46 (0.46, 0.46)	6909.41 (1628.69, 29311.85)	14863.75 (3503.69, 63056.57)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	10	0.15 (0.15, 0.15)	3944.88 (1673.06, 9301.55)	25649.40 (10878.15, 60478.25)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)	4024.87 (2896.84, 5592.15)	804.97 (579.37, 1118.43)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)	891.47 (644.20, 1233.67)	178.29 (128.84, 246.73)

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Race								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)	39.48 (30.54, 51.05)	963.00 (744.86, 1245.03)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)	497.54 (405.24, 610.85)	1070.32 (871.77, 1314.09)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)	307.26 (254.79, 370.54)	1997.80 (1656.64, 2409.21)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	235.68 (208.62, 266.25)	47.14 (41.72, 53.25)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	60.85 (55.49, 66.74)	12.17 (11.10, 13.35)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)	90.00 (57.79, 140.15)	2195.11 (1409.59, 3418.37)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)	1241.95 (888.72, 1735.57)	2671.71 (1911.84, 3733.61)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)	438.34 (321.05, 598.49)	2850.10 (2087.45, 3891.38)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)	477.98 (391.21, 583.98)	95.60 (78.24, 116.80)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)	102.67 (87.22, 120.86)	20.53 (17.44, 24.17)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)	5.17 (4.85, 5.51)	1.00 (0.92, 1.10)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)	5.03 (4.98, 5.08)	1.00 (0.99, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)	25.34 (15.92, 40.34)	618.16 (388.41, 983.82)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)	309.37 (205.71, 465.28)	665.53 (442.52, 1000.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)	147.23 (104.74, 206.97)	957.30 (680.98, 1345.73)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)	149.23 (120.60, 184.66)	29.85 (24.12, 36.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)	40.90 (33.87, 49.39)	8.18 (6.77, 9.88)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)	497.72 (369.31, 670.79)	12139.52 (9007.47, 16360.62)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)	21506.39 (17275.13, 26774.02)	46265.22 (37162.81, 57597.12)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)	11464.65 (9381.16, 14010.87)	74542.60 (60995.85, 91097.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	7879.81 (7061.06, 8793.49)	1575.96 (1412.21, 1758.70)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	1604.93 (1459.48, 1764.88)	320.99 (291.90, 352.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)	1424.84 (885.19, 2293.50)	34752.27 (21589.96, 55938.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)	59505.71 (41439.47, 85448.23)	128010.56 (89145.89, 183818.93)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)	37700.88 (26439.51, 53758.79)	245129.25 (171908.41, 349536.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)	22982.81 (19438.98, 27172.70)	4596.56 (3887.80, 5434.54)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)	4351.04 (3713.50, 5098.04)	870.21 (742.70, 1019.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)	5.03 (4.98, 5.07)	0.97 (0.92, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)	5.03 (4.97, 5.09)	1.00 (0.99, 1.02)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)	332.53 (182.33, 606.48)	8110.59 (4447.02, 14792.29)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)	12191.15 (7328.44, 20280.45)	26225.98 (15765.18, 43627.94)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)	6217.65 (4037.24, 9575.64)	40426.83 (26249.91, 62260.35)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)	4179.42 (3288.18, 5312.24)	835.88 (657.64, 1062.45)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)	1017.70 (813.39, 1273.33)	203.54 (162.68, 254.67)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)	52.36 (36.96, 74.19)	1277.19 (901.45, 1809.55)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)	581.22 (433.79, 778.75)	1250.33 (933.18, 1675.28)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)	289.23 (230.08, 363.59)	1880.56 (1495.95, 2364.05)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)	287.52 (246.06, 335.96)	57.50 (49.21, 67.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)	67.43 (57.65, 78.88)	13.49 (11.53, 15.78)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	41	0.04 (0.04, 0.04)	181.80 (94.19, 350.91)	4434.11 (2297.21, 8558.82)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	0.46 (0.46, 0.46)	1781.98 (1092.92, 2905.47)	3833.44 (2351.12, 6250.33)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	0.15 (0.15, 0.15)	875.53 (562.24, 1363.40)	5692.67 (3655.64, 8864.79)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	41	5.00 (5.00, 5.00)	594.95 (449.39, 787.65)	118.99 (89.88, 157.53)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	126.60 (100.56, 159.39)	25.32 (20.11, 31.88)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.44 (4.78, 6.20)	1.09 (0.96, 1.24)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)	15.57 (8.64, 28.06)	379.80 (210.74, 684.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)	254.10 (156.63, 412.22)	546.62 (336.95, 886.77)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)	164.76 (106.92, 253.88)	1071.24 (695.20, 1650.69)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	129.72 (100.35, 167.67)	25.94 (20.07, 33.53)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	40.02 (31.24, 51.26)	8.00 (6.25, 10.25)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)	740.47 (500.34, 1095.85)	18060.27 (12203.37, 26728.14)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)	27084.48 (19598.89, 37429.12)	58264.99 (42161.74, 80518.71)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)	17130.84 (12694.51, 23117.54)	111383.88 (82539.05, 150309.09)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)	8792.10 (7578.00, 10200.72)	1758.42 (1515.60, 2040.14)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)	1613.70 (1397.16, 1863.80)	322.74 (279.43, 372.76)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	41	0.04 (0.04, 0.04)	2716.15 (1383.55, 5332.27)	66247.63 (33745.24, 130055.36)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	41	0.46 (0.46, 0.46)	66670.69 (34953.45, 127168.57)	143424.09 (75192.97, 273569.04)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	41	0.15 (0.15, 0.15)	57419.01 (36096.35, 91337.28)	373335.56 (234696.69, 593870.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	41	5.00 (5.00, 5.00)	31147.74 (22646.51, 42840.23)	6229.55 (4529.30, 8568.05)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	4781.44 (3554.50, 6431.90)	956.29 (710.90, 1286.38)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)	234.33 (89.85, 611.13)	5715.29 (2191.44, 14905.54)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)	11379.24 (6701.88, 19321.02)	24479.38 (14417.29, 41563.98)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)	6000.89 (3571.69, 10082.24)	39017.47 (23222.97, 65554.20)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	4580.78 (3577.96, 5864.68)	916.16 (715.59, 1172.94)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	799.53 (571.93, 1117.70)	159.91 (114.39, 223.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)	40.37 (22.95, 71.01)	984.71 (559.87, 1731.91)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)	567.04 (342.56, 938.63)	1219.84 (736.92, 2019.22)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)	343.28 (223.28, 527.75)	2231.97 (1451.78, 3431.42)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)	254.55 (194.61, 332.95)	50.91 (38.92, 66.59)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)	59.37 (44.51, 79.18)	11.87 (8.90, 15.84)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	24	0.04 (0.04, 0.04)	80.91 (34.60, 189.19)	1973.41 (843.94, 4614.48)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	0.46 (0.46, 0.46)	653.30 (355.58, 1200.27)	1405.40 (764.94, 2582.06)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	0.15 (0.15, 0.15)	484.01 (280.87, 834.07)	3147.00 (1826.20, 5423.07)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)	442.76 (336.38, 582.78)	88.55 (67.28, 116.56)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)	88.85 (67.37, 117.16)	17.77 (13.47, 23.43)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	5.84 (4.48, 7.62)	1.17 (0.90, 1.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.04 (0.04, 0.04)	33.18 (13.39, 82.23)	809.32 (326.57, 2005.71)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.46 (0.46, 0.46)	418.82 (219.88, 797.75)	900.98 (473.02, 1716.14)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.15 (0.15, 0.15)	223.79 (116.10, 431.37)	1455.08 (754.88, 2804.73)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)	150.88 (100.80, 225.83)	30.18 (20.16, 45.17)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)	53.94 (39.62, 73.45)	10.79 (7.92, 14.69)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	68	0.04 (0.04, 0.04)	755.07 (395.03, 1443.27)	18416.43 (9634.89, 35201.75)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	68	0.46 (0.46, 0.46)	16695.75 (9607.13, 29014.72)	35916.43 (20667.16, 62417.38)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	68	0.15 (0.15, 0.15)	18514.02 (9999.05, 34280.18)	120377.27 (65013.30, 222888.06)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	68	5.00 (5.00, 5.00)	7713.80 (5491.05, 10836.31)	1542.76 (1098.21, 2167.26)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	68	5.00 (5.00, 5.00)	1549.11 (1331.25, 1802.62)	309.82 (266.25, 360.52)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	24	0.04 (0.04, 0.04)	678.16 (222.67, 2065.34)	16540.44 (5431.08, 50374.12)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	24	0.46 (0.46, 0.46)	30346.00 (13844.52, 66515.83)	65281.28 (29782.78, 143090.96)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	24	0.15 (0.15, 0.15)	32659.86 (14905.55, 71561.69)	212352.79 (96915.15, 465290.59)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)	18976.06 (12949.89, 27806.48)	3795.21 (2589.98, 5561.30)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)	3662.46 (2665.57, 5032.16)	732.49 (533.11, 1006.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	5.23 (4.77, 5.74)	1.05 (0.95, 1.15)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.04 (0.04, 0.04)	412.33 (112.29, 1514.03)	10056.75 (2738.84, 36927.46)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.46 (0.46, 0.46)	21635.28 (10414.62, 44945.04)	46542.50 (22404.26, 96687.19)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.15 (0.15, 0.15)	8176.53 (4263.60, 15680.56)	53163.36 (27721.69, 101954.22)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)	4751.37 (3585.98, 6295.51)	950.27 (717.20, 1259.10)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)	1047.51 (718.23, 1527.75)	209.50 (143.65, 305.55)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.04 (0.04, 0.04)	42.86 (10.88, 168.77)	1045.25 (265.42, 4116.34)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.46 (0.46, 0.46)	471.45 (148.24, 1499.30)	1014.19 (318.91, 3225.35)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.15 (0.15, 0.15)	247.17 (107.67, 567.43)	1607.09 (700.04, 3689.39)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)	250.28 (137.27, 456.30)	50.06 (27.45, 91.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)	53.86 (33.44, 86.74)	10.77 (6.69, 17.35)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.04 (0.04, 0.04)	182.84 (37.69, 886.88)	4459.40 (919.33, 21631.24)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.46 (0.46, 0.46)	2783.86 (689.78, 11235.23)	5988.73 (1483.88, 24169.58)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.15 (0.15, 0.15)	1278.50 (456.46, 3580.90)	8312.72 (2967.91, 23282.81)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	735.41 (313.77, 1723.65)	147.08 (62.75, 344.73)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	114.18 (78.62, 165.81)	22.84 (15.72, 33.16)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)	64.97 (22.43, 188.21)	1584.62 (547.01, 4590.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)	746.30 (319.91, 1740.98)	1605.46 (688.21, 3745.25)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)	585.25 (274.15, 1249.36)	3805.27 (1782.54, 8123.29)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	272.27 (189.97, 390.21)	54.45 (37.99, 78.04)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	57.13 (40.83, 79.94)	11.43 (8.17, 15.99)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.04 (0.04, 0.04)	243.78 (58.10, 1022.93)	5945.94 (1417.03, 24949.50)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.46 (0.46, 0.46)	13992.49 (4673.73, 41891.55)	30101.08 (10054.27, 90118.42)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.15 (0.15, 0.15)	14133.90 (5955.19, 33545.01)	91897.91 (38720.38, 218108.01)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)	7463.71 (4049.75, 13755.68)	1492.74 (809.95, 2751.14)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)	1510.87 (1015.53, 2247.83)	302.17 (203.11, 449.57)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.04 (0.04, 0.04)	3009.35 (767.75, 11795.78)	73398.80 (18725.58, 287701.90)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.46 (0.46, 0.46)	100104.52 (12472.39, 803447.77)	215348.01 (26831.00, 1728402.21)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.15 (0.15, 0.15)	85374.36 (32747.77, 222573.38)	555099.86 (212924.36, 1447161.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	18232.76 (7720.59, 43058.05)	3646.55 (1544.12, 8611.61)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	5300.80 (3521.38, 7979.40)	1060.16 (704.28, 1595.88)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	7.38 (3.75, 14.52)	1.48 (0.75, 2.90)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)	1380.36 (502.83, 3789.31)	33667.23 (12264.19, 92422.15)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)	22315.64 (8557.34, 58194.23)	48006.11 (18408.82, 125189.27)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)	17148.38 (11231.12, 26183.23)	111497.90 (73024.16, 170242.05)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	6666.98 (4423.15, 10049.09)	1333.40 (884.63, 2009.82)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	1129.92 (836.57, 1526.14)	225.98 (167.31, 305.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	13	0.04 (0.04, 0.04)	35.11 (15.23, 80.93)	856.41 (371.55, 1973.99)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	0.46 (0.46, 0.46)	348.25 (192.96, 628.54)	749.17 (415.09, 1352.13)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	0.15 (0.15, 0.15)	248.82 (140.20, 441.60)	1617.83 (911.58, 2871.24)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5.00 (5.00, 5.00)	249.90 (171.91, 363.29)	49.98 (34.38, 72.66)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5.00 (5.00, 5.00)	50.74 (38.38, 67.08)	10.15 (7.68, 13.42)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)	40.37 (5.08, 321.00)	984.62 (123.83, 7829.26)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)	783.51 (403.85, 1520.08)	1685.52 (868.78, 3270.05)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)	464.42 (46.09, 4680.05)	3019.62 (299.65, 30429.46)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	384.18 (236.91, 622.99)	76.84 (47.38, 124.60)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	119.70 (39.55, 362.30)	23.94 (7.91, 72.46)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)	158.33 (64.02, 391.55)	3861.65 (1561.50, 9550.04)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)	312.48 (77.79, 1255.20)	672.22 (167.35, 2700.23)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)	331.32 (110.53, 993.16)	2154.22 (718.65, 6457.48)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	237.82 (119.06, 475.04)	47.56 (23.81, 95.01)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	57.63 (48.18, 68.93)	11.53 (9.64, 13.79)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	13	0.04 (0.04, 0.04)	280.59 (99.86, 788.43)	6843.56 (2435.49, 19229.92)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	13	0.46 (0.46, 0.46)	15591.79 (5846.05, 41584.30)	33541.55 (12576.21, 89457.46)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	13	0.15 (0.15, 0.15)	18579.06 (6537.48, 52800.37)	120800.16 (42506.40, 343305.41)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	13	5.00 (5.00, 5.00)	6029.57 (4549.30, 7991.49)	1205.91 (909.86, 1598.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	13	5.00 (5.00, 5.00)	1398.46 (1094.26, 1787.24)	279.69 (218.85, 357.45)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)	7771.15 (620.66, 97300.21)	189540.28 (15138.16, 2373175.95)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)	16356.82 (850.38, 314617.66)	35187.30 (1829.37, 676815.44)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)	120765.87 (40414.87, 360867.02)	785213.69 (262775.50, 2346339.51)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	43658.14 (24258.44, 78571.97)	8731.63 (4851.69, 15714.39)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	4592.19 (4438.79, 4750.89)	918.44 (887.76, 950.18)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.04 (0.04, 0.04)	8230.63 (1967.51, 34430.89)	200746.95 (47988.10, 839777.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.46 (0.46, 0.46)	114704.18 (51998.52, 253027.37)	246755.25 (111860.86, 544320.48)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.15 (0.15, 0.15)	15155.35 (4194.31, 54761.04)	98539.36 (27271.20, 356053.55)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	6950.85 (5380.65, 8979.27)	1390.17 (1076.13, 1795.85)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	884.45 (587.82, 1330.78)	176.89 (117.56, 266.16)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)	93.83 (44.99, 195.67)	2288.47 (1097.36, 4772.44)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)	756.24 (380.07, 1504.72)	1626.84 (817.61, 3236.99)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)	427.49 (236.95, 771.25)	2779.54 (1540.67, 5014.62)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	338.60 (231.50, 495.25)	67.72 (46.30, 99.05)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	73.05 (53.03, 100.63)	14.61 (10.61, 20.13)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.04 (0.04, 0.04)	205.71 (86.65, 488.40)	5017.41 (2113.34, 11912.13)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.46 (0.46, 0.46)	1476.91 (926.72, 2353.74)	3177.17 (1993.58, 5063.44)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.15 (0.15, 0.15)	702.76 (357.80, 1380.31)	4569.32 (2326.39, 8974.68)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	593.70 (364.28, 967.60)	118.74 (72.86, 193.52)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	145.38 (100.25, 210.83)	29.08 (20.05, 42.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	19	0.04 (0.04, 0.04)	14.25 (2.92, 69.47)	347.47 (71.26, 1694.28)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	0.46 (0.46, 0.46)	102.97 (25.12, 422.03)	221.51 (54.05, 907.87)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	0.15 (0.15, 0.15)	118.17 (28.93, 482.73)	768.36 (188.10, 3138.66)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	98.77 (54.81, 178.00)	19.75 (10.96, 35.60)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	35.73 (22.89, 55.77)	7.15 (4.58, 11.15)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.04 (0.04, 0.04)	1320.84 (464.45, 3756.30)	32215.59 (11328.06, 91617.12)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.46 (0.46, 0.46)	21977.91 (10749.96, 44933.05)	47279.57 (23125.65, 96661.40)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.15 (0.15, 0.15)	21174.05 (10901.48, 41126.57)	137672.66 (70880.89, 267402.95)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	11953.93 (8267.49, 17284.13)	2390.79 (1653.50, 3456.83)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	1936.75 (1362.78, 2752.48)	387.35 (272.56, 550.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.04 (0.04, 0.04)	6646.75 (1855.75, 23806.68)	162115.79 (45262.20, 580650.72)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.46 (0.46, 0.46)	78764.94 (46691.57, 132870.15)	169441.64 (100444.39, 285834.47)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.15 (0.15, 0.15)	58528.22 (30292.12, 113083.94)	380547.57 (196957.87, 735266.16)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	34766.43 (17704.88, 68269.60)	6953.29 (3540.98, 13653.92)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	6821.06 (3879.49, 11993.06)	1364.21 (775.90, 2398.61)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	5.27 (4.75, 5.84)	1.05 (0.95, 1.17)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	19	0.04 (0.04, 0.04)	175.26 (14.66, 2095.36)	4274.53 (357.52, 51106.34)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	19	0.46 (0.46, 0.46)	4114.14 (668.82, 25307.51)	8850.48 (1438.79, 54442.30)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	19	0.15 (0.15, 0.15)	4030.46 (1037.70, 15654.44)	26205.86 (6747.08, 101784.40)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	2976.98 (1474.53, 6010.31)	595.40 (294.91, 1202.06)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	781.92 (389.87, 1568.23)	156.38 (77.97, 313.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	28	0.04 (0.04, 0.04)	16.70 (6.17, 45.21)	407.29 (150.45, 1102.59)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	0.46 (0.46, 0.46)	196.33 (106.25, 362.77)	422.35 (228.58, 780.41)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	0.15 (0.15, 0.15)	152.14 (81.05, 285.61)	989.23 (526.97, 1857.00)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	194.26 (127.00, 297.15)	38.85 (25.40, 59.43)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	52.50 (35.25, 78.17)	10.50 (7.05, 15.63)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	159.60 (45.35, 561.68)	3892.74 (1106.13, 13699.49)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	3390.80 (818.37, 14049.34)	7294.40 (1760.50, 30223.38)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	1105.02 (850.46, 1435.77)	7184.78 (5529.64, 9335.33)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	621.80 (381.83, 1012.59)	124.36 (76.37, 202.52)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	97.00 (70.20, 134.04)	19.40 (14.04, 26.81)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.04 (0.04, 0.04)	32.72 (7.54, 141.96)	797.94 (183.89, 3462.45)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.46 (0.46, 0.46)	234.74 (42.32, 1301.89)	504.97 (91.05, 2800.68)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.15 (0.15, 0.15)	160.16 (46.35, 553.38)	1041.33 (301.38, 3598.03)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	124.38 (48.62, 318.16)	24.88 (9.72, 63.63)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	55.99 (29.22, 107.28)	11.20 (5.84, 21.46)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	28	0.04 (0.04, 0.04)	285.93 (114.33, 715.10)	6973.95 (2788.52, 17441.49)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	28	0.46 (0.46, 0.46)	11546.93 (4426.09, 30123.97)	24840.11 (9521.55, 64803.63)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	28	0.15 (0.15, 0.15)	12839.98 (5858.62, 28140.57)	83484.89 (38092.48, 182968.61)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	7390.14 (5138.46, 10628.52)	1478.03 (1027.69, 2125.70)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	1244.63 (843.99, 1835.47)	248.93 (168.80, 367.09)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	9159.82 (1419.66, 59100.20)	223410.29 (34625.91, 1441468.38)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	35578.75 (15837.10, 79929.27)	76538.13 (34069.26, 171946.37)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	59904.33 (27625.49, 129899.20)	389495.02 (179619.58, 844598.18)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	18917.31 (9322.55, 38386.96)	3783.46 (1864.51, 7677.39)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	7123.09 (6048.50, 8388.60)	1424.62 (1209.70, 1677.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.04 (0.04, 0.04)	92.16 (9.82, 864.68)	2247.74 (239.56, 21089.64)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.46 (0.46, 0.46)	2633.83 (88.80, 78121.14)	5665.97 (191.03, 168056.66)
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.15 (0.15, 0.15)	34177.32 (16267.50, 71805.10)	222219.24 (105770.46, 466873.18)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	3479.40 (1777.16, 6812.11)	695.88 (355.43, 1362.42)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	822.10 (441.02, 1532.47)	164.42 (88.20, 306.49)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	23.64 (6.62, 84.37)	576.52 (161.52, 2057.83)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	210.29 (57.32, 771.50)	452.39 (123.31, 1659.67)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	178.23 (95.65, 332.09)	1158.83 (621.93, 2159.24)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	193.74 (101.58, 369.54)	38.75 (20.32, 73.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	43.04 (29.69, 62.38)	8.61 (5.94, 12.48)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)	25.60 (6.23, 105.12)	624.38 (152.05, 2563.99)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)	871.79 (303.82, 2501.56)	1875.42 (653.58, 5381.43)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)	173.46 (129.65, 232.07)	1127.85 (843.01, 1508.94)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	323.00 (208.88, 499.46)	64.60 (41.78, 99.89)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	153.78 (119.71, 197.54)	30.76 (23.94, 39.51)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	5	0.04 (0.04, 0.04)	230.30 (55.80, 950.44)	5617.02 (1361.05, 23181.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	5	0.46 (0.46, 0.46)	9359.08 (4262.70, 20548.56)	20133.54 (9170.05, 44204.72)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	5	0.15 (0.15, 0.15)	8776.70 (3630.49, 21217.65)	57065.70 (23605.29, 137956.10)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	9575.89 (6457.54, 14200.10)	1915.18 (1291.51, 2840.02)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	1298.08 (943.68, 1785.56)	259.62 (188.74, 357.11)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	2	0.04 (0.04, 0.04)	1439.73 (1322.27, 1567.61)	35115.31 (32250.58, 38234.51)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	2	0.46 (0.46, 0.46)	112274.20 (91802.55, 137310.97)	241527.81 (197488.54, 295387.69)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	2	0.15 (0.15, 0.15)	26194.80 (4078.69, 168232.56)	170317.33 (26519.41, 1093839.81)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	8733.94 (4603.81, 16569.26)	1746.79 (920.76, 3313.85)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	3188.31 (2812.81, 3613.95)	637.66 (562.56, 722.79)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

MOCK

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Underrepresented minority status								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	390	0.04 (0.04, 0.04)	48.57 (37.58, 62.76)	1184.56 (916.67, 1530.73)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	0.46 (0.46, 0.46)	527.65 (425.91, 653.70)	1135.11 (916.24, 1406.26)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	0.15 (0.15, 0.15)	296.28 (249.25, 352.19)	1926.40 (1620.58, 2289.92)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	390	5.00 (5.00, 5.00)	276.22 (245.55, 310.71)	55.24 (49.11, 62.14)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	390	5.00 (5.00, 5.00)	63.91 (57.20, 71.40)	12.78 (11.44, 14.28)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	118	0.04 (0.04, 0.04)	120.53 (80.31, 180.89)	2939.66 (1958.69, 4411.94)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	0.46 (0.46, 0.46)	1354.03 (992.00, 1848.20)	2912.84 (2134.02, 3975.90)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	0.15 (0.15, 0.15)	701.74 (541.83, 908.83)	4562.65 (3522.96, 5909.17)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	118	5.00 (5.00, 5.00)	508.30 (427.49, 604.39)	101.66 (85.50, 120.88)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	118	5.00 (5.00, 5.00)	114.62 (99.35, 132.24)	22.92 (19.87, 26.45)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.21 (4.88, 5.57)	1.04 (0.98, 1.11)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.18 (4.85, 5.52)	1.04 (0.97, 1.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)	20.44 (12.30, 33.97)	498.54 (299.99, 828.50)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)	224.71 (141.39, 357.11)	483.39 (304.17, 768.23)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)	172.70 (114.46, 260.58)	1122.91 (744.23, 1694.26)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)	131.26 (106.12, 162.34)	26.25 (21.22, 32.47)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)	42.73 (36.17, 50.48)	8.55 (7.23, 10.10)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	390	0.04 (0.04, 0.04)	689.90 (512.96, 927.88)	16826.90 (12511.18, 22631.33)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	390	0.46 (0.46, 0.46)	21049.49 (16596.30, 26697.59)	45282.34 (35702.49, 57432.69)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	390	0.15 (0.15, 0.15)	17694.42 (14199.42, 22049.67)	115048.24 (92323.94, 143365.83)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	390	5.00 (5.00, 5.00)	8798.94 (7782.49, 9948.14)	1759.79 (1556.50, 1989.63)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	390	5.00 (5.00, 5.00)	1600.06 (1454.00, 1760.79)	320.01 (290.80, 352.16)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	118	0.04 (0.04, 0.04)	2200.69 (1283.82, 3772.38)	53675.47 (31312.65, 92009.34)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	118	0.46 (0.46, 0.46)	54780.82 (39160.42, 76631.91)	117846.22 (84243.14, 164852.98)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	118	0.15 (0.15, 0.15)	48694.65 (35503.52, 66786.88)	316610.23 (230842.11, 434245.02)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	118	5.00 (5.00, 5.00)	24964.55 (20108.06, 30993.99)	4992.91 (4021.61, 6198.80)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	118	5.00 (5.00, 5.00)	5034.15 (4224.62, 5998.80)	1006.83 (844.92, 1199.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	5.09 (4.96, 5.22)	1.02 (0.99, 1.04)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5.06 (4.94, 5.18)	1.01 (0.99, 1.04)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.04 (0.04, 0.04)	264.78 (120.65, 581.09)	6457.96 (2942.62, 14172.83)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.46 (0.46, 0.46)	10602.00 (5876.24, 19128.28)	22807.35 (12641.15, 41149.35)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.15 (0.15, 0.15)	6615.17 (4294.54, 10189.79)	43011.50 (27922.88, 66253.53)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)	4212.40 (3363.76, 5275.13)	842.48 (672.75, 1055.03)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)	857.62 (679.77, 1081.99)	171.52 (135.95, 216.40)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)	39.48 (30.54, 51.05)	963.00 (744.86, 1245.03)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)	497.54 (405.24, 610.85)	1070.32 (871.77, 1314.09)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)	307.26 (254.79, 370.54)	1997.80 (1656.64, 2409.21)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	235.68 (208.62, 266.25)	47.14 (41.72, 53.25)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	60.85 (55.49, 66.74)	12.17 (11.10, 13.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)	90.00 (57.79, 140.15)	2195.11 (1409.59, 3418.37)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)	1241.95 (888.72, 1735.57)	2671.71 (1911.84, 3733.61)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)	438.34 (321.05, 598.49)	2850.10 (2087.45, 3891.38)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)	477.98 (391.21, 583.98)	95.60 (78.24, 116.80)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)	102.67 (87.22, 120.86)	20.53 (17.44, 24.17)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)	5.17 (4.85, 5.51)	1.00 (0.92, 1.10)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)	5.03 (4.98, 5.08)	1.00 (0.99, 1.01)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)	25.34 (15.92, 40.34)	618.16 (388.41, 983.82)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)	309.37 (205.71, 465.28)	665.53 (442.52, 1000.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)	147.23 (104.74, 206.97)	957.30 (680.98, 1345.73)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)	149.23 (120.60, 184.66)	29.85 (24.12, 36.93)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)	40.90 (33.87, 49.39)	8.18 (6.77, 9.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.04 (0.04, 0.04)	497.72 (369.31, 670.79)	12139.52 (9007.47, 16360.62)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.46 (0.46, 0.46)	21506.39 (17275.13, 26774.02)	46265.22 (37162.81, 57597.12)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.15 (0.15, 0.15)	11464.65 (9381.16, 14010.87)	74542.60 (60995.85, 91097.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	7879.81 (7061.06, 8793.49)	1575.96 (1412.21, 1758.70)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	1604.93 (1459.48, 1764.88)	320.99 (291.90, 352.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	106	0.04 (0.04, 0.04)	1424.84 (885.19, 2293.50)	34752.27 (21589.96, 55938.98)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	106	0.46 (0.46, 0.46)	59505.71 (41439.47, 85448.23)	128010.56 (89145.89, 183818.93)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	106	0.15 (0.15, 0.15)	37700.88 (26439.51, 53758.79)	245129.25 (171908.41, 349536.99)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	106	5.00 (5.00, 5.00)	22982.81 (19438.98, 27172.70)	4596.56 (3887.80, 5434.54)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	106	5.00 (5.00, 5.00)	4351.04 (3713.50, 5098.04)	870.21 (742.70, 1019.61)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.15 (4.86, 5.47)	5.03 (4.98, 5.07)	0.97 (0.92, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.02 (4.98, 5.07)	5.03 (4.97, 5.09)	1.00 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	114	0.04 (0.04, 0.04)	332.53 (182.33, 606.48)	8110.59 (4447.02, 14792.29)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	114	0.46 (0.46, 0.46)	12191.15 (7328.44, 20280.45)	26225.98 (15765.18, 43627.94)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	114	0.15 (0.15, 0.15)	6217.65 (4037.24, 9575.64)	40426.83 (26249.91, 62260.35)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	114	5.00 (5.00, 5.00)	4179.42 (3288.18, 5312.24)	835.88 (657.64, 1062.45)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	114	5.00 (5.00, 5.00)	1017.70 (813.39, 1273.33)	203.54 (162.68, 254.67)

Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Underrepresented minority status								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	181	0.04 (0.04, 0.04)	36.73 (26.65, 50.63)	895.95 (650.02, 1234.94)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	0.46 (0.46, 0.46)	400.48 (306.08, 524.00)	861.53 (658.45, 1127.24)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	0.15 (0.15, 0.15)	214.36 (173.26, 265.21)	1393.77 (1126.53, 1724.40)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	181	5.00 (5.00, 5.00)	248.55 (214.50, 288.01)	49.71 (42.90, 57.60)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	181	5.00 (5.00, 5.00)	59.03 (51.36, 67.85)	11.81 (10.27, 13.57)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	71	0.04 (0.04, 0.04)	111.21 (69.34, 178.36)	2712.38 (1691.13, 4350.34)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	0.46 (0.46, 0.46)	1222.28 (854.36, 1748.63)	2629.40 (1837.93, 3761.72)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	0.15 (0.15, 0.15)	610.00 (453.37, 820.73)	3966.16 (2947.81, 5336.32)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	71	5.00 (5.00, 5.00)	494.65 (404.66, 604.66)	98.93 (80.93, 120.93)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	71	5.00 (5.00, 5.00)	110.30 (93.65, 129.90)	22.06 (18.73, 25.98)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.22 (4.80, 5.67)	1.04 (0.96, 1.13)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.24 (4.80, 5.71)	1.05 (0.96, 1.14)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)	14.36 (7.89, 26.16)	350.29 (192.34, 637.93)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)	154.14 (90.20, 263.43)	331.60 (194.03, 566.70)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)	121.78 (75.27, 197.02)	791.78 (489.40, 1280.99)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	108.97 (85.45, 138.96)	21.79 (17.09, 27.79)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	38.04 (31.20, 46.37)	7.61 (6.24, 9.27)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	181	0.04 (0.04, 0.04)	519.14 (357.83, 753.17)	12661.96 (8727.54, 18370.03)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	181	0.46 (0.46, 0.46)	14244.97 (10665.51, 19025.74)	30644.24 (22943.98, 40928.78)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	181	0.15 (0.15, 0.15)	13006.94 (9876.97, 17128.80)	84570.51 (64219.55, 111370.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	181	5.00 (5.00, 5.00)	7910.62 (6782.34, 9226.60)	1582.12 (1356.47, 1845.32)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	181	5.00 (5.00, 5.00)	1446.91 (1284.18, 1630.26)	289.38 (256.84, 326.05)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	71	0.04 (0.04, 0.04)	1858.36 (994.18, 3473.72)	45325.78 (24248.22, 84724.81)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	71	0.46 (0.46, 0.46)	43415.32 (29720.43, 63420.69)	93396.41 (63935.53, 136432.59)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	71	0.15 (0.15, 0.15)	40128.75 (27997.11, 57517.25)	260915.16 (182035.81, 373974.33)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	71	5.00 (5.00, 5.00)	23833.49 (18541.21, 30636.36)	4766.70 (3708.24, 6127.27)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	71	5.00 (5.00, 5.00)	4859.37 (3964.39, 5956.39)	971.87 (792.88, 1191.28)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.04 (0.04, 0.04)	164.94 (64.72, 420.32)	4022.92 (1578.64, 10251.81)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.46 (0.46, 0.46)	6952.24 (3487.02, 13861.00)	14955.88 (7501.39, 29818.22)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.15 (0.15, 0.15)	4466.48 (2673.13, 7462.94)	29040.80 (17380.55, 48523.68)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	3597.37 (2765.38, 4679.66)	719.47 (553.08, 935.93)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	781.92 (591.39, 1033.85)	156.38 (118.28, 206.77)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)	31.68 (23.12, 43.41)	772.70 (563.90, 1058.82)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)	384.39 (299.73, 492.95)	826.91 (644.79, 1060.46)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)	239.94 (191.02, 301.40)	1560.10 (1242.00, 1959.68)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)	214.83 (184.95, 249.53)	42.97 (36.99, 49.91)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)	57.13 (51.06, 63.93)	11.43 (10.21, 12.79)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	0.04 (0.04, 0.04)	73.87 (42.23, 129.21)	1801.76 (1030.12, 3151.42)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	0.46 (0.46, 0.46)	1008.74 (661.72, 1537.77)	2170.04 (1423.50, 3308.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	0.15 (0.15, 0.15)	299.56 (205.75, 436.16)	1947.74 (1337.75, 2835.87)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5.00 (5.00, 5.00)	432.17 (334.90, 557.68)	86.43 (66.98, 111.54)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5.00 (5.00, 5.00)	94.48 (76.96, 115.99)	18.90 (15.39, 23.20)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.20 (4.82, 5.62)	5.22 (4.80, 5.66)	1.00 (0.89, 1.13)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.04 (0.04, 0.04)	18.35 (10.28, 32.77)	447.62 (250.65, 799.39)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.46 (0.46, 0.46)	237.11 (142.35, 394.96)	510.08 (306.23, 849.65)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.15 (0.15, 0.15)	104.95 (69.01, 159.60)	682.35 (448.68, 1037.71)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	129.31 (99.10, 168.72)	25.86 (19.82, 33.74)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	35.60 (28.21, 44.93)	7.12 (5.64, 8.99)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	172	0.04 (0.04, 0.04)	375.00 (260.72, 539.37)	9146.25 (6358.94, 13155.32)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	172	0.46 (0.46, 0.46)	16991.73 (13028.72, 22160.20)	36553.15 (28027.79, 47671.72)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	172	0.15 (0.15, 0.15)	8216.25 (6448.57, 10468.49)	53421.68 (41928.31, 68065.61)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	172	5.00 (5.00, 5.00)	7193.83 (6298.02, 8217.05)	1438.77 (1259.60, 1643.41)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	172	5.00 (5.00, 5.00)	1556.05 (1386.98, 1745.73)	311.21 (277.40, 349.15)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	52	0.04 (0.04, 0.04)	1005.71 (554.44, 1824.26)	24529.53 (13523.05, 44494.23)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	52	0.46 (0.46, 0.46)	42452.46 (27166.86, 66338.60)	91325.07 (58442.21, 142709.68)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	52	0.15 (0.15, 0.15)	23605.20 (15352.37, 36294.42)	153479.84 (99820.36, 235984.54)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	52	5.00 (5.00, 5.00)	20158.67 (16341.77, 24867.09)	4031.73 (3268.35, 4973.42)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	52	5.00 (5.00, 5.00)	4020.63 (3294.37, 4907.00)	804.13 (658.87, 981.40)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.20 (4.82, 5.62)	5.00 (5.00, 5.00)	0.96 (0.89, 1.04)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.04 (0.04, 0.04)	240.00 (112.74, 510.91)	5853.63 (2749.71, 12461.33)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.46 (0.46, 0.46)	8413.91 (4458.11, 15879.83)	18100.28 (9590.42, 34161.19)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.15 (0.15, 0.15)	3999.42 (2350.38, 6805.43)	26004.04 (15282.07, 44248.60)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	3563.34 (2637.53, 4814.14)	712.67 (527.51, 962.83)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	954.56 (719.83, 1265.83)	190.91 (143.97, 253.17)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.04 (0.04, 0.04)	124.28 (99.94, 154.55)	3031.31 (2437.62, 3769.58)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.46 (0.46, 0.46)	1334.65 (1092.59, 1630.34)	2871.15 (2350.42, 3507.25)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.15 (0.15, 0.15)	880.38 (750.27, 1033.06)	5724.20 (4878.20, 6716.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)	393.99 (353.85, 438.69)	78.80 (70.77, 87.74)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)	83.47 (75.42, 92.38)	16.69 (15.08, 18.48)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	47	0.04 (0.04, 0.04)	188.19 (119.58, 296.17)	4589.98 (2916.52, 7223.68)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	0.46 (0.46, 0.46)	2386.78 (1661.91, 3427.82)	5134.52 (3575.15, 7374.03)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	0.15 (0.15, 0.15)	1524.38 (1111.41, 2090.79)	9911.44 (7226.34, 13594.24)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	591.01 (480.01, 727.67)	118.20 (96.00, 145.53)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	141.82 (114.54, 175.59)	28.36 (22.91, 35.12)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.20 (4.81, 5.62)	1.04 (0.96, 1.12)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)	87.64 (49.18, 156.20)	2137.62 (1199.41, 3809.73)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)	1063.66 (646.90, 1748.92)	2288.18 (1391.63, 3762.34)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)	729.80 (501.18, 1062.72)	4745.13 (3258.63, 6909.74)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	282.80 (215.17, 371.70)	56.56 (43.03, 74.34)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	69.03 (56.08, 84.96)	13.81 (11.22, 16.99)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.04 (0.04, 0.04)	1796.28 (1361.07, 2370.65)	43811.81 (33196.95, 57820.81)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.46 (0.46, 0.46)	78320.72 (61837.98, 99196.88)	168486.00 (133027.82, 213395.45)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.15 (0.15, 0.15)	49843.03 (41010.26, 60578.20)	324076.92 (266646.67, 393876.47)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)	12588.04 (11185.36, 14166.62)	2517.61 (2237.07, 2833.32)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)	2244.75 (2023.36, 2490.37)	448.95 (404.67, 498.07)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	47	0.04 (0.04, 0.04)	5612.57 (3191.90, 9869.03)	136891.92 (77851.14, 240708.09)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	47	0.46 (0.46, 0.46)	198521.66 (125720.70, 313479.41)	427066.07 (270454.33, 674366.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	47	0.15 (0.15, 0.15)	142151.08 (97042.61, 208227.37)	924259.27 (630966.27, 1353884.10)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	32271.72 (25411.06, 40984.68)	6454.34 (5082.21, 8196.94)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	6122.13 (5013.80, 7475.45)	1224.43 (1002.76, 1495.09)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.37 (4.87, 5.92)	1.07 (0.97, 1.18)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)	5.24 (4.78, 5.73)	1.05 (0.96, 1.15)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.04 (0.04, 0.04)	1865.39 (879.93, 3954.51)	45497.43 (21461.72, 96451.55)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.46 (0.46, 0.46)	60440.97 (35843.63, 101917.97)	130022.52 (77107.95, 219249.16)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.15 (0.15, 0.15)	33431.24 (22289.33, 50142.71)	217368.25 (144924.14, 326025.43)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	8077.35 (6401.68, 10191.62)	1615.47 (1280.34, 2038.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	1255.53 (1000.09, 1576.21)	251.11 (200.02, 315.24)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	187	0.04 (0.04, 0.04)	95.72 (76.29, 120.09)	2334.54 (1860.67, 2929.09)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	0.46 (0.46, 0.46)	1404.56 (1122.25, 1757.87)	3021.53 (2414.23, 3781.59)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	0.15 (0.15, 0.15)	830.79 (692.35, 996.91)	5401.75 (4501.60, 6481.88)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5.00 (5.00, 5.00)	342.10 (308.10, 379.86)	68.42 (61.62, 75.97)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5.00 (5.00, 5.00)	78.43 (71.04, 86.59)	15.69 (14.21, 17.32)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.04 (0.04, 0.04)	167.20 (102.51, 272.71)	4078.07 (2500.34, 6651.38)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.46 (0.46, 0.46)	2384.59 (1654.84, 3436.14)	5129.80 (3559.94, 7391.93)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.15 (0.15, 0.15)	1446.77 (1033.24, 2025.82)	9406.84 (6718.05, 13171.77)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	655.62 (539.10, 797.32)	131.12 (107.82, 159.46)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	133.28 (110.90, 160.18)	26.66 (22.18, 32.04)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.11 (4.90, 5.32)	5.11 (4.89, 5.34)	1.00 (0.94, 1.06)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)	80.61 (54.45, 119.34)	1966.06 (1327.99, 2910.70)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)	802.75 (576.18, 1118.41)	1726.90 (1239.50, 2405.96)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)	495.50 (360.62, 680.82)	3221.72 (2344.76, 4426.68)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	249.45 (208.86, 297.94)	49.89 (41.77, 59.59)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	67.23 (55.39, 81.60)	13.45 (11.08, 16.32)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	187	0.04 (0.04, 0.04)	1554.37 (1147.51, 2105.50)	37911.57 (27988.01, 51353.67)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	187	0.46 (0.46, 0.46)	55483.60 (43451.36, 70847.72)	119358.07 (93473.94, 152409.85)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	187	0.15 (0.15, 0.15)	43785.44 (35271.46, 54354.55)	284690.74 (229333.30, 353410.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	187	5.00 (5.00, 5.00)	11366.28 (10008.83, 12907.82)	2273.26 (2001.77, 2581.56)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	187	5.00 (5.00, 5.00)	1817.55 (1617.96, 2041.75)	363.51 (323.59, 408.35)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.04 (0.04, 0.04)	4249.40 (2566.31, 7036.34)	103643.97 (62592.95, 171617.95)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.46 (0.46, 0.46)	171621.13 (111895.62, 263225.79)	369196.79 (240713.38, 566259.64)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.15 (0.15, 0.15)	163747.94 (115297.41, 232558.46)	1064681.01 (749658.06, 1512083.59)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	34674.42 (29133.01, 41269.87)	6934.88 (5826.60, 8253.97)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	5574.16 (4628.94, 6712.39)	1114.83 (925.79, 1342.48)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.11 (4.90, 5.34)	1.02 (0.98, 1.07)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.11 (4.90, 5.32)	5.14 (4.87, 5.42)	1.01 (0.94, 1.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	56	0.04 (0.04, 0.04)	1070.22 (690.39, 1659.02)	26102.97 (16838.87, 40463.81)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	56	0.46 (0.46, 0.46)	46056.25 (30384.72, 69810.68)	99077.65 (65364.56, 150178.94)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	56	0.15 (0.15, 0.15)	30233.41 (20381.15, 44848.27)	196576.15 (132517.21, 291601.23)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	7402.23 (6245.64, 8772.99)	1480.45 (1249.13, 1754.60)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	1280.36 (1078.44, 1520.09)	256.07 (215.69, 304.02)

Table 7a. The ratios of GMTs/GMCs between groups by Age

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age							
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.12 (4.89, 5.35)	0.98 (0.93, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	1.01 (0.99, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	107.79 (91.99, 126.30)	33.67 (26.81, 42.27)	3.20 (2.43, 4.22)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1372.32 (1178.18, 1598.45)	390.92 (325.39, 469.66)	3.51 (2.77, 4.46)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	852.99 (754.08, 964.87)	229.08 (195.08, 269.00)	3.72 (3.04, 4.56)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	364.80 (338.35, 393.31)	228.10 (204.99, 253.80)	1.60 (1.40, 1.82)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	80.68 (75.15, 86.62)	57.90 (53.05, 63.20)	1.39 (1.24, 1.56)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	175.55 (124.58, 247.36)	92.62 (64.23, 133.56)	1.90 (1.15, 3.13)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2385.49 (1836.56, 3098.49)	1121.72 (854.30, 1472.86)	2.13 (1.46, 3.10)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1478.25 (1166.20, 1873.79)	443.85 (346.45, 568.64)	3.33 (2.36, 4.69)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	628.19 (544.13, 725.24)	465.67 (396.90, 546.36)	1.35 (1.09, 1.67)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	136.73 (118.93, 157.20)	102.92 (90.44, 117.13)	1.33 (1.10, 1.61)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.09 (4.92, 5.27)	5.22 (4.91, 5.54)	0.98 (0.91, 1.05)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.19)	5.10 (4.91, 5.29)	0.99 (0.95, 1.04)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	83.32 (59.92, 115.86)	16.52 (10.84, 25.17)	5.04 (2.95, 8.61)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	897.31 (677.16, 1189.05)	197.05 (135.01, 287.61)	4.55 (2.84, 7.30)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	577.55 (451.71, 738.44)	111.87 (81.64, 153.31)	5.16 (3.46, 7.70)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	262.15 (225.01, 305.42)	120.14 (99.70, 144.77)	2.18 (1.71, 2.78)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	67.94 (58.88, 78.39)	36.63 (31.28, 42.89)	1.85 (1.50, 2.30)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	1660.08 (1348.16, 2044.16)	428.64 (329.49, 557.62)	3.87 (2.77, 5.42)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	64902.03 (54667.76, 77052.25)	15803.76 (12971.51, 19254.42)	4.11 (3.16, 5.33)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	46443.53 (40069.32, 53831.73)	9923.86 (8268.09, 11911.22)	4.68 (3.70, 5.92)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	11906.53 (10905.08, 12999.96)	7480.26 (6764.17, 8272.15)	1.59 (1.39, 1.82)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	2000.72 (1847.92, 2166.15)	1510.22 (1388.84, 1642.21)	1.32 (1.18, 1.49)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	4765.44 (3268.92, 6947.08)	1412.22 (909.12, 2193.75)	3.37 (1.89, 6.03)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	182230.11 (133129.63, 249439.69)	42982.14 (32187.37, 57397.20)	4.24 (2.77, 6.50)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	154480.14 (119203.38, 200196.61)	31653.33 (23910.26, 41903.91)	4.88 (3.33, 7.15)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	33663.74 (29201.96, 38807.23)	22114.19 (18694.67, 26159.19)	1.52 (1.22, 1.90)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5793.68 (5052.80, 6643.20)	4464.66 (3864.51, 5158.02)	1.30 (1.06, 1.58)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.23 (4.97, 5.50)	5.00 (5.00, 5.00)	1.05 (0.99, 1.10)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.18 (4.93, 5.45)	5.00 (5.00, 5.00)	1.04 (0.99, 1.09)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1333.39 (892.57, 1991.92)	204.27 (112.76, 370.04)	6.53 (3.19, 13.37)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51286.07 (36987.41, 71112.34)	7751.46 (4835.02, 12427.08)	6.62 (3.73, 11.75)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	31460.53 (23599.98, 41939.22)	4193.83 (2882.65, 6101.41)	7.50 (4.68, 12.03)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7662.36 (6672.78, 8798.69)	3577.93 (2913.36, 4394.08)	2.14 (1.67, 2.74)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1270.48 (1107.46, 1457.49)	876.13 (715.13, 1073.38)	1.45 (1.13, 1.85)

Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Risk for Severe Covid-19							
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.13 (4.88, 5.39)	0.98 (0.93, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.05 (4.96, 5.13)	5.00 (5.00, 5.00)	1.01 (0.99, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	47.63 (39.65, 57.23)	41.47 (32.54, 52.85)	1.15 (0.85, 1.56)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	536.69 (453.76, 634.78)	500.26 (411.49, 608.18)	1.07 (0.83, 1.39)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	360.67 (313.82, 414.53)	283.21 (238.52, 336.27)	1.27 (1.02, 1.59)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	260.65 (239.38, 283.80)	248.73 (221.97, 278.72)	1.05 (0.91, 1.21)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	63.75 (58.83, 69.09)	61.51 (56.07, 67.48)	1.04 (0.92, 1.17)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	106.44 (74.25, 152.57)	104.44 (71.16, 153.27)	1.02 (0.60, 1.73)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1138.23 (843.79, 1535.41)	1356.98 (1022.09, 1801.60)	0.84 (0.55, 1.27)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	609.49 (452.25, 821.39)	546.42 (422.51, 706.67)	1.12 (0.75, 1.66)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	495.10 (421.30, 581.83)	493.21 (417.45, 582.73)	1.00 (0.80, 1.27)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	112.96 (96.74, 131.90)	107.46 (94.00, 122.84)	1.05 (0.86, 1.29)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.07 (4.93, 5.21)	5.24 (4.91, 5.59)	0.97 (0.90, 1.04)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.13 (4.92, 5.35)	0.98 (0.93, 1.02)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23.85 (16.37, 34.74)	22.93 (14.88, 35.35)	1.04 (0.58, 1.85)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	328.27 (237.52, 453.70)	254.87 (172.76, 375.99)	1.29 (0.77, 2.14)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	186.87 (139.95, 249.53)	149.58 (108.03, 207.12)	1.25 (0.81, 1.94)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	152.45 (129.23, 179.85)	138.17 (113.99, 167.46)	1.10 (0.85, 1.42)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	47.57 (40.57, 55.78)	40.03 (34.05, 47.05)	1.19 (0.95, 1.49)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	788.33 (628.28, 989.15)	505.53 (382.04, 668.94)	1.56 (1.09, 2.24)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	25218.56 (20861.91, 30485.03)	20002.76 (16219.13, 24669.05)	1.26 (0.95, 1.68)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	14665.26 (12316.35, 17462.16)	13431.75 (11065.89, 16303.43)	1.09 (0.84, 1.42)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	8505.34 (7687.07, 9410.71)	8160.92 (7341.30, 9072.04)	1.04 (0.90, 1.21)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1579.79 (1455.42, 1714.78)	1611.68 (1474.81, 1761.25)	0.98 (0.87, 1.11)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2191.39 (1415.51, 3392.54)	1676.39 (1057.90, 2656.46)	1.31 (0.69, 2.47)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57248.83 (39324.67, 83342.81)	56885.60 (42170.77, 76734.93)	1.01 (0.62, 1.63)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52396.96 (36673.08, 74862.57)	40475.81 (30296.14, 54075.90)	1.29 (0.81, 2.06)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25589.17 (21385.56, 30619.05)	23508.65 (19753.35, 27977.87)	1.09 (0.85, 1.40)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	4605.30 (3926.30, 5401.73)	4727.93 (4071.07, 5490.78)	0.97 (0.78, 1.21)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.13 (4.95, 5.31)	5.02 (4.98, 5.06)	1.02 (0.99, 1.06)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.06 (4.98, 5.15)	0.99 (0.97, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	274.00 (178.04, 421.70)	311.00 (168.65, 573.51)	0.88 (0.42, 1.87)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	13055.30 (9073.92, 18783.61)	11058.57 (6794.47, 17998.77)	1.18 (0.64, 2.18)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8504.90 (6092.45, 11872.62)	5853.12 (3970.26, 8628.91)	1.45 (0.87, 2.44)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4779.69 (4093.32, 5581.16)	4030.96 (3261.88, 4981.38)	1.19 (0.91, 1.54)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1016.94 (865.76, 1194.51)	926.46 (752.98, 1139.91)	1.10 (0.84, 1.43)

Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.15 (4.86, 5.47)	0.97 (0.91, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	28.66 (21.95, 37.40)	35.11 (26.58, 46.37)	0.82 (0.56, 1.20)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	310.14 (245.07, 392.48)	415.13 (332.20, 518.78)	0.75 (0.54, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	208.18 (171.26, 253.07)	234.84 (193.06, 285.65)	0.89 (0.67, 1.17)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218.22 (192.88, 246.88)	230.73 (202.48, 262.93)	0.95 (0.79, 1.13)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	55.81 (49.56, 62.85)	58.46 (52.59, 64.99)	0.95 (0.81, 1.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	74.86 (48.78, 114.87)	97.97 (62.56, 153.42)	0.76 (0.41, 1.42)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	780.80 (540.54, 1127.84)	1234.28 (887.43, 1716.69)	0.63 (0.39, 1.04)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	409.69 (283.87, 591.26)	453.34 (336.59, 610.58)	0.90 (0.56, 1.45)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	415.91 (340.53, 507.97)	479.77 (394.81, 583.01)	0.87 (0.66, 1.15)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	99.66 (81.87, 121.30)	103.80 (88.90, 121.20)	0.96 (0.75, 1.23)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.28 (4.89, 5.71)	0.95 (0.88, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.13 (4.88, 5.39)	0.98 (0.93, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	12.85 (8.04, 20.54)	17.51 (10.54, 29.07)	0.73 (0.37, 1.46)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	199.36 (133.22, 298.33)	196.52 (124.51, 310.17)	1.01 (0.55, 1.86)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	101.06 (70.68, 144.51)	114.54 (78.40, 167.35)	0.88 (0.52, 1.49)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	115.12 (93.76, 141.33)	121.33 (96.91, 151.91)	0.95 (0.70, 1.29)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	37.45 (30.69, 45.72)	36.44 (30.17, 44.02)	1.03 (0.78, 1.35)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	517.19 (372.31, 718.46)	408.25 (296.40, 562.30)	1.27 (0.80, 2.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	14819.22 (11316.43, 19406.23)	16069.84 (12657.39, 20402.28)	0.92 (0.64, 1.32)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	8024.85 (6241.95, 10317.00)	10486.35 (8411.64, 13072.79)	0.77 (0.55, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	6995.80 (6065.33, 8069.01)	7611.40 (6742.55, 8592.21)	0.92 (0.76, 1.11)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1434.80 (1281.45, 1606.50)	1530.44 (1382.90, 1693.72)	0.94 (0.81, 1.09)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1574.27 (890.19, 2784.07)	1372.31 (802.96, 2345.38)	1.15 (0.52, 2.51)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	36161.42 (22715.38, 57566.66)	44987.70 (31884.97, 63474.82)	0.80 (0.45, 1.43)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	30982.72 (19829.43, 48409.31)	31832.73 (22783.88, 44475.43)	0.97 (0.56, 1.70)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	22038.60 (17325.51, 28033.81)	22134.18 (18074.96, 27105.02)	1.00 (0.73, 1.36)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	3999.22 (3250.75, 4920.03)	4596.29 (3862.21, 5469.90)	0.87 (0.66, 1.14)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	136.92 (79.51, 235.78)	224.13 (109.00, 460.83)	0.61 (0.25, 1.51)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	6781.74 (4298.65, 10699.16)	7995.43 (4513.85, 14162.38)	0.85 (0.41, 1.76)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4158.58 (2849.46, 6069.16)	4202.05 (2670.15, 6612.81)	0.99 (0.55, 1.79)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3651.05 (2981.32, 4471.23)	3561.18 (2777.01, 4566.79)	1.03 (0.74, 1.41)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	867.67 (702.90, 1071.05)	878.11 (687.08, 1122.25)	0.99 (0.72, 1.37)

MOCK

Table 7d. The ratios of GMTs/GMCs between groups by Age ≥ 65 , Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.11 (4.90, 5.33)	5.00 (5.00, 5.00)	1.02 (0.98, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	99.95 (80.72, 123.76)	117.22 (92.60, 148.38)	0.85 (0.62, 1.17)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1194.09 (968.01, 1472.96)	1601.60 (1285.26, 1995.80)	0.75 (0.55, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	803.81 (680.81, 949.02)	911.14 (758.75, 1094.14)	0.88 (0.69, 1.13)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	337.73 (304.82, 374.20)	397.40 (356.10, 443.49)	0.85 (0.73, 0.99)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	77.42 (70.60, 84.89)	84.47 (75.74, 94.21)	0.92 (0.79, 1.06)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	228.12 (122.64, 424.32)	147.66 (100.04, 217.96)	1.54 (0.74, 3.22)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2575.10 (1644.37, 4032.62)	2268.01 (1652.51, 3112.75)	1.14 (0.66, 1.97)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1440.91 (930.92, 2230.27)	1503.44 (1150.43, 1964.77)	0.96 (0.57, 1.60)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	722.21 (565.32, 922.64)	572.91 (482.58, 680.16)	1.26 (0.93, 1.70)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	148.20 (117.80, 186.44)	129.65 (108.96, 154.27)	1.14 (0.86, 1.52)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.17 (4.84, 5.53)	5.00 (5.00, 5.00)	1.03 (0.97, 1.11)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.13 (4.88, 5.40)	0.97 (0.93, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	72.54 (42.91, 122.63)	91.29 (59.85, 139.23)	0.79 (0.41, 1.56)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	805.47 (504.67, 1285.56)	963.50 (678.73, 1367.75)	0.84 (0.47, 1.50)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	564.92 (395.66, 806.59)	586.02 (419.87, 817.92)	0.96 (0.59, 1.57)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	252.75 (200.68, 318.34)	268.54 (219.28, 328.86)	0.94 (0.69, 1.28)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	73.16 (58.26, 91.87)	64.70 (53.88, 77.69)	1.13 (0.84, 1.51)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	1457.59 (1105.15, 1922.43)	1918.06 (1403.10, 2622.03)	0.76 (0.50, 1.15)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	54754.00 (43287.94, 69257.18)	78390.31 (61104.62, 100565.90)	0.70 (0.50, 0.98)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	35328.80 (28909.66, 43173.26)	62929.13 (51065.56, 77548.85)	0.56 (0.42, 0.75)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	11309.10 (9909.35, 12906.58)	12607.06 (11261.61, 14113.25)	0.90 (0.75, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1817.86 (1620.23, 2039.61)	2225.42 (1999.88, 2476.38)	0.82 (0.70, 0.96)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	4485.89 (2499.82, 8049.86)	4959.53 (3028.68, 8121.32)	0.90 (0.42, 1.95)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	154860.47 (89078.89, 269219.42)	202905.04 (140104.72, 293854.88)	0.76 (0.39, 1.49)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	163519.98 (102447.32, 261000.32)	148786.45 (110215.28, 200856.09)	1.10 (0.63, 1.92)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	35364.94 (28852.23, 43347.74)	32585.47 (26854.43, 39539.57)	1.09 (0.82, 1.44)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6251.73 (5057.67, 7727.69)	5509.77 (4611.24, 6583.39)	1.13 (0.86, 1.50)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.32 (4.89, 5.79)	5.13 (4.88, 5.39)	1.04 (0.94, 1.14)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.39 (4.86, 5.98)	0.93 (0.84, 1.03)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	954.95 (524.94, 1737.21)	1661.51 (979.36, 2818.79)	0.57 (0.26, 1.28)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	42433.21 (26242.87, 68612.03)	58107.67 (37527.97, 89972.93)	0.73 (0.38, 1.40)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	30823.45 (18710.02, 50779.47)	31887.56 (22577.71, 45036.32)	0.97 (0.53, 1.77)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7761.30 (6479.54, 9296.61)	7597.84 (6244.64, 9244.29)	1.02 (0.78, 1.33)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1353.22 (1078.40, 1698.06)	1218.73 (1027.05, 1446.19)	1.11 (0.84, 1.48)

MOCK

Table 7e. The ratios of GMTs/GMCs between groups by Sex

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Sex							
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.22 (4.81, 5.67)	5.00 (5.00, 5.00)	1.04 (0.96, 1.13)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	42.81 (31.52, 58.13)	43.27 (34.49, 54.28)	0.99 (0.67, 1.45)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	493.21 (389.71, 624.19)	522.56 (430.73, 633.95)	0.94 (0.69, 1.28)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	307.86 (250.35, 378.59)	298.82 (252.25, 353.97)	1.03 (0.79, 1.35)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	237.53 (206.70, 272.96)	262.98 (235.81, 293.28)	0.90 (0.76, 1.08)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	59.51 (53.34, 66.39)	64.09 (58.42, 70.32)	0.93 (0.80, 1.07)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	118.71 (74.65, 188.77)	94.64 (64.61, 138.63)	1.25 (0.69, 2.27)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	964.05 (676.43, 1373.95)	1668.37 (1261.61, 2206.27)	0.58 (0.37, 0.91)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	449.00 (313.10, 643.88)	676.46 (533.12, 858.33)	0.66 (0.43, 1.03)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	508.62 (417.04, 620.31)	481.52 (405.35, 572.00)	1.06 (0.81, 1.37)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	108.09 (92.74, 125.99)	109.37 (93.92, 127.36)	0.99 (0.80, 1.23)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.24 (4.79, 5.72)	5.15 (4.92, 5.39)	1.02 (0.92, 1.12)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.18 (4.84, 5.55)	5.02 (4.98, 5.07)	1.03 (0.96, 1.11)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21.48 (13.87, 33.27)	24.83 (14.62, 42.16)	0.86 (0.43, 1.73)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	253.73 (166.20, 387.35)	286.84 (182.47, 450.90)	0.88 (0.47, 1.65)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	143.79 (106.07, 194.92)	171.63 (112.39, 262.11)	0.84 (0.49, 1.43)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	135.78 (113.05, 163.06)	146.82 (115.07, 187.33)	0.92 (0.68, 1.26)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	40.92 (34.89, 47.98)	42.38 (34.55, 51.99)	0.97 (0.74, 1.25)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	508.79 (370.24, 699.18)	620.94 (466.25, 826.95)	0.82 (0.53, 1.26)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22616.25 (17863.23, 28633.96)	20411.45 (16364.80, 25458.74)	1.11 (0.80, 1.54)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	12911.06 (10212.26, 16323.08)	14411.24 (11853.21, 17521.31)	0.90 (0.66, 1.22)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	8287.51 (7367.43, 9322.51)	8229.37 (7350.92, 9212.80)	1.01 (0.85, 1.19)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1545.47 (1382.32, 1727.88)	1646.04 (1511.38, 1792.68)	0.94 (0.82, 1.08)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1832.99 (1059.68, 3170.61)	1755.59 (1084.77, 2841.26)	1.04 (0.50, 2.16)
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	51676.07 (35098.76, 76082.93)	61820.10 (45290.40, 84382.66)	0.84 (0.51, 1.38)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	37335.31 (25538.81, 54580.67)	48651.79 (35860.32, 66006.03)	0.77 (0.47, 1.26)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24353.26 (20077.79, 29539.17)	23714.97 (19546.94, 28771.76)	1.03 (0.78, 1.35)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	4520.01 (3682.62, 5547.81)	4851.27 (4228.08, 5566.32)	0.93 (0.73, 1.19)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.09 (4.99, 5.20)	0.98 (0.96, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.18)	5.03 (4.97, 5.09)	1.01 (0.98, 1.03)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	212.00 (113.30, 396.69)	421.55 (205.54, 864.57)	0.50 (0.19, 1.31)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	9578.82 (5979.12, 15345.71)	13644.57 (7448.32, 24995.50)	0.70 (0.32, 1.53)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5435.14 (3493.96, 8454.81)	7426.49 (4776.87, 11545.80)	0.73 (0.39, 1.38)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4218.45 (3435.30, 5180.14)	4169.79 (3205.80, 5423.64)	1.01 (0.72, 1.42)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	915.82 (740.49, 1132.67)	976.73 (763.72, 1249.15)	0.94 (0.68, 1.30)

Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.10 (4.90, 5.31)	0.98 (0.94, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.05)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	51.41 (31.86, 82.95)	41.46 (33.92, 50.68)	1.24 (0.74, 2.08)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	460.31 (328.17, 645.67)	510.11 (432.41, 601.76)	0.90 (0.62, 1.32)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	289.14 (213.10, 392.31)	305.36 (264.33, 352.76)	0.95 (0.67, 1.33)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	280.63 (226.69, 347.40)	246.75 (224.49, 271.22)	1.14 (0.90, 1.44)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	66.46 (56.22, 78.57)	61.18 (56.59, 66.15)	1.09 (0.90, 1.31)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	87.94 (43.76, 176.71)	108.98 (77.95, 152.37)	0.81 (0.37, 1.74)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1473.72 (907.26, 2393.83)	1270.55 (983.01, 1642.20)	1.16 (0.67, 2.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	689.18 (453.58, 1047.15)	542.39 (428.48, 686.58)	1.27 (0.79, 2.05)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	445.42 (341.13, 581.59)	506.07 (436.03, 587.35)	0.88 (0.65, 1.19)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	123.31 (98.90, 153.75)	106.37 (94.04, 120.30)	1.16 (0.90, 1.49)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.21 (4.95, 5.49)	0.96 (0.91, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.10 (4.93, 5.27)	0.98 (0.95, 1.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	29.59 (14.63, 59.84)	22.47 (15.28, 33.05)	1.32 (0.59, 2.95)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	274.31 (136.91, 549.59)	271.77 (191.37, 385.93)	1.01 (0.46, 2.21)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	196.15 (117.29, 328.04)	153.94 (114.59, 206.81)	1.27 (0.70, 2.31)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146.47 (108.33, 198.03)	142.01 (119.32, 169.01)	1.03 (0.73, 1.46)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	47.04 (34.09, 64.90)	41.29 (35.70, 47.76)	1.14 (0.80, 1.62)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	807.52 (493.05, 1322.56)	538.04 (425.25, 680.74)	1.50 (0.87, 2.59)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	20250.50 (13157.85, 31166.39)	21517.43 (18044.93, 25658.17)	0.94 (0.59, 1.50)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	18385.99 (12954.05, 26095.66)	13063.71 (11083.14, 15398.21)	1.41 (0.96, 2.07)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	9266.35 (7705.46, 11143.44)	8097.92 (7395.37, 8867.20)	1.14 (0.93, 1.41)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1561.22 (1331.87, 1830.07)	1598.15 (1481.98, 1723.43)	0.98 (0.82, 1.17)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2246.63 (955.99, 5279.72)	1701.66 (1134.98, 2551.27)	1.32 (0.51, 3.39)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63289.38 (39980.42, 100187.71)	56090.28 (42396.57, 74206.93)	1.13 (0.66, 1.93)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	55118.85 (32914.84, 92301.46)	41053.83 (31500.20, 53504.97)	1.34 (0.75, 2.40)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24287.87 (18395.73, 32067.24)	23998.69 (20488.88, 28109.75)	1.01 (0.74, 1.39)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5699.07 (4785.57, 6786.94)	4516.36 (3926.49, 5194.86)	1.26 (1.01, 1.58)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.18 (4.83, 5.55)	5.04 (4.98, 5.10)	1.03 (0.96, 1.10)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.05 (4.98, 5.12)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	419.00 (120.30, 1459.32)	292.03 (171.48, 497.32)	1.43 (0.37, 5.58)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18063.87 (8636.41, 37782.27)	11042.33 (7136.59, 17085.61)	1.64 (0.69, 3.86)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7534.49 (3706.57, 15315.63)	6373.04 (4499.18, 9027.35)	1.18 (0.53, 2.61)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4668.27 (3153.86, 6909.86)	4139.02 (3427.49, 4998.27)	1.13 (0.73, 1.74)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	1172.49 (867.17, 1585.31)	921.51 (764.15, 1111.28)	1.27 (0.89, 1.81)

MOCK

Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.15 (4.86, 5.47)	0.97 (0.91, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	48.57 (37.58, 62.76)	39.48 (30.54, 51.05)	1.23 (0.85, 1.77)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	527.65 (425.91, 653.70)	497.54 (405.24, 610.85)	1.06 (0.79, 1.43)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	296.28 (249.25, 352.19)	307.26 (254.79, 370.54)	0.96 (0.75, 1.25)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	276.22 (245.55, 310.71)	235.68 (208.62, 266.25)	1.17 (0.99, 1.39)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	63.91 (57.20, 71.40)	60.85 (55.49, 66.74)	1.05 (0.91, 1.21)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120.53 (80.31, 180.89)	90.00 (57.79, 140.15)	1.34 (0.74, 2.44)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1354.03 (992.00, 1848.20)	1241.95 (888.72, 1735.57)	1.09 (0.69, 1.73)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	701.74 (541.83, 908.83)	438.34 (321.05, 598.49)	1.60 (1.07, 2.41)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	508.30 (427.49, 604.39)	477.98 (391.21, 583.98)	1.06 (0.82, 1.39)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	114.62 (99.35, 132.24)	102.67 (87.22, 120.86)	1.12 (0.90, 1.39)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.21 (4.88, 5.57)	5.17 (4.85, 5.51)	1.01 (0.92, 1.11)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.18 (4.85, 5.52)	5.03 (4.98, 5.08)	1.03 (0.96, 1.10)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	20.44 (12.30, 33.97)	25.34 (15.92, 40.34)	0.81 (0.40, 1.61)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	224.71 (141.39, 357.11)	309.37 (205.71, 465.28)	0.73 (0.39, 1.35)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	172.70 (114.46, 260.58)	147.23 (104.74, 206.97)	1.17 (0.68, 2.02)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	131.26 (106.12, 162.34)	149.23 (120.60, 184.66)	0.88 (0.65, 1.19)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	42.73 (36.17, 50.48)	40.90 (33.87, 49.39)	1.04 (0.81, 1.35)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	689.90 (512.96, 927.88)	497.72 (369.31, 670.79)	1.39 (0.91, 2.11)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21049.49 (16596.30, 26697.59)	21506.39 (17275.13, 26774.02)	0.98 (0.71, 1.36)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17694.42 (14199.42, 22049.67)	11464.65 (9381.16, 14010.87)	1.54 (1.14, 2.08)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	8798.94 (7782.49, 9948.14)	7879.81 (7061.06, 8793.49)	1.12 (0.95, 1.32)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1600.06 (1454.00, 1760.79)	1604.93 (1459.48, 1764.88)	1.00 (0.87, 1.14)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2200.69 (1283.82, 3772.38)	1424.84 (885.19, 2293.50)	1.54 (0.75, 3.18)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54780.82 (39160.42, 76631.91)	59505.71 (41439.47, 85448.23)	0.92 (0.56, 1.52)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	48694.65 (35503.52, 66786.88)	37700.88 (26439.51, 53758.79)	1.29 (0.80, 2.09)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	24964.55 (20108.06, 30993.99)	22982.81 (19438.98, 27172.70)	1.09 (0.83, 1.43)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5034.15 (4224.62, 5998.80)	4351.04 (3713.50, 5098.04)	1.16 (0.91, 1.47)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.46 (0.46, 0.46)	0.46 (0.46, 0.46)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.15 (0.15, 0.15)	0.15 (0.15, 0.15)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.09 (4.96, 5.22)	5.03 (4.98, 5.07)	1.01 (0.99, 1.04)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.18)	5.03 (4.97, 5.09)	1.01 (0.98, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	264.78 (120.65, 581.09)	332.53 (182.33, 606.48)	0.80 (0.29, 2.15)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	10602.00 (5876.24, 19128.28)	12191.15 (7328.44, 20280.45)	0.87 (0.40, 1.91)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6615.17 (4294.54, 10189.79)	6217.65 (4037.24, 9575.64)	1.06 (0.57, 1.97)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4212.40 (3363.76, 5275.13)	4179.42 (3288.18, 5312.24)	1.01 (0.72, 1.41)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	857.62 (679.77, 1081.99)	1017.70 (813.39, 1273.33)	0.84 (0.61, 1.16)

MOCK

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Arm							
Vaccine vs Placebo	Negative	-	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID50	99.2% (96.7%, 99.8%)	96.5% (87.4%, 99.1%)	96.5% (87.4%, 99.1%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID80	93.3% (90.2%, 95.5%)	97.1% (87.2%, 99.1%)	97.1% (87.2%, 99.1%)
Vaccine vs Placebo	Positive	-	Day 29	Anti N IgG (IU/ml)	1.6% (0.3%, 8.1%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti RBD IgG (IU/ml)	1.3% (0.2%, 8.9%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID50	1.3% (0.2%, 8.9%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID80	20.8% (14%, 29.8%)	0.6% (0.1%, 2.2%)	0.6% (0.1%, 2.2%)
Vaccine vs Placebo	Negative	-	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	98.9% (96.6%, 99.7%)	98.9% (96.6%, 99.7%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID80	99.7% (97.7%, 100%)	99.3% (97.2%, 99.8%)	99.3% (97.2%, 99.8%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Vaccine vs Placebo	Positive	-	Day 57	Anti N IgG (IU/ml)	1.3% (0.2%, 8.9%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Baseline SARS-CoV-2							
Positive vs Negative	-	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti N IgG (IU/ml)	98.4% (91.9%, 99.7%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti RBD IgG (IU/ml)	98.7% (91.1%, 99.8%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID50	0.8% (0.2%, 3.3%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID50	98.7% (91.1%, 99.8%)	96.5% (87.4%, 99.1%)	96.5% (87.4%, 99.1%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID80	6.7% (4.5%, 9.8%)	0.5% (0.1%, 2.6%)	0.5% (0.1%, 2.6%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID80	79.2% (70.2%, 86%)	97.1% (87.3%, 99.1%)	97.1% (87.3%, 99.1%)
Positive vs Negative	-	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti N IgG (IU/ml)	98.7% (91.1%, 99.8%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Positive vs Negative	-	Placebo	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	98.9% (96.6%, 99.7%)	98.9% (96.6%, 99.7%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID80	99.7% (97.7%, 100%)	99.3% (97.2%, 99.8%)	99.3% (97.2%, 99.8%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age							
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.1% (0.3%, 4.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-2.9% (-15.4%, 5.7%)	-2.9% (-15.4%, 5.7%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	4.8% (1.2%, 8.9%)	0.7% (0.1%, 3.3%)	0.7% (0.1%, 3.3%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-1% (-15.7%, 8.8%)	-1% (-15.7%, 8.8%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	2% (0.4%, 10.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	1.7% (0.2%, 11.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.7% (0.2%, 11.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	19.5% (8.8%, 31%)	0.7% (0.2%, 2.8%)	0.7% (0.2%, 2.8%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	4.6% (1.4%, 13.7%)	4.6% (1.4%, 13.7%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	1.3% (0.2%, 9.3%)	2.9% (0.7%, 11.6%)	2.9% (0.7%, 11.6%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	1.7% (0.2%, 11.2%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Risk for Severe Covid-19							
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.2% (0.3%, 4.6%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-3.6% (-17.2%, 3.6%)	-3.6% (-17.2%, 3.6%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	2.2% (-2%, 6.9%)	0.2% (-2.4%, 3.7%)	0.2% (-2.4%, 3.7%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.4% (-17.1%, -0.6%)	-3.4% (-17.1%, -0.6%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0.5% (-6.7%, 10.4%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	1.7% (0.2%, 11.5%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.7% (0.2%, 11.5%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	12% (0%, 24.6%)	-2.4% (-9.2%, -0.6%)	-2.4% (-9.2%, -0.6%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	1.7% (-2.1%, 8.5%)	1.7% (-2.1%, 8.5%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	-0.5% (-3.3%, -0.1%)	-1% (-4.1%, -0.2%)	-1% (-4.1%, -0.2%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	1.7% (0.2%, 11.5%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.4% (0.3%, 5.3%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-5.5% (-21.8%, -1.2%)	-5.5% (-21.8%, -1.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	0.2% (-5.9%, 6.1%)	0% (-4.2%, 4.1%)	0% (-4.2%, 4.1%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.4% (-22.5%, -0.4%)	-3.4% (-22.5%, -0.4%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0.2% (-10.7%, 12.1%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	2% (0.3%, 13.9%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	2% (0.3%, 13.9%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	9.6% (-6.5%, 25.4%)	-3.7% (-14.1%, -0.9%)	-3.7% (-14.1%, -0.9%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	2% (0.3%, 13.9%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age ≥ 65 , Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	2.5% (0.3%, 17.2%)	2.5% (0.3%, 17.2%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	3% (-0.8%, 7.5%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.4% (-22.3%, -0.4%)	-3.4% (-22.3%, -0.4%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	6% (-5.8%, 16.2%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	2.2% (-17.2%, 18.1%)	2.2% (-17.2%, 18.1%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	-2.8% (-18.8%, -0.4%)	-6.2% (-23.2%, -1.4%)	-6.2% (-23.2%, -1.4%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Sex							
Male vs Female	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.3% (-6.1%, 4.1%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	2.2% (-8.5%, 26.3%)	2.2% (-8.5%, 26.3%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (-5.7%, 5.4%)	-1.3% (-6.1%, -0.3%)	-1.3% (-6.1%, -0.3%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	4.2% (-1.6%, 28.2%)	4.2% (-1.6%, 28.2%)
Male vs Female	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	2% (-2.1%, 15.9%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	2.6% (0.3%, 16.4%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	2.6% (0.3%, 16.4%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	10.7% (-5.5%, 26.2%)	0% (-3.6%, 3.3%)	0% (-3.6%, 3.3%)
Male vs Female	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-1.8% (-5.7%, -0.6%)	0% (-5.7%, -0.6%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0.8% (0.1%, 5.7%)	0.1% (-3.9%, 5.1%)	0.1% (-3.9%, 5.1%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	2.6% (0.3%, 16.4%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1% (0.2%, 3.8%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-4% (-14.2%, -1.1%)	-4% (-14.2%, -1.1%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.5% (-10.1%, 5%)	0.6% (0.1%, 3%)	0.6% (0.1%, 3%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-2.7% (-13.6%, -0.5%)	-2.7% (-13.6%, -0.5%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	1.9% (0.4%, 9.5%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	1.6% (0.2%, 10.5%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.6% (0.2%, 10.5%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	6.1% (-22.3%, 21.2%)	0.7% (0.2%, 2.6%)	0.7% (0.2%, 2.6%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	2.4% (-1.5%, 23.5%)	2.4% (-1.5%, 23.5%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	-0.4% (-2.6%, 0%)	-0.8% (-3.2%, -0.2%)	-0.8% (-3.2%, -0.2%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	1.6% (0.2%, 10.5%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.5% (0.4%, 5.7%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0.3% (-18.4%, 14.4%)	0.3% (-18.4%, 14.4%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-4.4% (-10.4%, 1%)	0.9% (0.2%, 4.5%)	0.9% (0.2%, 4.5%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	4% (-1.7%, 26.4%)	4% (-1.7%, 26.4%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	-2.6% (-18.6%, 1.3%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	-3.1% (-19.1%, -0.4%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-3.1% (-19.1%, -0.4%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	6.5% (-9.1%, 22%)	1% (0.2%, 3.8%)	1% (0.2%, 3.8%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	1% (-3.3%, 6.1%)	1% (-3.3%, 6.1%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0.8% (0.1%, 5.4%)	0.1% (-4.1%, 4.8%)	0.1% (-4.1%, 4.8%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	-3.1% (-19.1%, -0.4%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative						Comparison	
		N	Resp rate	Vaccine	N	Resp rate	Placebo		
Day 29	Anti N IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	43.07 (35.88, 51.71)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.04 (0.04, 0.04)	100% (100%, 100%)	1050.57 (875.11, 1261.21)
Day 29	Anti RBD IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	509.98 (439.60, 591.63)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.46 (0.46, 0.46)	100% (100%, 100%)	1097.09 (945.68, 1272.74)
Day 29	Anti Spike IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	302.60 (265.80, 344.49)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.15 (0.15, 0.15)	100% (100%, 100%)	1967.47 (1728.19, 2239.87)
Day 29	Pseudovirus-nAb ID50	749	11062/11062 = 100.0% (100.0%, 100.0%)	251.94 (231.24, 274.49)	132	393.3/11130 = 3.5% (0.9%, 12.6%)	5.19 (4.95, 5.43)	96.5% (87.4%, 99.1%)	48.58 (44.08, 53.55)
Day 29	Pseudovirus-nAb ID80	749	11002.7/11062 = 99.5% (97.4%, 99.9%)	62.12 (57.88, 66.67)	132	263.3/11130 = 2.4% (0.4%, 12.0%)	5.09 (4.94, 5.24)	97.1% (87.2%, 99.1%)	12.21 (11.31, 13.18)
Day 57	Anti N IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	570.94 (461.75, 705.94)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.04 (0.04, 0.04)	100% (100%, 100%)	13925.31 (11262.30, 17217.99)
Day 57	Anti RBD IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	21313.15 (18157.78, 25016.84)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.46 (0.46, 0.46)	100% (100%, 100%)	45849.52 (39061.59, 53817.01)
Day 57	Anti Spike IgG (IU/ml)	749	11062/11062 = 100.0% (100.0%, 100.0%)	13758.85 (11869.43, 15949.02)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.15 (0.15, 0.15)	100% (100%, 100%)	89459.35 (77174.47, 103699.77)
Day 57	Pseudovirus-nAb ID50	749	11062/11062 = 100.0% (100.0%, 100.0%)	8253.83 (7607.43, 8955.14)	132	121/11130 = 1.1% (0.3%, 3.4%)	5.05 (4.99, 5.11)	98.9% (96.6%, 99.7%)	1633.30 (1504.04, 1773.66)
Day 57	Pseudovirus-nAb ID80	749	11062/11062 = 100.0% (100.0%, 100.0%)	1602.88 (1497.22, 1715.99)	132	78.2/11130 = 0.7% (0.2%, 2.8%)	5.04 (4.98, 5.10)	99.3% (97.2%, 99.8%)	317.85 (296.59, 340.64)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	104.93 (77.54, 141.98)	226 1094/1094 = 100.0% (100.0%, 100.0%)	23.14 (16.43, 32.60)	0% (0%, 0%)	4.53 (2.87, 7.16)		
Day 29	Anti RBD IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	1299.63 (1037.04, 1628.70)	226 1094/1094 = 100.0% (100.0%, 100.0%)	270.27 (198.78, 367.46)	0% (0%, 0%)	4.81 (3.28, 7.04)		
Day 29	Anti Spike IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	561.28 (456.56, 690.02)	226 1094/1094 = 100.0% (100.0%, 100.0%)	157.50 (121.73, 203.80)	0% (0%, 0%)	3.56 (2.56, 4.96)		
Day 29	Pseudovirus-nAb ID50	224 1184/1184 = 100.0% (100.0%, 100.0%)	493.68 (432.71, 563.23)	226 1094/1094 = 100.0% (100.0%, 100.0%)	141.35 (121.40, 164.59)	0% (0%, 0%)	3.49 (2.86, 4.27)		
Day 29	Pseudovirus-nAb ID80	224 1184/1184 = 100.0% (100.0%, 100.0%)	108.79 (97.67, 121.17)	226 1087.9/1094 = 99.4% (97.8%, 99.9%)	41.66 (36.61, 47.41)	0.6% (0.1%, 2.2%)	2.61 (2.21, 3.09)		
Day 57	Anti N IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	1790.43 (1245.27, 2574.24)	226 1094/1094 = 100.0% (100.0%, 100.0%)	302.00 (186.90, 487.98)	0% (0%, 0%)	5.93 (3.25, 10.82)		
Day 57	Anti RBD IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	56974.62 (44687.72, 72639.80)	226 1094/1094 = 100.0% (100.0%, 100.0%)	11492.32 (7839.54, 16847.11)	0% (0%, 0%)	4.96 (3.15, 7.80)		
Day 57	Anti Spike IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	43125.84 (34123.09, 54503.80)	226 1094/1094 = 100.0% (100.0%, 100.0%)	6382.66 (4697.19, 8672.91)	0% (0%, 0%)	6.76 (4.59, 9.94)		
Day 57	Pseudovirus-nAb ID50	224 1184/1184 = 100.0% (100.0%, 100.0%)	24003.54 (20902.14, 27565.12)	226 1094/1094 = 100.0% (100.0%, 100.0%)	4193.33 (3551.23, 4951.52)	0% (0%, 0%)	5.72 (4.61, 7.11)		
Day 57	Pseudovirus-nAb ID80	224 1184/1184 = 100.0% (100.0%, 100.0%)	4697.51 (4168.96, 5293.07)	226 1094/1094 = 100.0% (100.0%, 100.0%)	946.69 (803.89, 1114.85)	0% (0%, 0%)	4.96 (4.05, 6.08)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	104.93 (77.54, 141.98)	749 11062/11062 = 100.0% (100.0%, 100.0%)	43.07 (35.88, 51.71)	0% (0%, 0%)	2.44 (1.71, 3.47)		
Day 29	Anti RBD IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	1299.63 (1037.04, 1628.70)	749 11062/11062 = 100.0% (100.0%, 100.0%)	509.98 (439.60, 591.63)	0% (0%, 0%)	2.55 (1.95, 3.34)		
Day 29	Anti Spike IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	561.28 (456.56, 690.02)	749 11062/11062 = 100.0% (100.0%, 100.0%)	302.60 (265.80, 344.49)	0% (0%, 0%)	1.85 (1.45, 2.37)		
Day 29	Pseudovirus-nAb ID50	224 1184/1184 = 100.0% (100.0%, 100.0%)	493.68 (432.71, 563.23)	749 11062/11062 = 100.0% (100.0%, 100.0%)	251.94 (231.24, 274.49)	0% (0%, 0%)	1.96 (1.67, 2.29)		
Day 29	Pseudovirus-nAb ID80	224 1184/1184 = 100.0% (100.0%, 100.0%)	108.79 (97.67, 121.17)	749 11002.7/11062 = 99.5% (97.4%, 99.9%)	62.12 (57.88, 66.67)	0.5% (0.1%, 2.6%)	1.75 (1.54, 1.99)		
Day 57	Anti N IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	1790.43 (1245.27, 2574.24)	749 11062/11062 = 100.0% (100.0%, 100.0%)	570.94 (461.75, 705.94)	0% (0%, 0%)	3.14 (2.06, 4.78)		
Day 57	Anti RBD IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	56974.62 (44687.72, 72639.80)	749 11062/11062 = 100.0% (100.0%, 100.0%)	21313.15 (18157.78, 25016.84)	0% (0%, 0%)	2.67 (2.00, 3.58)		
Day 57	Anti Spike IgG (IU/ml)	224 1184/1184 = 100.0% (100.0%, 100.0%)	43125.84 (34123.09, 54503.80)	749 11062/11062 = 100.0% (100.0%, 100.0%)	13758.85 (11869.43, 15949.02)	0% (0%, 0%)	3.13 (2.38, 4.13)		
Day 57	Pseudovirus-nAb ID50	224 1184/1184 = 100.0% (100.0%, 100.0%)	24003.54 (20902.14, 27565.12)	749 11062/11062 = 100.0% (100.0%, 100.0%)	8253.83 (7607.43, 8955.14)	0% (0%, 0%)	2.91 (2.48, 3.41)		
Day 57	Pseudovirus-nAb ID80	224 1184/1184 = 100.0% (100.0%, 100.0%)	4697.51 (4168.96, 5293.07)	749 11062/11062 = 100.0% (100.0%, 100.0%)	1602.88 (1497.22, 1715.99)	0% (0%, 0%)	2.93 (2.55, 3.36)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients							
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative			Comparison	
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	23.14 (16.43, 32.60)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.04 (0.04, 0.04)	100% (100%, 100%)	564.45 (400.69, 795.15)
Day 29	Anti RBD IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	270.27 (198.78, 367.46)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.46 (0.46, 0.46)	100% (100%, 100%)	581.40 (427.62, 790.49)
Day 29	Anti Spike IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	157.50 (121.73, 203.80)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.15 (0.15, 0.15)	100% (100%, 100%)	1024.08 (791.46, 1325.07)
Day 29	Pseudovirus-nAb ID50	226	1094/1094 = 100.0% (100.0%, 100.0%)	141.35 (121.40, 164.59)	132	393.3/11130 = 3.5% (0.9%, 12.6%)	5.19 (4.95, 5.43)	96.5% (87.4%, 99.1%)	27.26 (23.25, 31.96)
Day 29	Pseudovirus-nAb ID80	226	1087.9/1094 = 99.4% (97.8%, 99.9%)	41.66 (36.61, 47.41)	132	263.3/11130 = 2.4% (0.4%, 12.0%)	5.09 (4.94, 5.24)	97.1% (87.3%, 99.1%)	8.19 (7.17, 9.35)
Day 57	Anti N IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	302.00 (186.90, 487.98)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.04 (0.04, 0.04)	100% (100%, 100%)	7365.93 (4558.64, 11902.01)
Day 57	Anti RBD IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	11492.32 (7839.54, 16847.11)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.46 (0.46, 0.46)	100% (100%, 100%)	24722.65 (16864.66, 36242.03)
Day 57	Anti Spike IgG (IU/ml)	226	1094/1094 = 100.0% (100.0%, 100.0%)	6382.66 (4697.19, 8672.91)	132	0/11130 = 0.0% (0.0%, 0.0%)	0.15 (0.15, 0.15)	100% (100%, 100%)	41499.74 (30540.93, 56390.83)
Day 57	Pseudovirus-nAb ID50	226	1094/1094 = 100.0% (100.0%, 100.0%)	4193.33 (3551.23, 4951.52)	132	121/11130 = 1.1% (0.3%, 3.4%)	5.05 (4.99, 5.11)	98.9% (96.6%, 99.7%)	829.79 (702.42, 980.26)
Day 57	Pseudovirus-nAb ID80	226	1094/1094 = 100.0% (100.0%, 100.0%)	946.69 (803.89, 1114.85)	132	78.2/11130 = 0.7% (0.2%, 2.8%)	5.04 (4.98, 5.10)	99.3% (97.2%, 99.8%)	187.73 (159.34, 221.17)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Chapter 2

Graphical Description of Immunogenicity Data

2.1 Pairs plots of antibody markers for overall per-protocol cohort

2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm

Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm

PsV Neutralization 80% Titer: baseline negative vaccine arm




Figure 2.9: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm

2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.10: Pair plots of D29 Ab markers: baseline positive vaccine arm




Figure 2.11: Pair plots of D57 Ab markers: baseline positive vaccine arm




Figure 2.12: Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.13: Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm

Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm

PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.17: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.18: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm

2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.19: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.22: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.23: RCDF plots for D29 bAb markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D29 nAb markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D57 bAb markers: by baseline status for the vaccine arm




Figure 2.26: RCDF plots for D57 nAb markers: by baseline status for the vaccine arm




Figure 2.27: RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm




Figure 2.28: RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm




Figure 2.29: RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm




Figure 2.30: RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm




Figure 2.31: RCDF plots for D29 bAb markers: baseline negative vaccine arm




Figure 2.32: RCDF plots for D29 nAb markers: baseline negative vaccine arm




Figure 2.33: RCDF plots for D57 bAb markers: baseline negative vaccine arm




Figure 2.34: RCDF plots for D57 nAb markers: baseline negative vaccine arm




Figure 2.35: RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.36: RCDF plots for D29 fold-rise over D1 nAb markers: baseline/negative vaccine arm




Figure 2.37: RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.38: RCDF plots for D57 fold-rise over D1 nAb markers: baseline/negative vaccine arm




Figure 2.39: RCDF plots for D29 bAb markers: baseline positive vaccine arm




Figure 2.40: RCDF plots for D29 nAb markers: baseline positive vaccine arm




Figure 2.41: RCDF plots for D57 bAb markers: baseline positive vaccine arm




Figure 2.42: RCDF plots for D57 nAb markers: baseline positive vaccine arm




Figure 2.43: RCDF plots for D29 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.44: RCDF plots for D29 fold-rise over D1 nAb markers: baseline/positive vaccine arm




Figure 2.45: RCDF plots for D57 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.46: RCDF plots for D57 fold-rise over D1 nAb markers: baseline/positive vaccine arm

2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

2.3.1 Baseline SARS-CoV-2 negative




Figure 2.47: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm




Figure 2.48: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

2.3.2 Baseline SARS-CoV-2 positive




Figure 2.49: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm




Figure 2.50: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

2.4 Box plots of antibody markers for overall per-protocol cohort

MOCK

2.4.1 Baseline SARS-CoV-2 negative




Figure 2.51: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.52: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.53: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.54: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

2.4.2 Baseline SARS-CoV-2 positive




Figure 2.55: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.56: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.57: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.58: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.59: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.60: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.61: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.62: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.63: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.64: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.65: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.66: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

2.5.1 Baseline SARS-CoV-2 negative




Figure 2.67: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

2.5.2 Baseline SARS-CoV-2 positive




Figure 2.68: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

2.6.1 Baseline SARS-CoV-2 negative




Figure 2.69: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT479




Figure 2.70: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.71: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481




Figure 2.72: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.73: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.74: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.75: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.76: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.77: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.78: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.79: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.80: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.81: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.82: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.83: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.84: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.85: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.86: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.87: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.88: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.89: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.90: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.91: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.92: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.93: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.94: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.95: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.96: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.97: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.98: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.99: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.100: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.101: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.102: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.103: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.104: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6.2 Baseline SARS-CoV-2 positive




Figure 2.105: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.106: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.107: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.108: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.109: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.110: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.111: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.112: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.113: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.114: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.115: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.116: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.117: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.118: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.119: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.120: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.121: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT531




Figure 2.122: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.123: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.124: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.125: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.126: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.127: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.128: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.129: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.130: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.131: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.132: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.133: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.134: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.135: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.136: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.137: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.138: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.139: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.140: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7 Boxplots of antibody markers by demographics for per-protocol cohort

2.7.1 Baseline SARS-CoV-2 negative




Figure 2.141: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.142: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7.2 Baseline SARS-CoV-2 positive

MOCK

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.153: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.154: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.155: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.156: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT567




Figure 2.157: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.158: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT569




Figure 2.159: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.160: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT571




Figure 2.161: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.162: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT573




Figure 2.163: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.164: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT575




Figure 2.165: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.166: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT577




Figure 2.167: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.168: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT579




Figure 2.169: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.170: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

Chapter 3

Appendix

- This report was built from the [CoVPN/correlates_reporting](#) repository with commit hash c88c33ec61667fbab88343ed1cf55b2d80afb704. A diff of the changes introduced by that commit may be viewed at https://github.com/CoVPN/correlates_reporting/commit/c88c33ec61667fbab88343ed1cf55b2d80afb704
- The sha256 hash sum of the raw input file, “COVID_VEtiral_practicedata_primarystage1.csv”: 2353971c2e14399ede55ef6ba0d4e624626433dc15ec507c2482bb886210019a
- The sha256 hash sum of the processed file, “practice_data.csv”: 41ab2015272a48237c9a26a52e8b520753ff2ade1c96a43bf7